Mitch Report
Antony Kaspi & Mark Ziemann
date generated: 2022-05-10
Background
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Input profiles
Here is the first few lines of the input profile.
## x
## 5_8S_rRNA 12.7959349
## 7SK 0.6300779
## A1BG 2.0722835
## A1BG-AS1 2.0755802
## A1CF -1.0374222
## A2M 1.8496539| Profile metrics | |
|---|---|
| num_genesets | 2512 |
| num_genes_in_profile | 26025 |
| duplicated_genes_present | 0 |
| num_profile_genes_in_sets | 9028 |
| num_profile_genes_not_in_sets | 16997 |
Here is a plot of the input profiles. Note the dynamic ranges. 
Here is the contour plot of the profile including all detected genes.
Input genesets
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt| Gene sets metrics | |
|---|---|
| num_genesets | 2512 |
| num_genesets_excluded | 1031 |
| num_genesets_included | 1481 |
Differential pathway expression
Interactive enrichment scatterplot
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Results table
Top N= 50 gene sets| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 1.83e-06 | -0.831 | 1.26e-05 |
| Cohesin Loading onto Chromatin | 10 | 1.05e-05 | -0.804 | 6.09e-05 |
| MET activates RAP1 and RAC1 | 11 | 6.11e-06 | -0.787 | 3.76e-05 |
| APC truncation mutants have impaired AXIN binding | 14 | 4.19e-07 | -0.781 | 3.27e-06 |
| AXIN missense mutants destabilize the destruction complex | 14 | 4.19e-07 | -0.781 | 3.27e-06 |
| Signaling by AMER1 mutants | 14 | 4.19e-07 | -0.781 | 3.27e-06 |
| Signaling by APC mutants | 14 | 4.19e-07 | -0.781 | 3.27e-06 |
| Signaling by AXIN mutants | 14 | 4.19e-07 | -0.781 | 3.27e-06 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 4.19e-07 | -0.781 | 3.27e-06 |
| S33 mutants of beta-catenin aren’t phosphorylated | 15 | 1.66e-07 | -0.780 | 1.45e-06 |
| S37 mutants of beta-catenin aren’t phosphorylated | 15 | 1.66e-07 | -0.780 | 1.45e-06 |
| S45 mutants of beta-catenin aren’t phosphorylated | 15 | 1.66e-07 | -0.780 | 1.45e-06 |
| Signaling by CTNNB1 phospho-site mutants | 15 | 1.66e-07 | -0.780 | 1.45e-06 |
| Signaling by GSK3beta mutants | 15 | 1.66e-07 | -0.780 | 1.45e-06 |
| T41 mutants of beta-catenin aren’t phosphorylated | 15 | 1.66e-07 | -0.780 | 1.45e-06 |
| Signaling by Hippo | 20 | 6.57e-09 | -0.749 | 7.73e-08 |
| Establishment of Sister Chromatid Cohesion | 11 | 1.81e-05 | -0.746 | 9.73e-05 |
| Beta-catenin phosphorylation cascade | 17 | 1.25e-07 | -0.740 | 1.16e-06 |
| ERKs are inactivated | 13 | 4.14e-06 | -0.737 | 2.66e-05 |
| Interleukin-6 signaling | 11 | 3.09e-05 | -0.725 | 1.59e-04 |
| HDMs demethylate histones | 22 | 6.47e-09 | -0.715 | 7.67e-08 |
| Synthesis of PIPs at the late endosome membrane | 11 | 7.55e-05 | -0.689 | 3.46e-04 |
| Deadenylation of mRNA | 22 | 3.47e-08 | -0.679 | 3.45e-07 |
| Unwinding of DNA | 12 | 4.94e-05 | 0.676 | 2.39e-04 |
| Cell-extracellular matrix interactions | 16 | 3.25e-06 | -0.672 | 2.14e-05 |
| Ephrin signaling | 19 | 4.19e-07 | -0.670 | 3.27e-06 |
| tRNA processing in the mitochondrion | 20 | 2.52e-07 | 0.666 | 2.11e-06 |
| FOXO-mediated transcription of cell cycle genes | 15 | 1.01e-05 | -0.658 | 5.98e-05 |
| RHO GTPases activate KTN1 | 11 | 1.59e-04 | -0.658 | 6.76e-04 |
| Synthesis of PIPs at the Golgi membrane | 15 | 1.39e-05 | -0.648 | 7.70e-05 |
| Synthesis of PIPs at the early endosome membrane | 16 | 7.56e-06 | -0.646 | 4.61e-05 |
| RAF-independent MAPK1/3 activation | 23 | 8.89e-08 | -0.644 | 8.44e-07 |
| Signaling by Activin | 15 | 1.82e-05 | -0.639 | 9.75e-05 |
| RORA activates gene expression | 18 | 3.10e-06 | -0.635 | 2.08e-05 |
| Formation of ATP by chemiosmotic coupling | 18 | 3.19e-06 | 0.634 | 2.11e-05 |
| ALK mutants bind TKIs | 12 | 1.52e-04 | -0.631 | 6.53e-04 |
| Activation of RAC1 | 13 | 8.69e-05 | -0.629 | 3.95e-04 |
| Regulation of PTEN mRNA translation | 12 | 2.31e-04 | -0.614 | 9.32e-04 |
| CTLA4 inhibitory signaling | 17 | 1.21e-05 | -0.613 | 6.77e-05 |
| STAT5 activation downstream of FLT3 ITD mutants | 10 | 8.26e-04 | -0.611 | 2.83e-03 |
| ERK/MAPK targets | 22 | 8.88e-07 | -0.605 | 6.51e-06 |
| Complex I biogenesis | 57 | 5.61e-15 | 0.598 | 2.08e-13 |
| Signal transduction by L1 | 21 | 2.30e-06 | -0.595 | 1.58e-05 |
| Signaling by Leptin | 10 | 1.11e-03 | -0.595 | 3.70e-03 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 6.51e-04 | -0.594 | 2.35e-03 |
| Prolonged ERK activation events | 14 | 1.27e-04 | -0.591 | 5.58e-04 |
| Signaling by WNT in cancer | 33 | 4.49e-09 | -0.590 | 5.74e-08 |
| Frs2-mediated activation | 12 | 4.25e-04 | -0.587 | 1.63e-03 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 12 | 4.44e-04 | -0.585 | 1.70e-03 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 10 | 1.48e-03 | -0.580 | 4.69e-03 |
Results (complete table)
Click HERE to show results for all gene sets
| set | setSize | pANOVA | s.dist | p.adjustANOVA |
|---|---|---|---|---|
| CLEC7A (Dectin-1) induces NFAT activation | 11 | 1.83e-06 | -0.831000 | 1.26e-05 |
| Cohesin Loading onto Chromatin | 10 | 1.05e-05 | -0.804000 | 6.09e-05 |
| MET activates RAP1 and RAC1 | 11 | 6.11e-06 | -0.787000 | 3.76e-05 |
| APC truncation mutants have impaired AXIN binding | 14 | 4.19e-07 | -0.781000 | 3.27e-06 |
| AXIN missense mutants destabilize the destruction complex | 14 | 4.19e-07 | -0.781000 | 3.27e-06 |
| Signaling by AMER1 mutants | 14 | 4.19e-07 | -0.781000 | 3.27e-06 |
| Signaling by APC mutants | 14 | 4.19e-07 | -0.781000 | 3.27e-06 |
| Signaling by AXIN mutants | 14 | 4.19e-07 | -0.781000 | 3.27e-06 |
| Truncations of AMER1 destabilize the destruction complex | 14 | 4.19e-07 | -0.781000 | 3.27e-06 |
| S33 mutants of beta-catenin aren’t phosphorylated | 15 | 1.66e-07 | -0.780000 | 1.45e-06 |
| S37 mutants of beta-catenin aren’t phosphorylated | 15 | 1.66e-07 | -0.780000 | 1.45e-06 |
| S45 mutants of beta-catenin aren’t phosphorylated | 15 | 1.66e-07 | -0.780000 | 1.45e-06 |
| Signaling by CTNNB1 phospho-site mutants | 15 | 1.66e-07 | -0.780000 | 1.45e-06 |
| Signaling by GSK3beta mutants | 15 | 1.66e-07 | -0.780000 | 1.45e-06 |
| T41 mutants of beta-catenin aren’t phosphorylated | 15 | 1.66e-07 | -0.780000 | 1.45e-06 |
| Signaling by Hippo | 20 | 6.57e-09 | -0.749000 | 7.73e-08 |
| Establishment of Sister Chromatid Cohesion | 11 | 1.81e-05 | -0.746000 | 9.73e-05 |
| Beta-catenin phosphorylation cascade | 17 | 1.25e-07 | -0.740000 | 1.16e-06 |
| ERKs are inactivated | 13 | 4.14e-06 | -0.737000 | 2.66e-05 |
| Interleukin-6 signaling | 11 | 3.09e-05 | -0.725000 | 1.59e-04 |
| HDMs demethylate histones | 22 | 6.47e-09 | -0.715000 | 7.67e-08 |
| Synthesis of PIPs at the late endosome membrane | 11 | 7.55e-05 | -0.689000 | 3.46e-04 |
| Deadenylation of mRNA | 22 | 3.47e-08 | -0.679000 | 3.45e-07 |
| Unwinding of DNA | 12 | 4.94e-05 | 0.676000 | 2.39e-04 |
| Cell-extracellular matrix interactions | 16 | 3.25e-06 | -0.672000 | 2.14e-05 |
| Ephrin signaling | 19 | 4.19e-07 | -0.670000 | 3.27e-06 |
| tRNA processing in the mitochondrion | 20 | 2.52e-07 | 0.666000 | 2.11e-06 |
| FOXO-mediated transcription of cell cycle genes | 15 | 1.01e-05 | -0.658000 | 5.98e-05 |
| RHO GTPases activate KTN1 | 11 | 1.59e-04 | -0.658000 | 6.76e-04 |
| Synthesis of PIPs at the Golgi membrane | 15 | 1.39e-05 | -0.648000 | 7.70e-05 |
| Synthesis of PIPs at the early endosome membrane | 16 | 7.56e-06 | -0.646000 | 4.61e-05 |
| RAF-independent MAPK1/3 activation | 23 | 8.89e-08 | -0.644000 | 8.44e-07 |
| Signaling by Activin | 15 | 1.82e-05 | -0.639000 | 9.75e-05 |
| RORA activates gene expression | 18 | 3.10e-06 | -0.635000 | 2.08e-05 |
| Formation of ATP by chemiosmotic coupling | 18 | 3.19e-06 | 0.634000 | 2.11e-05 |
| ALK mutants bind TKIs | 12 | 1.52e-04 | -0.631000 | 6.53e-04 |
| Activation of RAC1 | 13 | 8.69e-05 | -0.629000 | 3.95e-04 |
| Regulation of PTEN mRNA translation | 12 | 2.31e-04 | -0.614000 | 9.32e-04 |
| CTLA4 inhibitory signaling | 17 | 1.21e-05 | -0.613000 | 6.77e-05 |
| STAT5 activation downstream of FLT3 ITD mutants | 10 | 8.26e-04 | -0.611000 | 2.83e-03 |
| ERK/MAPK targets | 22 | 8.88e-07 | -0.605000 | 6.51e-06 |
| Complex I biogenesis | 57 | 5.61e-15 | 0.598000 | 2.08e-13 |
| Signal transduction by L1 | 21 | 2.30e-06 | -0.595000 | 1.58e-05 |
| Signaling by Leptin | 10 | 1.11e-03 | -0.595000 | 3.70e-03 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 6.51e-04 | -0.594000 | 2.35e-03 |
| Prolonged ERK activation events | 14 | 1.27e-04 | -0.591000 | 5.58e-04 |
| Signaling by WNT in cancer | 33 | 4.49e-09 | -0.590000 | 5.74e-08 |
| Frs2-mediated activation | 12 | 4.25e-04 | -0.587000 | 1.63e-03 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | 12 | 4.44e-04 | -0.585000 | 1.70e-03 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | 10 | 1.48e-03 | -0.580000 | 4.69e-03 |
| MAPK3 (ERK1) activation | 10 | 1.50e-03 | -0.580000 | 4.74e-03 |
| MET receptor recycling | 10 | 1.64e-03 | -0.575000 | 5.13e-03 |
| Signaling by PDGFR in disease | 19 | 1.63e-05 | -0.571000 | 8.90e-05 |
| Platelet sensitization by LDL | 15 | 1.29e-04 | -0.571000 | 5.62e-04 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | 26 | 5.39e-07 | -0.568000 | 4.10e-06 |
| Mitotic Telophase/Cytokinesis | 13 | 3.97e-04 | -0.567000 | 1.53e-03 |
| Heme signaling | 42 | 3.13e-10 | -0.561000 | 5.58e-09 |
| Signaling by PDGFRA extracellular domain mutants | 12 | 7.87e-04 | -0.560000 | 2.72e-03 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 7.87e-04 | -0.560000 | 2.72e-03 |
| Receptor Mediated Mitophagy | 11 | 1.34e-03 | -0.558000 | 4.29e-03 |
| RHO GTPases Activate WASPs and WAVEs | 36 | 6.89e-09 | -0.558000 | 8.04e-08 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 8.91e-04 | -0.554000 | 3.03e-03 |
| Signaling by ALK fusions and activated point mutants | 55 | 1.16e-12 | -0.554000 | 2.91e-11 |
| Signaling by ALK in cancer | 55 | 1.16e-12 | -0.554000 | 2.91e-11 |
| Adenylate cyclase inhibitory pathway | 12 | 9.22e-04 | -0.552000 | 3.10e-03 |
| Downstream signal transduction | 29 | 2.77e-07 | -0.551000 | 2.29e-06 |
| PKA-mediated phosphorylation of CREB | 18 | 5.38e-05 | -0.550000 | 2.57e-04 |
| Circadian Clock | 67 | 9.84e-15 | -0.546000 | 3.55e-13 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | 28 | 5.65e-07 | -0.546000 | 4.27e-06 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | 25 | 3.03e-06 | -0.539000 | 2.04e-05 |
| Regulation of signaling by CBL | 17 | 1.25e-04 | -0.537000 | 5.51e-04 |
| p130Cas linkage to MAPK signaling for integrins | 12 | 1.29e-03 | -0.536000 | 4.17e-03 |
| Processing and activation of SUMO | 10 | 3.31e-03 | -0.536000 | 9.35e-03 |
| Nephrin family interactions | 20 | 3.53e-05 | -0.534000 | 1.78e-04 |
| PKA activation | 16 | 2.23e-04 | -0.533000 | 9.08e-04 |
| FCGR3A-mediated phagocytosis | 56 | 6.00e-12 | -0.531000 | 1.31e-10 |
| Leishmania phagocytosis | 56 | 6.00e-12 | -0.531000 | 1.31e-10 |
| Parasite infection | 56 | 6.00e-12 | -0.531000 | 1.31e-10 |
| Activation of BAD and translocation to mitochondria | 15 | 3.81e-04 | -0.530000 | 1.48e-03 |
| Transcriptional activation of mitochondrial biogenesis | 53 | 2.76e-11 | -0.528000 | 5.68e-10 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | 30 | 6.08e-07 | -0.526000 | 4.52e-06 |
| RHOV GTPase cycle | 37 | 3.16e-08 | -0.525000 | 3.17e-07 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 25 | 5.48e-06 | -0.525000 | 3.44e-05 |
| MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 4.29e-07 | -0.524000 | 3.31e-06 |
| N-Glycan antennae elongation | 14 | 6.80e-04 | -0.524000 | 2.44e-03 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 50 | 1.45e-10 | -0.524000 | 2.79e-09 |
| Aflatoxin activation and detoxification | 14 | 7.22e-04 | 0.522000 | 2.55e-03 |
| MECP2 regulates neuronal receptors and channels | 17 | 2.04e-04 | -0.520000 | 8.46e-04 |
| COPI-mediated anterograde transport | 79 | 1.84e-15 | -0.517000 | 7.36e-14 |
| DNA strand elongation | 32 | 4.27e-07 | 0.516000 | 3.31e-06 |
| STAT3 nuclear events downstream of ALK signaling | 10 | 4.75e-03 | -0.516000 | 1.28e-02 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 4.10e-11 | -0.514000 | 8.20e-10 |
| Selenocysteine synthesis | 91 | 2.35e-17 | 0.514000 | 1.34e-15 |
| Viral mRNA Translation | 87 | 1.17e-16 | 0.513000 | 5.77e-15 |
| Peptide chain elongation | 87 | 1.23e-16 | 0.513000 | 5.86e-15 |
| Downregulation of TGF-beta receptor signaling | 26 | 6.08e-06 | -0.512000 | 3.75e-05 |
| Postmitotic nuclear pore complex (NPC) reformation | 27 | 4.10e-06 | -0.512000 | 2.64e-05 |
| Uptake and function of anthrax toxins | 11 | 3.39e-03 | -0.510000 | 9.51e-03 |
| Signaling by KIT in disease | 19 | 1.19e-04 | -0.510000 | 5.25e-04 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 19 | 1.19e-04 | -0.510000 | 5.25e-04 |
| Signaling by BMP | 23 | 2.39e-05 | -0.509000 | 1.25e-04 |
| Signaling by NODAL | 18 | 2.08e-04 | -0.505000 | 8.58e-04 |
| RHOBTB1 GTPase cycle | 23 | 2.89e-05 | -0.504000 | 1.50e-04 |
| Growth hormone receptor signaling | 20 | 9.63e-05 | -0.504000 | 4.32e-04 |
| Constitutive Signaling by AKT1 E17K in Cancer | 26 | 9.15e-06 | -0.502000 | 5.49e-05 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 5.95e-03 | -0.502000 | 1.56e-02 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 45 | 5.71e-09 | -0.502000 | 6.93e-08 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 12 | 2.63e-03 | -0.501000 | 7.67e-03 |
| MET promotes cell motility | 29 | 3.39e-06 | -0.498000 | 2.21e-05 |
| Signaling by TGF-beta Receptor Complex | 74 | 1.44e-13 | -0.497000 | 4.44e-12 |
| VxPx cargo-targeting to cilium | 19 | 1.85e-04 | -0.495000 | 7.80e-04 |
| Response to metal ions | 10 | 6.72e-03 | 0.495000 | 1.73e-02 |
| Activation of gene expression by SREBF (SREBP) | 42 | 2.92e-08 | -0.494000 | 3.00e-07 |
| Eukaryotic Translation Termination | 91 | 3.39e-16 | 0.494000 | 1.57e-14 |
| Activation of the TFAP2 (AP-2) family of transcription factors | 11 | 4.57e-03 | -0.494000 | 1.24e-02 |
| Nucleotide biosynthesis | 12 | 3.28e-03 | -0.490000 | 9.27e-03 |
| RAC2 GTPase cycle | 86 | 3.80e-15 | -0.490000 | 1.44e-13 |
| Caspase activation via Dependence Receptors in the absence of ligand | 10 | 7.66e-03 | -0.487000 | 1.94e-02 |
| Citric acid cycle (TCA cycle) | 22 | 8.12e-05 | -0.485000 | 3.70e-04 |
| rRNA processing in the mitochondrion | 24 | 3.95e-05 | 0.485000 | 1.97e-04 |
| RAC3 GTPase cycle | 91 | 1.34e-15 | -0.484000 | 5.53e-14 |
| Spry regulation of FGF signaling | 16 | 8.46e-04 | -0.482000 | 2.89e-03 |
| RHOU GTPase cycle | 40 | 1.39e-07 | -0.481000 | 1.27e-06 |
| Signaling by FLT3 ITD and TKD mutants | 16 | 9.09e-04 | -0.479000 | 3.07e-03 |
| Eukaryotic Translation Elongation | 92 | 2.23e-15 | 0.478000 | 8.69e-14 |
| Interleukin-27 signaling | 10 | 8.89e-03 | -0.478000 | 2.21e-02 |
| DCC mediated attractive signaling | 14 | 1.97e-03 | -0.478000 | 6.04e-03 |
| STING mediated induction of host immune responses | 15 | 1.37e-03 | -0.477000 | 4.36e-03 |
| Miscellaneous transport and binding events | 23 | 7.52e-05 | -0.477000 | 3.46e-04 |
| Signaling by TGFB family members | 98 | 4.54e-16 | -0.474000 | 2.04e-14 |
| Regulation of RUNX1 Expression and Activity | 18 | 5.03e-04 | -0.474000 | 1.86e-03 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 125 | 5.77e-20 | 0.473000 | 4.27e-18 |
| Gastrin-CREB signalling pathway via PKC and MAPK | 17 | 7.33e-04 | -0.473000 | 2.58e-03 |
| TBC/RABGAPs | 43 | 8.11e-08 | -0.473000 | 7.80e-07 |
| Signaling by FGFR3 fusions in cancer | 10 | 9.76e-03 | -0.472000 | 2.40e-02 |
| RHOF GTPase cycle | 41 | 1.83e-07 | -0.471000 | 1.57e-06 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 24 | 6.75e-05 | -0.470000 | 3.17e-04 |
| Insulin processing | 25 | 4.91e-05 | -0.469000 | 2.39e-04 |
| Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 2.42e-03 | -0.468000 | 7.19e-03 |
| Pre-NOTCH Processing in Golgi | 18 | 6.47e-04 | -0.464000 | 2.34e-03 |
| COPI-independent Golgi-to-ER retrograde traffic | 33 | 3.97e-06 | -0.464000 | 2.57e-05 |
| RHOC GTPase cycle | 72 | 1.03e-11 | -0.463000 | 2.17e-10 |
| TGF-beta receptor signaling activates SMADs | 32 | 5.84e-06 | -0.463000 | 3.63e-05 |
| AKT phosphorylates targets in the cytosol | 14 | 2.72e-03 | -0.463000 | 7.90e-03 |
| Signaling by FLT3 fusion proteins | 19 | 4.90e-04 | -0.462000 | 1.83e-03 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | 12 | 5.66e-03 | -0.461000 | 1.49e-02 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 18 | 7.22e-04 | -0.460000 | 2.55e-03 |
| Regulation of IFNA signaling | 12 | 6.01e-03 | -0.458000 | 1.57e-02 |
| RHOH GTPase cycle | 35 | 2.73e-06 | -0.458000 | 1.85e-05 |
| IRE1alpha activates chaperones | 50 | 2.46e-08 | -0.456000 | 2.59e-07 |
| Recycling pathway of L1 | 27 | 4.17e-05 | -0.455000 | 2.06e-04 |
| Leading Strand Synthesis | 14 | 3.21e-03 | 0.455000 | 9.14e-03 |
| Polymerase switching | 14 | 3.21e-03 | 0.455000 | 9.14e-03 |
| Regulation of actin dynamics for phagocytic cup formation | 58 | 2.07e-09 | -0.455000 | 2.86e-08 |
| Lysosphingolipid and LPA receptors | 12 | 6.57e-03 | -0.453000 | 1.70e-02 |
| PI Metabolism | 77 | 6.67e-12 | -0.452000 | 1.43e-10 |
| MAP kinase activation | 63 | 5.40e-10 | -0.452000 | 8.51e-09 |
| RHOJ GTPase cycle | 54 | 9.16e-09 | -0.452000 | 1.04e-07 |
| FOXO-mediated transcription of cell death genes | 15 | 2.50e-03 | -0.451000 | 7.39e-03 |
| Regulation of IFNG signaling | 13 | 5.03e-03 | -0.449000 | 1.35e-02 |
| RHOBTB GTPase Cycle | 35 | 4.26e-06 | -0.449000 | 2.71e-05 |
| Signal regulatory protein family interactions | 11 | 9.97e-03 | -0.449000 | 2.45e-02 |
| RUNX2 regulates osteoblast differentiation | 23 | 1.99e-04 | -0.448000 | 8.35e-04 |
| DAG and IP3 signaling | 38 | 1.76e-06 | -0.448000 | 1.23e-05 |
| XBP1(S) activates chaperone genes | 48 | 9.96e-08 | -0.444000 | 9.39e-07 |
| FCGR3A-mediated IL10 synthesis | 32 | 1.36e-05 | -0.444000 | 7.60e-05 |
| Fcgamma receptor (FCGR) dependent phagocytosis | 82 | 3.81e-12 | -0.443000 | 8.81e-11 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 4.08e-03 | -0.443000 | 1.12e-02 |
| Transport of the SLBP Dependant Mature mRNA | 36 | 4.24e-06 | -0.443000 | 2.71e-05 |
| VEGFR2 mediated vascular permeability | 26 | 9.35e-05 | -0.443000 | 4.21e-04 |
| Processive synthesis on the lagging strand | 15 | 3.08e-03 | 0.441000 | 8.87e-03 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 37 | 3.39e-06 | -0.441000 | 2.21e-05 |
| N-glycan antennae elongation in the medial/trans-Golgi | 25 | 1.37e-04 | -0.441000 | 5.93e-04 |
| Protein methylation | 15 | 3.17e-03 | -0.440000 | 9.06e-03 |
| NOTCH2 intracellular domain regulates transcription | 11 | 1.18e-02 | -0.438000 | 2.83e-02 |
| Zinc transporters | 15 | 3.28e-03 | -0.438000 | 9.27e-03 |
| RAF activation | 34 | 1.01e-05 | -0.437000 | 5.96e-05 |
| Transport to the Golgi and subsequent modification | 161 | 1.43e-21 | -0.435000 | 1.12e-19 |
| Transport of the SLBP independent Mature mRNA | 35 | 8.47e-06 | -0.435000 | 5.14e-05 |
| Lewis blood group biosynthesis | 16 | 2.61e-03 | -0.435000 | 7.62e-03 |
| G-protein mediated events | 50 | 1.10e-07 | -0.434000 | 1.03e-06 |
| Ca-dependent events | 34 | 1.19e-05 | -0.434000 | 6.72e-05 |
| Synaptic adhesion-like molecules | 20 | 7.88e-04 | -0.434000 | 2.72e-03 |
| ER to Golgi Anterograde Transport | 131 | 9.72e-18 | -0.433000 | 6.26e-16 |
| SUMOylation of SUMOylation proteins | 35 | 9.13e-06 | -0.433000 | 5.49e-05 |
| Formation of a pool of free 40S subunits | 99 | 1.00e-13 | 0.432000 | 3.23e-12 |
| Syndecan interactions | 20 | 8.45e-04 | -0.431000 | 2.89e-03 |
| Regulation of gene expression by Hypoxia-inducible Factor | 11 | 1.33e-02 | -0.431000 | 3.18e-02 |
| PLC beta mediated events | 46 | 4.40e-07 | -0.430000 | 3.37e-06 |
| Nuclear Events (kinase and transcription factor activation) | 60 | 8.18e-09 | -0.430000 | 9.39e-08 |
| Respiratory electron transport | 103 | 4.49e-14 | 0.430000 | 1.55e-12 |
| EPHB-mediated forward signaling | 34 | 1.45e-05 | -0.430000 | 7.99e-05 |
| Defective GALNT12 causes CRCS1 | 12 | 1.00e-02 | 0.429000 | 2.45e-02 |
| Regulation of KIT signaling | 15 | 4.03e-03 | -0.429000 | 1.11e-02 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 93 | 9.70e-13 | 0.428000 | 2.52e-11 |
| Synthesis of PIPs at the plasma membrane | 50 | 1.66e-07 | -0.428000 | 1.45e-06 |
| Interleukin-35 Signalling | 12 | 1.04e-02 | -0.427000 | 2.53e-02 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | 181 | 3.41e-23 | -0.427000 | 2.81e-21 |
| PKA activation in glucagon signalling | 15 | 4.33e-03 | -0.425000 | 1.19e-02 |
| CD28 co-stimulation | 29 | 7.42e-05 | -0.425000 | 3.43e-04 |
| Nuclear events stimulated by ALK signaling in cancer | 19 | 1.37e-03 | -0.424000 | 4.37e-03 |
| Sialic acid metabolism | 31 | 5.20e-05 | -0.420000 | 2.50e-04 |
| Lagging Strand Synthesis | 20 | 1.15e-03 | 0.420000 | 3.80e-03 |
| Transport of Ribonucleoproteins into the Host Nucleus | 32 | 3.96e-05 | -0.420000 | 1.97e-04 |
| Carnitine metabolism | 11 | 1.60e-02 | -0.419000 | 3.71e-02 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 99 | 5.45e-13 | 0.419000 | 1.50e-11 |
| Association of TriC/CCT with target proteins during biosynthesis | 37 | 1.03e-05 | -0.419000 | 6.02e-05 |
| Integrin signaling | 24 | 3.86e-04 | -0.418000 | 1.49e-03 |
| VEGFA-VEGFR2 Pathway | 91 | 5.10e-12 | -0.418000 | 1.16e-10 |
| Signaling by NTRK1 (TRKA) | 113 | 1.50e-14 | -0.418000 | 5.30e-13 |
| Gap junction degradation | 10 | 2.21e-02 | -0.418000 | 4.92e-02 |
| Glycolysis | 66 | 4.27e-09 | -0.418000 | 5.55e-08 |
| Signaling by ALK | 26 | 2.30e-04 | -0.417000 | 9.31e-04 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 9.34e-03 | -0.416000 | 2.30e-02 |
| Defective EXT2 causes exostoses 2 | 13 | 9.34e-03 | -0.416000 | 2.30e-02 |
| MET activates PTK2 signaling | 18 | 2.24e-03 | -0.416000 | 6.78e-03 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 2.34e-06 | -0.416000 | 1.60e-05 |
| Cholesterol biosynthesis | 24 | 4.64e-04 | -0.413000 | 1.75e-03 |
| Regulation of localization of FOXO transcription factors | 12 | 1.33e-02 | -0.413000 | 3.17e-02 |
| Retrograde transport at the Trans-Golgi-Network | 49 | 5.91e-07 | -0.412000 | 4.45e-06 |
| TNFR1-induced proapoptotic signaling | 13 | 1.02e-02 | -0.411000 | 2.50e-02 |
| Signaling by cytosolic FGFR1 fusion mutants | 18 | 2.54e-03 | -0.411000 | 7.46e-03 |
| Sphingolipid de novo biosynthesis | 43 | 3.14e-06 | -0.411000 | 2.09e-05 |
| Signaling by VEGF | 100 | 1.29e-12 | -0.410000 | 3.19e-11 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 7.95e-05 | -0.409000 | 3.64e-04 |
| Signaling by SCF-KIT | 41 | 5.73e-06 | -0.409000 | 3.58e-05 |
| NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 6.24e-05 | -0.409000 | 2.95e-04 |
| Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 4.56e-06 | -0.409000 | 2.89e-05 |
| Signaling by NTRKs | 131 | 7.00e-16 | -0.408000 | 3.05e-14 |
| SUMOylation of ubiquitinylation proteins | 39 | 1.07e-05 | -0.407000 | 6.17e-05 |
| EPHA-mediated growth cone collapse | 15 | 6.32e-03 | -0.407000 | 1.64e-02 |
| IRF3-mediated induction of type I IFN | 12 | 1.47e-02 | -0.407000 | 3.48e-02 |
| Signaling by FGFR4 in disease | 11 | 1.97e-02 | -0.406000 | 4.46e-02 |
| Removal of the Flap Intermediate | 14 | 8.54e-03 | 0.406000 | 2.14e-02 |
| RHOG GTPase cycle | 74 | 1.58e-09 | -0.406000 | 2.29e-08 |
| Nuclear import of Rev protein | 34 | 4.34e-05 | -0.405000 | 2.13e-04 |
| ER Quality Control Compartment (ERQC) | 21 | 1.34e-03 | -0.404000 | 4.29e-03 |
| Signaling by Erythropoietin | 25 | 4.72e-04 | -0.404000 | 1.77e-03 |
| VEGFR2 mediated cell proliferation | 19 | 2.31e-03 | -0.404000 | 6.96e-03 |
| VLDLR internalisation and degradation | 11 | 2.07e-02 | -0.403000 | 4.67e-02 |
| Toll Like Receptor 3 (TLR3) Cascade | 90 | 4.45e-11 | -0.401000 | 8.67e-10 |
| activated TAK1 mediates p38 MAPK activation | 19 | 2.47e-03 | -0.401000 | 7.31e-03 |
| CaM pathway | 32 | 8.83e-05 | -0.400000 | 3.98e-04 |
| Calmodulin induced events | 32 | 8.83e-05 | -0.400000 | 3.98e-04 |
| MyD88 cascade initiated on plasma membrane | 81 | 4.86e-10 | -0.400000 | 7.92e-09 |
| Toll Like Receptor 10 (TLR10) Cascade | 81 | 4.86e-10 | -0.400000 | 7.92e-09 |
| Toll Like Receptor 5 (TLR5) Cascade | 81 | 4.86e-10 | -0.400000 | 7.92e-09 |
| Extra-nuclear estrogen signaling | 69 | 9.64e-09 | -0.399000 | 1.07e-07 |
| RHOQ GTPase cycle | 58 | 1.46e-07 | -0.399000 | 1.33e-06 |
| Tie2 Signaling | 17 | 4.41e-03 | -0.399000 | 1.20e-02 |
| Golgi-to-ER retrograde transport | 113 | 2.39e-13 | -0.399000 | 6.95e-12 |
| Receptor-type tyrosine-protein phosphatases | 18 | 3.44e-03 | -0.398000 | 9.62e-03 |
| Interactions of Rev with host cellular proteins | 37 | 2.95e-05 | -0.397000 | 1.52e-04 |
| Molecules associated with elastic fibres | 27 | 3.58e-04 | -0.397000 | 1.40e-03 |
| RUNX2 regulates bone development | 30 | 1.75e-04 | -0.396000 | 7.41e-04 |
| Interactions of Vpr with host cellular proteins | 37 | 3.16e-05 | -0.395000 | 1.61e-04 |
| Vpr-mediated nuclear import of PICs | 34 | 6.86e-05 | -0.394000 | 3.22e-04 |
| RET signaling | 37 | 3.33e-05 | -0.394000 | 1.69e-04 |
| Interleukin-15 signaling | 14 | 1.07e-02 | -0.394000 | 2.60e-02 |
| Signal amplification | 28 | 3.10e-04 | -0.394000 | 1.22e-03 |
| RHOD GTPase cycle | 52 | 8.94e-07 | -0.394000 | 6.52e-06 |
| Regulation of FOXO transcriptional activity by acetylation | 10 | 3.11e-02 | -0.394000 | 6.56e-02 |
| RUNX3 regulates NOTCH signaling | 14 | 1.08e-02 | -0.394000 | 2.61e-02 |
| Membrane Trafficking | 581 | 1.63e-59 | -0.393000 | 1.21e-56 |
| RHOB GTPase cycle | 69 | 1.73e-08 | -0.392000 | 1.86e-07 |
| ISG15 antiviral mechanism | 72 | 8.55e-09 | -0.392000 | 9.74e-08 |
| Interleukin-17 signaling | 68 | 2.32e-08 | -0.392000 | 2.45e-07 |
| Negative regulation of MAPK pathway | 43 | 8.89e-06 | -0.391000 | 5.37e-05 |
| Cytosolic tRNA aminoacylation | 24 | 9.19e-04 | -0.391000 | 3.10e-03 |
| Rev-mediated nuclear export of HIV RNA | 35 | 6.52e-05 | -0.390000 | 3.07e-04 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 27 | 4.52e-04 | -0.390000 | 1.72e-03 |
| Free fatty acids regulate insulin secretion | 10 | 3.32e-02 | -0.389000 | 6.92e-02 |
| Sema3A PAK dependent Axon repulsion | 16 | 7.14e-03 | -0.388000 | 1.83e-02 |
| Antiviral mechanism by IFN-stimulated genes | 80 | 1.96e-09 | -0.388000 | 2.79e-08 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 5.68e-05 | -0.388000 | 2.71e-04 |
| Intra-Golgi traffic | 43 | 1.13e-05 | -0.387000 | 6.47e-05 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 2.56e-04 | -0.386000 | 1.02e-03 |
| RHOBTB2 GTPase cycle | 23 | 1.38e-03 | -0.385000 | 4.39e-03 |
| Export of Viral Ribonucleoproteins from Nucleus | 33 | 1.30e-04 | -0.385000 | 5.67e-04 |
| SUMOylation of transcription cofactors | 44 | 1.05e-05 | -0.384000 | 6.09e-05 |
| Toll Like Receptor 9 (TLR9) Cascade | 91 | 2.43e-10 | -0.384000 | 4.50e-09 |
| Golgi Associated Vesicle Biogenesis | 55 | 8.53e-07 | -0.384000 | 6.28e-06 |
| The NLRP3 inflammasome | 15 | 1.04e-02 | -0.382000 | 2.53e-02 |
| L1CAM interactions | 94 | 1.52e-10 | -0.382000 | 2.89e-09 |
| CD28 dependent PI3K/Akt signaling | 18 | 5.27e-03 | -0.380000 | 1.40e-02 |
| GAB1 signalosome | 17 | 6.81e-03 | -0.379000 | 1.75e-02 |
| Role of LAT2/NTAL/LAB on calcium mobilization | 13 | 1.80e-02 | -0.379000 | 4.12e-02 |
| SUMOylation of immune response proteins | 11 | 2.98e-02 | -0.378000 | 6.30e-02 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 32 | 2.18e-04 | -0.378000 | 8.90e-04 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | 32 | 2.18e-04 | -0.378000 | 8.90e-04 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 21 | 2.76e-03 | -0.377000 | 8.01e-03 |
| Cristae formation | 31 | 3.31e-04 | 0.372000 | 1.30e-03 |
| Cellular response to heat stress | 96 | 2.79e-10 | -0.372000 | 5.05e-09 |
| Negative regulation of MET activity | 21 | 3.15e-03 | -0.372000 | 9.04e-03 |
| MyD88-independent TLR4 cascade | 94 | 4.54e-10 | -0.372000 | 7.64e-09 |
| TRIF(TICAM1)-mediated TLR4 signaling | 94 | 4.54e-10 | -0.372000 | 7.64e-09 |
| Gap junction trafficking and regulation | 20 | 4.02e-03 | -0.372000 | 1.11e-02 |
| FCERI mediated Ca+2 mobilization | 28 | 6.68e-04 | -0.371000 | 2.40e-03 |
| Oncogenic MAPK signaling | 77 | 1.73e-08 | -0.371000 | 1.86e-07 |
| COPI-dependent Golgi-to-ER retrograde traffic | 80 | 9.89e-09 | -0.371000 | 1.09e-07 |
| SARS-CoV-2 Infection | 71 | 6.68e-08 | -0.370000 | 6.51e-07 |
| Mitochondrial translation initiation | 90 | 1.33e-09 | 0.370000 | 1.97e-08 |
| Netrin-1 signaling | 45 | 1.79e-05 | -0.369000 | 9.66e-05 |
| Notch-HLH transcription pathway | 28 | 7.15e-04 | -0.369000 | 2.54e-03 |
| Rab regulation of trafficking | 120 | 3.10e-12 | -0.368000 | 7.29e-11 |
| Reactions specific to the complex N-glycan synthesis pathway | 10 | 4.38e-02 | -0.368000 | 8.77e-02 |
| G1/S-Specific Transcription | 29 | 5.98e-04 | 0.368000 | 2.18e-03 |
| Regulation of TP53 Activity through Acetylation | 29 | 6.14e-04 | -0.367000 | 2.23e-03 |
| Regulation of TP53 Expression and Degradation | 36 | 1.46e-04 | -0.366000 | 6.31e-04 |
| Cargo trafficking to the periciliary membrane | 47 | 1.43e-05 | -0.366000 | 7.91e-05 |
| Mitochondrial translation elongation | 90 | 2.08e-09 | 0.365000 | 2.86e-08 |
| Mitochondrial translation termination | 90 | 2.08e-09 | 0.365000 | 2.86e-08 |
| Protein ubiquitination | 73 | 6.79e-08 | -0.365000 | 6.58e-07 |
| CD209 (DC-SIGN) signaling | 20 | 4.75e-03 | -0.365000 | 1.28e-02 |
| Vesicle-mediated transport | 611 | 6.59e-54 | -0.365000 | 3.25e-51 |
| Asparagine N-linked glycosylation | 278 | 1.19e-25 | -0.364000 | 1.18e-23 |
| MyD88 dependent cascade initiated on endosome | 87 | 4.31e-09 | -0.364000 | 5.55e-08 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | 87 | 4.31e-09 | -0.364000 | 5.55e-08 |
| NS1 Mediated Effects on Host Pathways | 40 | 6.96e-05 | -0.363000 | 3.24e-04 |
| Keratan sulfate biosynthesis | 24 | 2.10e-03 | -0.363000 | 6.39e-03 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 86 | 6.11e-09 | -0.362000 | 7.36e-08 |
| PI3K events in ERBB2 signaling | 16 | 1.23e-02 | -0.361000 | 2.95e-02 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 3.81e-02 | -0.361000 | 7.82e-02 |
| HS-GAG biosynthesis | 27 | 1.17e-03 | -0.361000 | 3.82e-03 |
| Non-integrin membrane-ECM interactions | 42 | 5.30e-05 | -0.360000 | 2.54e-04 |
| Metal ion SLC transporters | 24 | 2.27e-03 | -0.360000 | 6.86e-03 |
| Defective C1GALT1C1 causes TNPS | 13 | 2.49e-02 | 0.359000 | 5.40e-02 |
| Assembly and cell surface presentation of NMDA receptors | 24 | 2.32e-03 | -0.359000 | 6.96e-03 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 2.51e-02 | -0.359000 | 5.43e-02 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 94 | 1.84e-09 | -0.359000 | 2.65e-08 |
| Glutathione conjugation | 30 | 6.81e-04 | 0.358000 | 2.44e-03 |
| Endosomal/Vacuolar pathway | 12 | 3.17e-02 | -0.358000 | 6.64e-02 |
| Blood group systems biosynthesis | 20 | 5.54e-03 | -0.358000 | 1.46e-02 |
| CRMPs in Sema3A signaling | 16 | 1.32e-02 | -0.358000 | 3.16e-02 |
| RHO GTPases activate IQGAPs | 11 | 3.99e-02 | -0.358000 | 8.15e-02 |
| Regulation of TP53 Degradation | 35 | 2.51e-04 | -0.357000 | 1.00e-03 |
| RND2 GTPase cycle | 41 | 7.44e-05 | -0.357000 | 3.43e-04 |
| Negative regulation of the PI3K/AKT network | 101 | 5.37e-10 | -0.357000 | 8.51e-09 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 14 | 2.10e-02 | -0.356000 | 4.72e-02 |
| Opioid Signalling | 81 | 3.06e-08 | -0.356000 | 3.12e-07 |
| COPII-mediated vesicle transport | 66 | 6.02e-07 | -0.355000 | 4.50e-06 |
| Regulation of MECP2 expression and activity | 30 | 7.66e-04 | -0.355000 | 2.68e-03 |
| SUMOylation of DNA replication proteins | 46 | 3.15e-05 | -0.355000 | 1.61e-04 |
| IRAK2 mediated activation of TAK1 complex | 10 | 5.25e-02 | -0.354000 | 1.02e-01 |
| RAB GEFs exchange GTP for GDP on RABs | 88 | 9.23e-09 | -0.354000 | 1.04e-07 |
| DARPP-32 events | 23 | 3.35e-03 | -0.353000 | 9.42e-03 |
| Listeria monocytogenes entry into host cells | 20 | 6.32e-03 | -0.353000 | 1.64e-02 |
| CaMK IV-mediated phosphorylation of CREB | 10 | 5.43e-02 | -0.351000 | 1.05e-01 |
| Resolution of D-Loop Structures | 33 | 4.75e-04 | 0.351000 | 1.78e-03 |
| Folding of actin by CCT/TriC | 10 | 5.45e-02 | -0.351000 | 1.05e-01 |
| Regulation of HSF1-mediated heat shock response | 78 | 8.65e-08 | -0.350000 | 8.27e-07 |
| Cargo concentration in the ER | 31 | 7.41e-04 | -0.350000 | 2.59e-03 |
| p75NTR signals via NF-kB | 16 | 1.56e-02 | -0.349000 | 3.65e-02 |
| Myogenesis | 25 | 2.53e-03 | -0.349000 | 7.43e-03 |
| Inflammasomes | 20 | 7.20e-03 | -0.347000 | 1.84e-02 |
| NOTCH1 Intracellular Domain Regulates Transcription | 47 | 3.86e-05 | -0.347000 | 1.93e-04 |
| Signaling by MET | 66 | 1.11e-06 | -0.347000 | 7.93e-06 |
| Clathrin-mediated endocytosis | 137 | 2.72e-12 | -0.346000 | 6.50e-11 |
| SRP-dependent cotranslational protein targeting to membrane | 110 | 3.95e-10 | 0.345000 | 6.88e-09 |
| Defective GALNT3 causes HFTC | 12 | 3.96e-02 | 0.343000 | 8.10e-02 |
| Mitochondrial translation | 96 | 6.45e-09 | 0.343000 | 7.67e-08 |
| Signalling to ERKs | 33 | 7.24e-04 | -0.340000 | 2.55e-03 |
| Platelet Aggregation (Plug Formation) | 29 | 1.57e-03 | -0.339000 | 4.92e-03 |
| RND3 GTPase cycle | 41 | 1.82e-04 | -0.338000 | 7.68e-04 |
| RND1 GTPase cycle | 42 | 1.52e-04 | -0.338000 | 6.53e-04 |
| Cell-Cell communication | 108 | 1.30e-09 | -0.338000 | 1.94e-08 |
| Signaling by NTRK3 (TRKC) | 16 | 1.96e-02 | -0.337000 | 4.44e-02 |
| E3 ubiquitin ligases ubiquitinate target proteins | 53 | 2.26e-05 | -0.336000 | 1.19e-04 |
| Apoptotic cleavage of cellular proteins | 35 | 5.81e-04 | -0.336000 | 2.13e-03 |
| HSF1 activation | 26 | 3.06e-03 | -0.336000 | 8.83e-03 |
| Selenoamino acid metabolism | 115 | 5.10e-10 | 0.335000 | 8.22e-09 |
| Signaling by EGFR | 50 | 4.21e-05 | -0.335000 | 2.07e-04 |
| Physiological factors | 10 | 6.71e-02 | -0.334000 | 1.24e-01 |
| Diseases of signal transduction by growth factor receptors and second messengers | 411 | 2.48e-31 | -0.334000 | 3.67e-29 |
| Regulation of lipid metabolism by PPARalpha | 113 | 8.83e-10 | -0.334000 | 1.36e-08 |
| SARS-CoV Infections | 151 | 1.77e-12 | -0.332000 | 4.30e-11 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 1.15e-03 | 0.332000 | 3.80e-03 |
| PPARA activates gene expression | 111 | 1.51e-09 | -0.332000 | 2.22e-08 |
| Metabolism of amine-derived hormones | 12 | 4.66e-02 | 0.332000 | 9.22e-02 |
| HCMV Early Events | 82 | 2.14e-07 | -0.331000 | 1.82e-06 |
| PI3K/AKT Signaling in Cancer | 94 | 3.11e-08 | -0.330000 | 3.13e-07 |
| NGF-stimulated transcription | 38 | 4.30e-04 | -0.330000 | 1.65e-03 |
| Ovarian tumor domain proteases | 38 | 4.30e-04 | -0.330000 | 1.65e-03 |
| SUMOylation of chromatin organization proteins | 57 | 1.76e-05 | -0.329000 | 9.53e-05 |
| FLT3 Signaling | 36 | 6.49e-04 | -0.328000 | 2.34e-03 |
| EGFR downregulation | 31 | 1.57e-03 | -0.328000 | 4.94e-03 |
| Signaling by BRAF and RAF1 fusions | 60 | 1.15e-05 | -0.327000 | 6.56e-05 |
| ADP signalling through P2Y purinoceptor 1 | 22 | 7.98e-03 | -0.327000 | 2.02e-02 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 33 | 1.19e-03 | -0.326000 | 3.87e-03 |
| Prolactin receptor signaling | 11 | 6.15e-02 | -0.326000 | 1.17e-01 |
| Regulated proteolysis of p75NTR | 11 | 6.26e-02 | -0.324000 | 1.18e-01 |
| Interleukin-20 family signaling | 19 | 1.44e-02 | -0.324000 | 3.43e-02 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | 110 | 4.70e-09 | 0.323000 | 5.90e-08 |
| Thrombin signalling through proteinase activated receptors (PARs) | 28 | 3.11e-03 | -0.323000 | 8.94e-03 |
| GPVI-mediated activation cascade | 30 | 2.22e-03 | -0.323000 | 6.73e-03 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | 37 | 6.83e-04 | -0.323000 | 2.44e-03 |
| PKMTs methylate histone lysines | 46 | 1.55e-04 | -0.322000 | 6.67e-04 |
| Glucagon signaling in metabolic regulation | 28 | 3.19e-03 | -0.322000 | 9.09e-03 |
| Gap junction trafficking | 18 | 1.82e-02 | -0.322000 | 4.16e-02 |
| RHO GTPases activate CIT | 19 | 1.52e-02 | -0.322000 | 3.58e-02 |
| TRAF3-dependent IRF activation pathway | 14 | 3.77e-02 | -0.321000 | 7.76e-02 |
| ERBB2 Regulates Cell Motility | 15 | 3.20e-02 | -0.320000 | 6.70e-02 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 6.73e-02 | -0.319000 | 1.24e-01 |
| Signaling by RAF1 mutants | 36 | 9.63e-04 | -0.318000 | 3.23e-03 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 17 | 2.35e-02 | -0.317000 | 5.16e-02 |
| RHOA GTPase cycle | 146 | 3.99e-11 | -0.316000 | 8.08e-10 |
| Ca2+ pathway | 59 | 2.69e-05 | -0.316000 | 1.40e-04 |
| Attenuation phase | 23 | 8.72e-03 | -0.316000 | 2.18e-02 |
| Elastic fibre formation | 37 | 8.91e-04 | -0.316000 | 3.03e-03 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 109 | 1.29e-08 | 0.315000 | 1.40e-07 |
| Activation of the pre-replicative complex | 33 | 1.75e-03 | 0.315000 | 5.46e-03 |
| EPH-Ephrin signaling | 91 | 2.09e-07 | -0.315000 | 1.79e-06 |
| Negative regulators of DDX58/IFIH1 signaling | 35 | 1.29e-03 | -0.314000 | 4.17e-03 |
| RAC1 GTPase cycle | 178 | 4.59e-13 | -0.314000 | 1.31e-11 |
| FGFR1 mutant receptor activation | 29 | 3.48e-03 | -0.313000 | 9.70e-03 |
| ESR-mediated signaling | 176 | 7.99e-13 | -0.313000 | 2.11e-11 |
| Activation of NMDA receptors and postsynaptic events | 70 | 6.33e-06 | -0.312000 | 3.88e-05 |
| trans-Golgi Network Vesicle Budding | 71 | 5.48e-06 | -0.312000 | 3.44e-05 |
| Diseases associated with visual transduction | 10 | 8.81e-02 | 0.311000 | 1.56e-01 |
| Diseases of the neuronal system | 10 | 8.81e-02 | 0.311000 | 1.56e-01 |
| Retinoid cycle disease events | 10 | 8.81e-02 | 0.311000 | 1.56e-01 |
| Post NMDA receptor activation events | 57 | 4.74e-05 | -0.311000 | 2.31e-04 |
| RHOBTB3 ATPase cycle | 10 | 8.88e-02 | -0.311000 | 1.57e-01 |
| tRNA Aminoacylation | 42 | 4.92e-04 | -0.311000 | 1.83e-03 |
| RHO GTPase cycle | 435 | 8.10e-29 | -0.311000 | 1.00e-26 |
| RAB geranylgeranylation | 62 | 2.36e-05 | -0.310000 | 1.24e-04 |
| Membrane binding and targetting of GAG proteins | 14 | 4.46e-02 | -0.310000 | 8.89e-02 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | 14 | 4.46e-02 | -0.310000 | 8.89e-02 |
| Intracellular signaling by second messengers | 293 | 6.34e-20 | -0.310000 | 4.47e-18 |
| SUMOylation of RNA binding proteins | 47 | 2.41e-04 | -0.309000 | 9.66e-04 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 35 | 1.54e-03 | -0.309000 | 4.85e-03 |
| The role of Nef in HIV-1 replication and disease pathogenesis | 23 | 1.04e-02 | -0.309000 | 2.53e-02 |
| Calnexin/calreticulin cycle | 26 | 6.54e-03 | -0.308000 | 1.69e-02 |
| Effects of PIP2 hydrolysis | 24 | 9.04e-03 | -0.308000 | 2.24e-02 |
| G alpha (z) signalling events | 40 | 7.72e-04 | -0.307000 | 2.68e-03 |
| FLT3 signaling in disease | 28 | 4.95e-03 | -0.307000 | 1.33e-02 |
| BBSome-mediated cargo-targeting to cilium | 21 | 1.50e-02 | -0.307000 | 3.55e-02 |
| Nonhomologous End-Joining (NHEJ) | 43 | 5.06e-04 | -0.306000 | 1.87e-03 |
| Cargo recognition for clathrin-mediated endocytosis | 99 | 1.36e-07 | -0.306000 | 1.25e-06 |
| TNFR1-induced NFkappaB signaling pathway | 26 | 6.94e-03 | -0.306000 | 1.78e-02 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 10 | 9.43e-02 | -0.306000 | 1.65e-01 |
| Keratan sulfate/keratin metabolism | 29 | 4.45e-03 | -0.305000 | 1.21e-02 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 1.79e-03 | -0.305000 | 5.54e-03 |
| Selective autophagy | 58 | 6.90e-05 | -0.302000 | 3.22e-04 |
| AKT phosphorylates targets in the nucleus | 10 | 9.93e-02 | -0.301000 | 1.72e-01 |
| Potential therapeutics for SARS | 82 | 2.57e-06 | -0.300000 | 1.75e-05 |
| Signaling by PDGF | 53 | 1.56e-04 | -0.300000 | 6.67e-04 |
| Signaling by FGFR1 in disease | 36 | 1.89e-03 | -0.299000 | 5.84e-03 |
| Diseases associated with glycosylation precursor biosynthesis | 18 | 2.80e-02 | -0.299000 | 5.98e-02 |
| Signaling by NOTCH1 | 72 | 1.16e-05 | -0.299000 | 6.61e-05 |
| Laminin interactions | 23 | 1.32e-02 | -0.298000 | 3.16e-02 |
| Mitophagy | 28 | 6.29e-03 | -0.298000 | 1.64e-02 |
| Pentose phosphate pathway | 13 | 6.31e-02 | -0.298000 | 1.18e-01 |
| Autophagy | 126 | 7.68e-09 | -0.298000 | 8.88e-08 |
| Cap-dependent Translation Initiation | 117 | 2.64e-08 | 0.298000 | 2.73e-07 |
| Eukaryotic Translation Initiation | 117 | 2.64e-08 | 0.298000 | 2.73e-07 |
| mRNA decay by 5’ to 3’ exoribonuclease | 15 | 4.63e-02 | -0.297000 | 9.18e-02 |
| Transcriptional regulation of white adipocyte differentiation | 82 | 3.45e-06 | -0.296000 | 2.24e-05 |
| Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 4.72e-02 | -0.296000 | 9.32e-02 |
| WNT ligand biogenesis and trafficking | 24 | 1.23e-02 | -0.295000 | 2.95e-02 |
| Late Phase of HIV Life Cycle | 135 | 3.16e-09 | -0.295000 | 4.22e-08 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 113 | 6.31e-08 | 0.294000 | 6.19e-07 |
| Nonsense-Mediated Decay (NMD) | 113 | 6.31e-08 | 0.294000 | 6.19e-07 |
| PI3K events in ERBB4 signaling | 10 | 1.08e-01 | -0.293000 | 1.85e-01 |
| SUMOylation of DNA damage response and repair proteins | 76 | 9.79e-06 | -0.293000 | 5.85e-05 |
| Toll Like Receptor 4 (TLR4) Cascade | 124 | 1.84e-08 | -0.292000 | 1.96e-07 |
| Reduction of cytosolic Ca++ levels | 12 | 7.98e-02 | -0.292000 | 1.43e-01 |
| Signaling by Non-Receptor Tyrosine Kinases | 54 | 2.04e-04 | -0.292000 | 8.46e-04 |
| Signaling by PTK6 | 54 | 2.04e-04 | -0.292000 | 8.46e-04 |
| mRNA decay by 3’ to 5’ exoribonuclease | 16 | 4.35e-02 | 0.291000 | 8.74e-02 |
| Translation of Structural Proteins | 29 | 6.61e-03 | -0.291000 | 1.71e-02 |
| Nuclear Pore Complex (NPC) Disassembly | 36 | 2.53e-03 | -0.291000 | 7.43e-03 |
| HCMV Infection | 106 | 2.28e-07 | -0.291000 | 1.93e-06 |
| TRAF6 mediated IRF7 activation | 16 | 4.41e-02 | -0.291000 | 8.83e-02 |
| NR1H2 and NR1H3-mediated signaling | 43 | 9.76e-04 | -0.291000 | 3.27e-03 |
| PIP3 activates AKT signaling | 256 | 1.29e-15 | -0.290000 | 5.45e-14 |
| Processing of Intronless Pre-mRNAs | 19 | 2.88e-02 | -0.290000 | 6.13e-02 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 96 | 9.53e-07 | -0.289000 | 6.82e-06 |
| Toll Like Receptor 2 (TLR2) Cascade | 96 | 9.53e-07 | -0.289000 | 6.82e-06 |
| Toll Like Receptor TLR1:TLR2 Cascade | 96 | 9.53e-07 | -0.289000 | 6.82e-06 |
| Toll Like Receptor TLR6:TLR2 Cascade | 96 | 9.53e-07 | -0.289000 | 6.82e-06 |
| Negative regulation of FGFR1 signaling | 31 | 5.35e-03 | -0.289000 | 1.42e-02 |
| Antigen processing: Ubiquitination & Proteasome degradation | 292 | 2.33e-17 | -0.288000 | 1.34e-15 |
| Chromatin modifying enzymes | 225 | 9.62e-14 | -0.288000 | 3.17e-12 |
| Chromatin organization | 225 | 9.62e-14 | -0.288000 | 3.17e-12 |
| Unfolded Protein Response (UPR) | 92 | 1.96e-06 | -0.287000 | 1.35e-05 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | 20 | 2.67e-02 | -0.286000 | 5.72e-02 |
| PCNA-Dependent Long Patch Base Excision Repair | 21 | 2.32e-02 | 0.286000 | 5.12e-02 |
| eNOS activation | 11 | 1.02e-01 | -0.285000 | 1.76e-01 |
| NOTCH3 Intracellular Domain Regulates Transcription | 22 | 2.08e-02 | -0.285000 | 4.67e-02 |
| Protein-protein interactions at synapses | 78 | 1.37e-05 | -0.285000 | 7.61e-05 |
| Unblocking of NMDA receptors, glutamate binding and activation | 19 | 3.17e-02 | -0.285000 | 6.64e-02 |
| Glutathione synthesis and recycling | 12 | 8.80e-02 | 0.284000 | 1.56e-01 |
| HSF1-dependent transactivation | 33 | 4.75e-03 | -0.284000 | 1.28e-02 |
| Translocation of ZAP-70 to Immunological synapse | 15 | 5.69e-02 | 0.284000 | 1.09e-01 |
| Activation of the AP-1 family of transcription factors | 10 | 1.20e-01 | -0.284000 | 2.01e-01 |
| Toll-like Receptor Cascades | 142 | 5.27e-09 | -0.284000 | 6.52e-08 |
| Activation of Matrix Metalloproteinases | 27 | 1.09e-02 | -0.283000 | 2.63e-02 |
| Interleukin-7 signaling | 23 | 1.94e-02 | -0.282000 | 4.40e-02 |
| RNA polymerase II transcribes snRNA genes | 71 | 4.09e-05 | -0.281000 | 2.03e-04 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 40 | 2.10e-03 | -0.281000 | 6.39e-03 |
| Signaling by RAS mutants | 40 | 2.10e-03 | -0.281000 | 6.39e-03 |
| Signaling by moderate kinase activity BRAF mutants | 40 | 2.10e-03 | -0.281000 | 6.39e-03 |
| Signaling downstream of RAS mutants | 40 | 2.10e-03 | -0.281000 | 6.39e-03 |
| Phospholipid metabolism | 190 | 2.39e-11 | -0.281000 | 4.99e-10 |
| Regulation of expression of SLITs and ROBOs | 166 | 4.35e-10 | 0.280000 | 7.48e-09 |
| CDC42 GTPase cycle | 153 | 2.36e-09 | -0.279000 | 3.21e-08 |
| MTOR signalling | 40 | 2.24e-03 | -0.279000 | 6.78e-03 |
| Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 644 | 7.03e-34 | -0.279000 | 1.49e-31 |
| Fanconi Anemia Pathway | 36 | 3.76e-03 | 0.279000 | 1.04e-02 |
| Formation of the cornified envelope | 31 | 7.19e-03 | -0.279000 | 1.84e-02 |
| HIV Life Cycle | 147 | 5.28e-09 | -0.279000 | 6.52e-08 |
| Role of phospholipids in phagocytosis | 22 | 2.38e-02 | -0.278000 | 5.21e-02 |
| Deadenylation-dependent mRNA decay | 53 | 4.54e-04 | -0.278000 | 1.72e-03 |
| Nuclear Envelope Breakdown | 53 | 4.65e-04 | -0.278000 | 1.75e-03 |
| Cell junction organization | 78 | 2.19e-05 | -0.278000 | 1.16e-04 |
| Macroautophagy | 112 | 3.72e-07 | -0.278000 | 3.01e-06 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 20 | 3.16e-02 | -0.278000 | 6.64e-02 |
| Cytosolic sensors of pathogen-associated DNA | 62 | 1.56e-04 | -0.278000 | 6.67e-04 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | 13 | 8.34e-02 | -0.277000 | 1.48e-01 |
| Signaling by ERBB2 | 50 | 6.95e-04 | -0.277000 | 2.47e-03 |
| Semaphorin interactions | 60 | 2.04e-04 | -0.277000 | 8.46e-04 |
| Defective B4GALT7 causes EDS, progeroid type | 19 | 3.65e-02 | -0.277000 | 7.56e-02 |
| Signaling by Rho GTPases | 628 | 1.89e-32 | -0.276000 | 3.49e-30 |
| The citric acid (TCA) cycle and respiratory electron transport | 173 | 3.93e-10 | 0.275000 | 6.88e-09 |
| Dopamine Neurotransmitter Release Cycle | 22 | 2.57e-02 | -0.275000 | 5.53e-02 |
| Retrograde neurotrophin signalling | 14 | 7.58e-02 | -0.274000 | 1.37e-01 |
| Cytochrome c-mediated apoptotic response | 13 | 8.75e-02 | -0.274000 | 1.55e-01 |
| Assembly Of The HIV Virion | 16 | 5.91e-02 | -0.272000 | 1.12e-01 |
| Synthesis of substrates in N-glycan biosythesis | 61 | 2.32e-04 | -0.272000 | 9.32e-04 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 51 | 7.72e-04 | -0.272000 | 2.68e-03 |
| Erythropoietin activates RAS | 14 | 7.87e-02 | -0.271000 | 1.41e-01 |
| Deubiquitination | 249 | 1.58e-13 | -0.271000 | 4.68e-12 |
| RAS processing | 19 | 4.17e-02 | -0.270000 | 8.41e-02 |
| SUMOylation of intracellular receptors | 27 | 1.52e-02 | -0.270000 | 3.58e-02 |
| Negative regulation of FGFR3 signaling | 27 | 1.55e-02 | -0.269000 | 3.64e-02 |
| Class I MHC mediated antigen processing & presentation | 354 | 3.32e-18 | -0.269000 | 2.24e-16 |
| Signaling by FGFR3 | 38 | 4.22e-03 | -0.268000 | 1.16e-02 |
| Leishmania infection | 191 | 1.62e-10 | -0.268000 | 3.04e-09 |
| Rap1 signalling | 15 | 7.29e-02 | -0.267000 | 1.33e-01 |
| Long-term potentiation | 21 | 3.39e-02 | -0.267000 | 7.05e-02 |
| Crosslinking of collagen fibrils | 10 | 1.43e-01 | 0.267000 | 2.31e-01 |
| Signaling by ERBB2 ECD mutants | 16 | 6.43e-02 | -0.267000 | 1.20e-01 |
| Integration of energy metabolism | 96 | 6.05e-06 | -0.267000 | 3.75e-05 |
| Signaling by Receptor Tyrosine Kinases | 481 | 8.43e-24 | -0.267000 | 7.35e-22 |
| Dectin-2 family | 18 | 5.00e-02 | 0.267000 | 9.81e-02 |
| TICAM1, RIP1-mediated IKK complex recruitment | 18 | 5.07e-02 | -0.266000 | 9.92e-02 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | 66 | 1.87e-04 | -0.266000 | 7.86e-04 |
| PECAM1 interactions | 11 | 1.27e-01 | -0.265000 | 2.11e-01 |
| Metabolism of Angiotensinogen to Angiotensins | 12 | 1.11e-01 | 0.265000 | 1.89e-01 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | 20 | 4.03e-02 | -0.265000 | 8.19e-02 |
| HDR through Homologous Recombination (HRR) | 66 | 2.02e-04 | 0.264000 | 8.43e-04 |
| DAP12 interactions | 33 | 8.59e-03 | -0.264000 | 2.15e-02 |
| Glucose metabolism | 83 | 3.13e-05 | -0.264000 | 1.61e-04 |
| InlB-mediated entry of Listeria monocytogenes into host cell | 15 | 7.67e-02 | -0.264000 | 1.39e-01 |
| IRAK1 recruits IKK complex | 10 | 1.49e-01 | -0.264000 | 2.38e-01 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 1.49e-01 | -0.264000 | 2.38e-01 |
| Uptake and actions of bacterial toxins | 28 | 1.60e-02 | -0.263000 | 3.71e-02 |
| Constitutive Signaling by EGFRvIII | 15 | 7.79e-02 | -0.263000 | 1.40e-01 |
| Signaling by EGFRvIII in Cancer | 15 | 7.79e-02 | -0.263000 | 1.40e-01 |
| Interferon Signaling | 175 | 2.02e-09 | -0.262000 | 2.85e-08 |
| Signaling by high-kinase activity BRAF mutants | 31 | 1.14e-02 | -0.262000 | 2.75e-02 |
| Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 1.65e-02 | -0.262000 | 3.81e-02 |
| Alpha-protein kinase 1 signaling pathway | 11 | 1.35e-01 | -0.260000 | 2.20e-01 |
| SUMOylation | 170 | 5.34e-09 | -0.259000 | 6.54e-08 |
| Costimulation by the CD28 family | 59 | 5.80e-04 | -0.259000 | 2.13e-03 |
| Diseases associated with glycosaminoglycan metabolism | 36 | 7.33e-03 | -0.258000 | 1.87e-02 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 26 | 2.29e-02 | -0.258000 | 5.06e-02 |
| Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 1.34e-03 | -0.257000 | 4.29e-03 |
| Nuclear Receptor transcription pathway | 46 | 2.56e-03 | -0.257000 | 7.50e-03 |
| SARS-CoV-1 Infection | 50 | 1.69e-03 | -0.257000 | 5.28e-03 |
| RNA Polymerase II Pre-transcription Events | 80 | 7.21e-05 | -0.257000 | 3.35e-04 |
| Platelet Adhesion to exposed collagen | 10 | 1.60e-01 | -0.257000 | 2.53e-01 |
| FCERI mediated MAPK activation | 29 | 1.68e-02 | -0.256000 | 3.87e-02 |
| Ub-specific processing proteases | 177 | 3.90e-09 | -0.256000 | 5.15e-08 |
| Thromboxane signalling through TP receptor | 21 | 4.22e-02 | -0.256000 | 8.47e-02 |
| Signaling by WNT | 281 | 1.47e-13 | -0.256000 | 4.44e-12 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 27 | 2.15e-02 | -0.256000 | 4.80e-02 |
| APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 3.05e-02 | 0.255000 | 6.45e-02 |
| Constitutive Signaling by Aberrant PI3K in Cancer | 67 | 3.07e-04 | -0.255000 | 1.21e-03 |
| Collagen degradation | 37 | 7.38e-03 | -0.254000 | 1.87e-02 |
| Regulation of PTEN gene transcription | 61 | 5.87e-04 | -0.254000 | 2.15e-03 |
| FOXO-mediated transcription | 59 | 7.41e-04 | -0.254000 | 2.59e-03 |
| Platelet calcium homeostasis | 25 | 2.86e-02 | -0.253000 | 6.09e-02 |
| RHO GTPases Activate ROCKs | 19 | 5.66e-02 | -0.253000 | 1.08e-01 |
| Budding and maturation of HIV virion | 28 | 2.08e-02 | -0.252000 | 4.68e-02 |
| Transcriptional Regulation by MECP2 | 56 | 1.09e-03 | -0.252000 | 3.64e-03 |
| Presynaptic depolarization and calcium channel opening | 11 | 1.48e-01 | 0.252000 | 2.37e-01 |
| Aspartate and asparagine metabolism | 10 | 1.68e-01 | 0.252000 | 2.62e-01 |
| Endogenous sterols | 21 | 4.58e-02 | -0.252000 | 9.12e-02 |
| Death Receptor Signalling | 138 | 3.51e-07 | -0.251000 | 2.85e-06 |
| Post-translational protein modification | 1277 | 6.02e-52 | -0.251000 | 2.23e-49 |
| Fatty acyl-CoA biosynthesis | 34 | 1.14e-02 | -0.251000 | 2.75e-02 |
| SUMO E3 ligases SUMOylate target proteins | 164 | 3.08e-08 | -0.250000 | 3.12e-07 |
| Signaling by FGFR1 | 48 | 2.71e-03 | -0.250000 | 7.89e-03 |
| Cellular response to starvation | 150 | 1.31e-07 | 0.249000 | 1.21e-06 |
| ADP signalling through P2Y purinoceptor 12 | 17 | 7.51e-02 | -0.249000 | 1.36e-01 |
| Signaling by NTRK2 (TRKB) | 24 | 3.49e-02 | -0.249000 | 7.26e-02 |
| Formation of RNA Pol II elongation complex | 57 | 1.17e-03 | -0.249000 | 3.82e-03 |
| RNA Polymerase II Transcription Elongation | 57 | 1.17e-03 | -0.249000 | 3.82e-03 |
| G beta:gamma signalling through CDC42 | 17 | 7.66e-02 | -0.248000 | 1.39e-01 |
| Acetylcholine regulates insulin secretion | 10 | 1.74e-01 | -0.248000 | 2.69e-01 |
| Inositol phosphate metabolism | 46 | 3.66e-03 | -0.248000 | 1.02e-02 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 8.64e-02 | -0.248000 | 1.53e-01 |
| Activation of ATR in response to replication stress | 37 | 9.25e-03 | 0.247000 | 2.29e-02 |
| Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 9.75e-02 | -0.247000 | 1.69e-01 |
| Mitochondrial tRNA aminoacylation | 21 | 5.02e-02 | -0.247000 | 9.85e-02 |
| Signal Transduction | 2187 | 8.01e-82 | -0.246000 | 1.19e-78 |
| TNF signaling | 44 | 4.77e-03 | -0.246000 | 1.28e-02 |
| Activation of BH3-only proteins | 29 | 2.21e-02 | -0.245000 | 4.92e-02 |
| Signaling by Nuclear Receptors | 243 | 4.22e-11 | -0.245000 | 8.32e-10 |
| Defective B3GAT3 causes JDSSDHD | 19 | 6.48e-02 | -0.245000 | 1.21e-01 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | 19 | 6.50e-02 | -0.245000 | 1.21e-01 |
| Apoptotic execution phase | 48 | 3.39e-03 | -0.244000 | 9.51e-03 |
| Sodium/Calcium exchangers | 11 | 1.62e-01 | -0.244000 | 2.55e-01 |
| PI-3K cascade:FGFR1 | 19 | 6.60e-02 | -0.244000 | 1.22e-01 |
| Dermatan sulfate biosynthesis | 11 | 1.63e-01 | -0.243000 | 2.56e-01 |
| Interleukin receptor SHC signaling | 21 | 5.44e-02 | -0.242000 | 1.05e-01 |
| Transcription of the HIV genome | 69 | 4.97e-04 | -0.242000 | 1.84e-03 |
| Signaling by ERBB2 in Cancer | 26 | 3.26e-02 | -0.242000 | 6.81e-02 |
| Estrogen-dependent gene expression | 110 | 1.19e-05 | -0.242000 | 6.71e-05 |
| Sema4D in semaphorin signaling | 24 | 4.05e-02 | -0.242000 | 8.23e-02 |
| Influenza Viral RNA Transcription and Replication | 134 | 1.36e-06 | 0.241000 | 9.66e-06 |
| MAPK family signaling cascades | 299 | 6.68e-13 | -0.241000 | 1.80e-11 |
| Synthesis of PA | 33 | 1.65e-02 | -0.241000 | 3.80e-02 |
| GRB2 events in ERBB2 signaling | 16 | 9.50e-02 | -0.241000 | 1.66e-01 |
| Viral Messenger RNA Synthesis | 44 | 5.70e-03 | -0.241000 | 1.50e-02 |
| MHC class II antigen presentation | 99 | 3.44e-05 | -0.241000 | 1.74e-04 |
| Defects in cobalamin (B12) metabolism | 13 | 1.34e-01 | -0.240000 | 2.18e-01 |
| Defects in vitamin and cofactor metabolism | 21 | 5.76e-02 | -0.239000 | 1.10e-01 |
| HCMV Late Events | 78 | 2.61e-04 | -0.239000 | 1.03e-03 |
| Neurexins and neuroligins | 50 | 3.45e-03 | -0.239000 | 9.64e-03 |
| Activation of Ca-permeable Kainate Receptor | 10 | 1.92e-01 | -0.238000 | 2.87e-01 |
| Ionotropic activity of kainate receptors | 10 | 1.92e-01 | -0.238000 | 2.87e-01 |
| Metabolism of cofactors | 19 | 7.19e-02 | 0.238000 | 1.32e-01 |
| p75NTR recruits signalling complexes | 13 | 1.37e-01 | -0.238000 | 2.22e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 9.90e-02 | -0.238000 | 1.72e-01 |
| SLC transporter disorders | 81 | 2.18e-04 | -0.238000 | 8.90e-04 |
| NF-kB is activated and signals survival | 13 | 1.38e-01 | -0.237000 | 2.24e-01 |
| SHC1 events in ERBB2 signaling | 22 | 5.40e-02 | -0.237000 | 1.04e-01 |
| Scavenging by Class A Receptors | 17 | 9.23e-02 | 0.236000 | 1.62e-01 |
| Formation of the ternary complex, and subsequently, the 43S complex | 50 | 3.92e-03 | 0.236000 | 1.08e-02 |
| EPH-ephrin mediated repulsion of cells | 48 | 4.74e-03 | -0.236000 | 1.28e-02 |
| Platelet activation, signaling and aggregation | 226 | 1.08e-09 | -0.235000 | 1.63e-08 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 51 | 3.77e-03 | -0.234000 | 1.04e-02 |
| Mitotic Prophase | 104 | 3.74e-05 | -0.234000 | 1.88e-04 |
| mTORC1-mediated signalling | 24 | 4.75e-02 | -0.234000 | 9.37e-02 |
| Adaptive Immune System | 651 | 1.94e-24 | -0.234000 | 1.79e-22 |
| Regulation of TP53 Activity | 155 | 5.14e-07 | -0.234000 | 3.92e-06 |
| Cell recruitment (pro-inflammatory response) | 23 | 5.25e-02 | -0.233000 | 1.02e-01 |
| Purinergic signaling in leishmaniasis infection | 23 | 5.25e-02 | -0.233000 | 1.02e-01 |
| HATs acetylate histones | 101 | 5.07e-05 | -0.233000 | 2.44e-04 |
| Cellular hexose transport | 17 | 9.68e-02 | 0.233000 | 1.69e-01 |
| Acetylcholine binding and downstream events | 10 | 2.03e-01 | 0.232000 | 3.00e-01 |
| Postsynaptic nicotinic acetylcholine receptors | 10 | 2.03e-01 | 0.232000 | 3.00e-01 |
| Metabolism of fat-soluble vitamins | 36 | 1.58e-02 | -0.232000 | 3.68e-02 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 57 | 2.40e-03 | -0.232000 | 7.14e-03 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | 57 | 2.40e-03 | -0.232000 | 7.14e-03 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 57 | 2.40e-03 | -0.232000 | 7.14e-03 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | 57 | 2.40e-03 | -0.232000 | 7.14e-03 |
| Signaling by NOTCH1 in Cancer | 57 | 2.40e-03 | -0.232000 | 7.14e-03 |
| Nuclear Envelope (NE) Reassembly | 73 | 6.15e-04 | -0.232000 | 2.23e-03 |
| Metabolism of steroids | 136 | 3.19e-06 | -0.231000 | 2.11e-05 |
| Condensation of Prometaphase Chromosomes | 11 | 1.84e-01 | 0.231000 | 2.78e-01 |
| Purine catabolism | 17 | 9.93e-02 | 0.231000 | 1.72e-01 |
| Cytosolic iron-sulfur cluster assembly | 13 | 1.52e-01 | 0.229000 | 2.43e-01 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 35 | 1.88e-02 | -0.229000 | 4.29e-02 |
| Maturation of nucleoprotein | 11 | 1.88e-01 | -0.229000 | 2.83e-01 |
| p75 NTR receptor-mediated signalling | 95 | 1.14e-04 | -0.229000 | 5.08e-04 |
| PINK1-PRKN Mediated Mitophagy | 21 | 7.01e-02 | -0.228000 | 1.28e-01 |
| HIV Infection | 222 | 4.56e-09 | -0.228000 | 5.77e-08 |
| SLBP independent Processing of Histone Pre-mRNAs | 10 | 2.14e-01 | 0.227000 | 3.13e-01 |
| Vasopressin regulates renal water homeostasis via Aquaporins | 36 | 1.84e-02 | -0.227000 | 4.21e-02 |
| Glutamate Neurotransmitter Release Cycle | 23 | 6.02e-02 | -0.226000 | 1.14e-01 |
| Fc epsilon receptor (FCERI) signaling | 127 | 1.05e-05 | -0.226000 | 6.09e-05 |
| Regulation of TLR by endogenous ligand | 15 | 1.29e-01 | 0.226000 | 2.13e-01 |
| RHO GTPases activate PAKs | 21 | 7.28e-02 | -0.226000 | 1.33e-01 |
| Interleukin-6 family signaling | 23 | 6.06e-02 | -0.226000 | 1.15e-01 |
| Phase 2 - plateau phase | 13 | 1.59e-01 | 0.226000 | 2.51e-01 |
| Insulin receptor signalling cascade | 50 | 5.87e-03 | -0.225000 | 1.54e-02 |
| MET activates RAS signaling | 11 | 1.96e-01 | -0.225000 | 2.92e-01 |
| Intrinsic Pathway for Apoptosis | 53 | 4.71e-03 | -0.224000 | 1.28e-02 |
| Formation of tubulin folding intermediates by CCT/TriC | 23 | 6.27e-02 | -0.224000 | 1.18e-01 |
| PI-3K cascade:FGFR3 | 16 | 1.21e-01 | -0.224000 | 2.01e-01 |
| Polo-like kinase mediated events | 16 | 1.21e-01 | 0.224000 | 2.02e-01 |
| DAP12 signaling | 26 | 4.84e-02 | -0.224000 | 9.54e-02 |
| RHO GTPase Effectors | 257 | 6.45e-10 | -0.224000 | 1.01e-08 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 5.38e-02 | 0.223000 | 1.04e-01 |
| Pexophagy | 11 | 2.01e-01 | -0.223000 | 2.98e-01 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 4.96e-02 | 0.222000 | 9.76e-02 |
| Negative regulation of FGFR4 signaling | 28 | 4.17e-02 | -0.222000 | 8.41e-02 |
| Interleukin-2 family signaling | 34 | 2.48e-02 | -0.222000 | 5.39e-02 |
| LDL clearance | 16 | 1.24e-01 | -0.222000 | 2.06e-01 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 1.68e-01 | -0.221000 | 2.61e-01 |
| TCF dependent signaling in response to WNT | 188 | 1.73e-07 | -0.221000 | 1.50e-06 |
| PI3K Cascade | 41 | 1.45e-02 | -0.221000 | 3.44e-02 |
| MAPK1/MAPK3 signaling | 260 | 9.38e-10 | -0.220000 | 1.43e-08 |
| G-protein beta:gamma signalling | 29 | 4.03e-02 | -0.220000 | 8.19e-02 |
| Glycosaminoglycan metabolism | 111 | 6.24e-05 | -0.220000 | 2.95e-04 |
| Neurotoxicity of clostridium toxins | 10 | 2.31e-01 | 0.219000 | 3.32e-01 |
| Signaling by FGFR4 | 38 | 1.97e-02 | -0.219000 | 4.46e-02 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 76 | 9.91e-04 | -0.218000 | 3.31e-03 |
| Regulation of innate immune responses to cytosolic DNA | 14 | 1.58e-01 | -0.218000 | 2.50e-01 |
| RHO GTPases activate PKNs | 53 | 6.08e-03 | -0.218000 | 1.59e-02 |
| RNA Polymerase III Abortive And Retractive Initiation | 41 | 1.60e-02 | -0.217000 | 3.71e-02 |
| RNA Polymerase III Transcription | 41 | 1.60e-02 | -0.217000 | 3.71e-02 |
| Surfactant metabolism | 19 | 1.01e-01 | -0.217000 | 1.75e-01 |
| RAF/MAP kinase cascade | 254 | 2.53e-09 | -0.217000 | 3.41e-08 |
| Caspase-mediated cleavage of cytoskeletal proteins | 12 | 1.93e-01 | -0.217000 | 2.88e-01 |
| Oncogene Induced Senescence | 31 | 3.66e-02 | -0.217000 | 7.57e-02 |
| Transcriptional regulation by RUNX3 | 94 | 2.81e-04 | -0.217000 | 1.11e-03 |
| Elevation of cytosolic Ca2+ levels | 13 | 1.76e-01 | -0.217000 | 2.70e-01 |
| Josephin domain DUBs | 10 | 2.36e-01 | -0.216000 | 3.38e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 20 | 9.40e-02 | -0.216000 | 1.64e-01 |
| Neurodegenerative Diseases | 20 | 9.40e-02 | -0.216000 | 1.64e-01 |
| DNA Double Strand Break Response | 52 | 7.12e-03 | -0.216000 | 1.82e-02 |
| WNT5A-dependent internalization of FZD4 | 15 | 1.48e-01 | -0.215000 | 2.38e-01 |
| Platelet homeostasis | 74 | 1.41e-03 | -0.215000 | 4.46e-03 |
| Signaling by ERBB2 KD Mutants | 25 | 6.41e-02 | -0.214000 | 1.20e-01 |
| Repression of WNT target genes | 14 | 1.66e-01 | -0.214000 | 2.59e-01 |
| Interleukin-12 family signaling | 51 | 8.29e-03 | -0.214000 | 2.09e-02 |
| Degradation of cysteine and homocysteine | 11 | 2.22e-01 | 0.213000 | 3.22e-01 |
| Adherens junctions interactions | 28 | 5.24e-02 | -0.212000 | 1.02e-01 |
| Sphingolipid metabolism | 84 | 7.90e-04 | -0.212000 | 2.72e-03 |
| ZBP1(DAI) mediated induction of type I IFNs | 19 | 1.10e-01 | -0.212000 | 1.88e-01 |
| FGFR4 ligand binding and activation | 11 | 2.24e-01 | 0.212000 | 3.25e-01 |
| Activated NTRK2 signals through FRS2 and FRS3 | 11 | 2.24e-01 | -0.212000 | 3.25e-01 |
| PTEN Regulation | 140 | 1.55e-05 | -0.211000 | 8.50e-05 |
| Aquaporin-mediated transport | 38 | 2.48e-02 | -0.210000 | 5.38e-02 |
| Retinoid metabolism and transport | 32 | 3.95e-02 | -0.210000 | 8.09e-02 |
| Interferon gamma signaling | 81 | 1.17e-03 | -0.209000 | 3.82e-03 |
| Glycogen synthesis | 15 | 1.62e-01 | -0.208000 | 2.56e-01 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 35 | 3.35e-02 | -0.208000 | 6.97e-02 |
| Beta-catenin independent WNT signaling | 141 | 2.08e-05 | -0.207000 | 1.11e-04 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 18 | 1.28e-01 | -0.207000 | 2.12e-01 |
| Formation of the beta-catenin:TCF transactivating complex | 53 | 9.13e-03 | -0.207000 | 2.26e-02 |
| Response of Mtb to phagocytosis | 22 | 9.38e-02 | -0.206000 | 1.64e-01 |
| CLEC7A (Dectin-1) signaling | 97 | 4.52e-04 | -0.206000 | 1.72e-03 |
| MAP2K and MAPK activation | 35 | 3.54e-02 | -0.205000 | 7.35e-02 |
| Synthesis of DNA | 118 | 1.16e-04 | 0.205000 | 5.14e-04 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 6.49e-02 | -0.205000 | 1.21e-01 |
| Degradation of the extracellular matrix | 97 | 4.98e-04 | -0.204000 | 1.84e-03 |
| Metabolism of carbohydrates | 265 | 9.93e-09 | -0.204000 | 1.09e-07 |
| Neurotransmitter release cycle | 47 | 1.55e-02 | -0.204000 | 3.62e-02 |
| Digestion and absorption | 10 | 2.64e-01 | 0.204000 | 3.69e-01 |
| A tetrasaccharide linker sequence is required for GAG synthesis | 25 | 7.78e-02 | -0.204000 | 1.40e-01 |
| NOD1/2 Signaling Pathway | 32 | 4.62e-02 | -0.204000 | 9.18e-02 |
| Mitochondrial biogenesis | 91 | 8.07e-04 | -0.203000 | 2.77e-03 |
| Gene expression (Transcription) | 1382 | 7.26e-37 | -0.202000 | 1.79e-34 |
| Transport of bile salts and organic acids, metal ions and amine compounds | 61 | 6.40e-03 | -0.202000 | 1.66e-02 |
| IRS-mediated signalling | 45 | 1.92e-02 | -0.202000 | 4.36e-02 |
| MyD88 deficiency (TLR2/4) | 15 | 1.77e-01 | 0.201000 | 2.70e-01 |
| Norepinephrine Neurotransmitter Release Cycle | 16 | 1.63e-01 | -0.201000 | 2.56e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway | 25 | 8.15e-02 | -0.201000 | 1.45e-01 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 14 | 1.93e-01 | -0.201000 | 2.88e-01 |
| Immune System | 1660 | 7.39e-43 | -0.201000 | 2.19e-40 |
| G-protein activation | 19 | 1.30e-01 | -0.201000 | 2.14e-01 |
| Cytokine Signaling in Immune system | 609 | 3.20e-17 | -0.200000 | 1.72e-15 |
| NRAGE signals death through JNK | 59 | 7.99e-03 | -0.200000 | 2.02e-02 |
| Formation of HIV elongation complex in the absence of HIV Tat | 44 | 2.24e-02 | -0.199000 | 4.97e-02 |
| Neddylation | 222 | 3.35e-07 | -0.199000 | 2.74e-06 |
| Transport of vitamins, nucleosides, and related molecules | 35 | 4.21e-02 | -0.198000 | 8.47e-02 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 16 | 1.70e-01 | -0.198000 | 2.64e-01 |
| Serotonin Neurotransmitter Release Cycle | 17 | 1.58e-01 | -0.198000 | 2.51e-01 |
| RIP-mediated NFkB activation via ZBP1 | 16 | 1.73e-01 | -0.197000 | 2.66e-01 |
| G alpha (q) signalling events | 156 | 2.25e-05 | -0.197000 | 1.19e-04 |
| Binding and Uptake of Ligands by Scavenger Receptors | 32 | 5.49e-02 | 0.196000 | 1.06e-01 |
| CDC6 association with the ORC:origin complex | 11 | 2.61e-01 | 0.196000 | 3.66e-01 |
| Depolymerisation of the Nuclear Lamina | 15 | 1.91e-01 | -0.195000 | 2.86e-01 |
| Gene Silencing by RNA | 97 | 8.93e-04 | -0.195000 | 3.03e-03 |
| Hemostasis | 496 | 1.15e-13 | -0.194000 | 3.62e-12 |
| Detoxification of Reactive Oxygen Species | 31 | 6.29e-02 | 0.193000 | 1.18e-01 |
| Phospholipase C-mediated cascade; FGFR4 | 12 | 2.49e-01 | 0.192000 | 3.52e-01 |
| RNA Polymerase III Transcription Initiation | 36 | 4.63e-02 | -0.192000 | 9.18e-02 |
| Synthesis of bile acids and bile salts | 28 | 7.88e-02 | -0.192000 | 1.41e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 7.92e-02 | -0.192000 | 1.42e-01 |
| Generic Transcription Pathway | 1129 | 1.00e-27 | -0.192000 | 1.06e-25 |
| DNA Damage/Telomere Stress Induced Senescence | 52 | 1.69e-02 | -0.191000 | 3.88e-02 |
| Activated point mutants of FGFR2 | 14 | 2.15e-01 | 0.191000 | 3.14e-01 |
| Phosphorylation of the APC/C | 20 | 1.41e-01 | 0.190000 | 2.28e-01 |
| Interleukin-12 signaling | 43 | 3.15e-02 | -0.190000 | 6.63e-02 |
| Negative regulation of FGFR2 signaling | 31 | 6.77e-02 | -0.190000 | 1.25e-01 |
| Metabolism of lipids | 657 | 9.65e-17 | -0.189000 | 4.93e-15 |
| Infection with Mycobacterium tuberculosis | 24 | 1.08e-01 | -0.189000 | 1.85e-01 |
| HIV elongation arrest and recovery | 32 | 6.36e-02 | -0.189000 | 1.19e-01 |
| Pausing and recovery of HIV elongation | 32 | 6.36e-02 | -0.189000 | 1.19e-01 |
| rRNA processing | 214 | 1.83e-06 | 0.189000 | 1.26e-05 |
| Formation of apoptosome | 11 | 2.78e-01 | -0.189000 | 3.84e-01 |
| Regulation of the apoptosome activity | 11 | 2.78e-01 | -0.189000 | 3.84e-01 |
| Translesion synthesis by POLI | 17 | 1.78e-01 | 0.189000 | 2.70e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 1.93e-01 | -0.188000 | 2.88e-01 |
| FGFR2c ligand binding and activation | 10 | 3.04e-01 | 0.188000 | 4.10e-01 |
| Homologous DNA Pairing and Strand Exchange | 42 | 3.62e-02 | 0.187000 | 7.49e-02 |
| Initial triggering of complement | 14 | 2.27e-01 | 0.187000 | 3.28e-01 |
| ECM proteoglycans | 47 | 2.69e-02 | -0.186000 | 5.76e-02 |
| Defective Intrinsic Pathway for Apoptosis | 22 | 1.30e-01 | -0.186000 | 2.14e-01 |
| Signaling by Interleukins | 391 | 2.73e-10 | -0.186000 | 5.00e-09 |
| RNA Polymerase II Transcription | 1247 | 1.62e-28 | -0.185000 | 1.84e-26 |
| Regulation of insulin secretion | 67 | 8.75e-03 | -0.185000 | 2.18e-02 |
| Lysosome Vesicle Biogenesis | 34 | 6.25e-02 | -0.185000 | 1.18e-01 |
| SUMOylation of transcription factors | 19 | 1.64e-01 | -0.184000 | 2.58e-01 |
| Chaperonin-mediated protein folding | 84 | 3.50e-03 | -0.184000 | 9.75e-03 |
| IRS-related events triggered by IGF1R | 48 | 2.76e-02 | -0.184000 | 5.90e-02 |
| Formation of Incision Complex in GG-NER | 43 | 3.73e-02 | -0.183000 | 7.70e-02 |
| Pyrimidine salvage | 10 | 3.17e-01 | 0.183000 | 4.23e-01 |
| Negative regulation of FLT3 | 14 | 2.37e-01 | -0.182000 | 3.38e-01 |
| Transcription of E2F targets under negative control by DREAM complex | 19 | 1.69e-01 | 0.182000 | 2.63e-01 |
| Termination of translesion DNA synthesis | 32 | 7.44e-02 | 0.182000 | 1.35e-01 |
| Ion homeostasis | 46 | 3.25e-02 | -0.182000 | 6.80e-02 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | 31 | 7.93e-02 | -0.182000 | 1.42e-01 |
| FGFR2 ligand binding and activation | 16 | 2.08e-01 | 0.182000 | 3.06e-01 |
| DNA Replication | 151 | 1.14e-04 | 0.182000 | 5.08e-04 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 4.17e-02 | -0.182000 | 8.41e-02 |
| HIV Transcription Elongation | 42 | 4.17e-02 | -0.182000 | 8.41e-02 |
| Tat-mediated elongation of the HIV-1 transcript | 42 | 4.17e-02 | -0.182000 | 8.41e-02 |
| Infectious disease | 740 | 3.26e-17 | -0.182000 | 1.72e-15 |
| Phosphorylation of CD3 and TCR zeta chains | 17 | 1.95e-01 | 0.181000 | 2.91e-01 |
| Mucopolysaccharidoses | 11 | 3.00e-01 | 0.181000 | 4.05e-01 |
| Metabolism of non-coding RNA | 53 | 2.34e-02 | -0.180000 | 5.15e-02 |
| snRNP Assembly | 53 | 2.34e-02 | -0.180000 | 5.15e-02 |
| Phenylalanine and tyrosine metabolism | 10 | 3.25e-01 | 0.180000 | 4.31e-01 |
| HDACs deacetylate histones | 54 | 2.24e-02 | -0.180000 | 4.97e-02 |
| Downregulation of ERBB2:ERBB3 signaling | 13 | 2.65e-01 | -0.179000 | 3.70e-01 |
| Class I peroxisomal membrane protein import | 19 | 1.80e-01 | -0.178000 | 2.73e-01 |
| Constitutive Signaling by Overexpressed ERBB2 | 11 | 3.09e-01 | -0.177000 | 4.16e-01 |
| Phospholipase C-mediated cascade; FGFR2 | 15 | 2.35e-01 | 0.177000 | 3.38e-01 |
| Beta-oxidation of very long chain fatty acids | 10 | 3.33e-01 | 0.177000 | 4.38e-01 |
| Degradation of beta-catenin by the destruction complex | 83 | 5.43e-03 | -0.176000 | 1.44e-02 |
| Signaling by FGFR | 83 | 5.45e-03 | -0.176000 | 1.44e-02 |
| Kinesins | 41 | 5.10e-02 | -0.176000 | 9.97e-02 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 2.40e-01 | -0.175000 | 3.41e-01 |
| Disease | 1458 | 1.89e-29 | -0.175000 | 2.54e-27 |
| Presynaptic phase of homologous DNA pairing and strand exchange | 39 | 5.88e-02 | 0.175000 | 1.12e-01 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 25 | 1.30e-01 | 0.175000 | 2.14e-01 |
| Triglyceride metabolism | 28 | 1.10e-01 | -0.175000 | 1.87e-01 |
| Translesion synthesis by REV1 | 16 | 2.28e-01 | 0.174000 | 3.29e-01 |
| G beta:gamma signalling through PI3Kgamma | 22 | 1.59e-01 | -0.173000 | 2.52e-01 |
| Glutamate and glutamine metabolism | 13 | 2.79e-01 | -0.173000 | 3.85e-01 |
| Interferon alpha/beta signaling | 57 | 2.42e-02 | -0.173000 | 5.28e-02 |
| Intraflagellar transport | 39 | 6.22e-02 | 0.173000 | 1.18e-01 |
| Acyl chain remodelling of PG | 13 | 2.82e-01 | -0.172000 | 3.89e-01 |
| Factors involved in megakaryocyte development and platelet production | 118 | 1.23e-03 | -0.172000 | 3.98e-03 |
| Anti-inflammatory response favouring Leishmania parasite infection | 109 | 1.90e-03 | -0.172000 | 5.85e-03 |
| Leishmania parasite growth and survival | 109 | 1.90e-03 | -0.172000 | 5.85e-03 |
| Activation of kainate receptors upon glutamate binding | 27 | 1.23e-01 | -0.172000 | 2.04e-01 |
| Influenza Infection | 153 | 2.48e-04 | 0.172000 | 9.95e-04 |
| Signaling by the B Cell Receptor (BCR) | 105 | 2.52e-03 | -0.171000 | 7.43e-03 |
| Glyoxylate metabolism and glycine degradation | 26 | 1.33e-01 | -0.170000 | 2.18e-01 |
| IRAK4 deficiency (TLR2/4) | 16 | 2.39e-01 | 0.170000 | 3.40e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | 28 | 1.20e-01 | -0.170000 | 2.00e-01 |
| Trafficking of AMPA receptors | 28 | 1.20e-01 | -0.170000 | 2.00e-01 |
| Disorders of Developmental Biology | 13 | 2.89e-01 | -0.170000 | 3.94e-01 |
| Disorders of Nervous System Development | 13 | 2.89e-01 | -0.170000 | 3.94e-01 |
| Loss of function of MECP2 in Rett syndrome | 13 | 2.89e-01 | -0.170000 | 3.94e-01 |
| Pervasive developmental disorders | 13 | 2.89e-01 | -0.170000 | 3.94e-01 |
| Pre-NOTCH Expression and Processing | 71 | 1.34e-02 | -0.170000 | 3.19e-02 |
| ATF6 (ATF6-alpha) activates chaperone genes | 10 | 3.53e-01 | -0.169000 | 4.56e-01 |
| Synthesis of IP2, IP, and Ins in the cytosol | 14 | 2.73e-01 | -0.169000 | 3.78e-01 |
| rRNA modification in the nucleus and cytosol | 60 | 2.34e-02 | -0.169000 | 5.15e-02 |
| Innate Immune System | 868 | 2.15e-17 | -0.169000 | 1.33e-15 |
| Host Interactions of HIV factors | 124 | 1.15e-03 | -0.169000 | 3.80e-03 |
| Glycerophospholipid biosynthesis | 114 | 1.83e-03 | -0.169000 | 5.66e-03 |
| Resolution of Abasic Sites (AP sites) | 38 | 7.17e-02 | 0.169000 | 1.31e-01 |
| Heparan sulfate/heparin (HS-GAG) metabolism | 50 | 3.93e-02 | -0.168000 | 8.06e-02 |
| IGF1R signaling cascade | 49 | 4.18e-02 | -0.168000 | 8.42e-02 |
| The phototransduction cascade | 27 | 1.31e-01 | -0.168000 | 2.14e-01 |
| Signaling by FGFR in disease | 60 | 2.47e-02 | -0.168000 | 5.38e-02 |
| ATF6 (ATF6-alpha) activates chaperones | 12 | 3.15e-01 | -0.167000 | 4.22e-01 |
| Telomere C-strand (Lagging Strand) Synthesis | 34 | 9.13e-02 | 0.167000 | 1.61e-01 |
| RNA Polymerase III Transcription Termination | 23 | 1.65e-01 | -0.167000 | 2.59e-01 |
| ABC transporters in lipid homeostasis | 15 | 2.62e-01 | 0.167000 | 3.67e-01 |
| Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 1.11e-04 | 0.167000 | 4.95e-04 |
| Metabolism of proteins | 1750 | 2.23e-31 | -0.166000 | 3.67e-29 |
| Apoptotic factor-mediated response | 19 | 2.11e-01 | -0.166000 | 3.09e-01 |
| DSCAM interactions | 10 | 3.64e-01 | -0.166000 | 4.67e-01 |
| Mitochondrial calcium ion transport | 22 | 1.79e-01 | -0.165000 | 2.72e-01 |
| Interleukin-1 family signaling | 130 | 1.12e-03 | -0.165000 | 3.71e-03 |
| Synthesis of IP3 and IP4 in the cytosol | 25 | 1.53e-01 | -0.165000 | 2.44e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription | 19 | 2.13e-01 | -0.165000 | 3.12e-01 |
| ERBB2 Activates PTK6 Signaling | 13 | 3.03e-01 | -0.165000 | 4.10e-01 |
| Pausing and recovery of Tat-mediated HIV elongation | 30 | 1.19e-01 | -0.165000 | 1.99e-01 |
| Tat-mediated HIV elongation arrest and recovery | 30 | 1.19e-01 | -0.165000 | 1.99e-01 |
| Antimicrobial peptides | 27 | 1.39e-01 | 0.164000 | 2.25e-01 |
| Interleukin-1 signaling | 97 | 5.13e-03 | -0.164000 | 1.37e-02 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 1.32e-01 | -0.164000 | 2.16e-01 |
| Activation of SMO | 18 | 2.28e-01 | -0.164000 | 3.29e-01 |
| Cellular Senescence | 153 | 4.56e-04 | -0.164000 | 1.72e-03 |
| Neurotransmitter receptors and postsynaptic signal transmission | 158 | 3.71e-04 | -0.164000 | 1.45e-03 |
| Transcriptional regulation by small RNAs | 69 | 1.88e-02 | -0.163000 | 4.29e-02 |
| Hyaluronan uptake and degradation | 10 | 3.71e-01 | 0.163000 | 4.73e-01 |
| Downregulation of ERBB2 signaling | 29 | 1.30e-01 | -0.162000 | 2.14e-01 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | 11 | 3.51e-01 | 0.162000 | 4.53e-01 |
| Deactivation of the beta-catenin transactivating complex | 41 | 7.34e-02 | -0.162000 | 1.33e-01 |
| mRNA Splicing - Minor Pathway | 52 | 4.42e-02 | 0.161000 | 8.83e-02 |
| Cell death signalling via NRAGE, NRIF and NADE | 76 | 1.51e-02 | -0.161000 | 3.56e-02 |
| Activated NOTCH1 Transmits Signal to the Nucleus | 30 | 1.28e-01 | -0.160000 | 2.12e-01 |
| PCP/CE pathway | 90 | 8.56e-03 | -0.160000 | 2.14e-02 |
| Sensory processing of sound by outer hair cells of the cochlea | 44 | 6.63e-02 | -0.160000 | 1.23e-01 |
| Tight junction interactions | 23 | 1.85e-01 | -0.160000 | 2.78e-01 |
| Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function | 24 | 1.77e-01 | 0.159000 | 2.70e-01 |
| Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function | 24 | 1.77e-01 | 0.159000 | 2.70e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 24 | 1.77e-01 | 0.159000 | 2.70e-01 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 24 | 1.77e-01 | 0.159000 | 2.70e-01 |
| Diseases of DNA Double-Strand Break Repair | 24 | 1.77e-01 | 0.159000 | 2.70e-01 |
| Regulation of TNFR1 signaling | 35 | 1.04e-01 | -0.159000 | 1.79e-01 |
| Transcriptional Regulation by TP53 | 356 | 2.69e-07 | -0.158000 | 2.23e-06 |
| Apoptosis | 170 | 3.75e-04 | -0.158000 | 1.46e-03 |
| Ion transport by P-type ATPases | 48 | 5.83e-02 | -0.158000 | 1.11e-01 |
| Response of EIF2AK1 (HRI) to heme deficiency | 15 | 2.91e-01 | -0.157000 | 3.95e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation | 35 | 1.07e-01 | 0.157000 | 1.84e-01 |
| Mitochondrial iron-sulfur cluster biogenesis | 13 | 3.26e-01 | 0.157000 | 4.31e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 50 | 5.48e-02 | -0.157000 | 1.05e-01 |
| Metabolism of amino acids and derivatives | 342 | 6.16e-07 | 0.157000 | 4.56e-06 |
| Epigenetic regulation of gene expression | 110 | 4.67e-03 | -0.156000 | 1.27e-02 |
| tRNA processing in the nucleus | 59 | 3.92e-02 | -0.155000 | 8.04e-02 |
| Signaling by ERBB4 | 53 | 5.12e-02 | -0.155000 | 1.00e-01 |
| Inactivation, recovery and regulation of the phototransduction cascade | 26 | 1.72e-01 | -0.155000 | 2.66e-01 |
| Activation of GABAB receptors | 37 | 1.04e-01 | -0.155000 | 1.79e-01 |
| GABA B receptor activation | 37 | 1.04e-01 | -0.155000 | 1.79e-01 |
| Signaling by NOTCH | 194 | 2.25e-04 | -0.154000 | 9.11e-04 |
| Programmed Cell Death | 196 | 2.11e-04 | -0.153000 | 8.68e-04 |
| Sema4D induced cell migration and growth-cone collapse | 20 | 2.36e-01 | -0.153000 | 3.38e-01 |
| Packaging Of Telomere Ends | 25 | 1.85e-01 | -0.153000 | 2.79e-01 |
| Presynaptic function of Kainate receptors | 18 | 2.62e-01 | -0.153000 | 3.66e-01 |
| Interleukin-4 and Interleukin-13 signaling | 97 | 9.40e-03 | -0.153000 | 2.31e-02 |
| G0 and Early G1 | 27 | 1.70e-01 | 0.152000 | 2.64e-01 |
| E2F mediated regulation of DNA replication | 22 | 2.16e-01 | 0.152000 | 3.15e-01 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 2.51e-01 | -0.152000 | 3.53e-01 |
| ADORA2B mediated anti-inflammatory cytokines production | 84 | 1.62e-02 | -0.152000 | 3.74e-02 |
| Synthesis, secretion, and deacylation of Ghrelin | 13 | 3.44e-01 | 0.152000 | 4.48e-01 |
| rRNA processing in the nucleus and cytosol | 190 | 3.23e-04 | 0.151000 | 1.27e-03 |
| Cell surface interactions at the vascular wall | 103 | 8.22e-03 | -0.151000 | 2.07e-02 |
| C-type lectin receptors (CLRs) | 128 | 3.26e-03 | -0.150000 | 9.25e-03 |
| RHO GTPases Activate Formins | 118 | 4.80e-03 | -0.150000 | 1.29e-02 |
| Visual phototransduction | 74 | 2.56e-02 | -0.150000 | 5.53e-02 |
| PI-3K cascade:FGFR4 | 17 | 2.85e-01 | -0.150000 | 3.91e-01 |
| Diseases of carbohydrate metabolism | 29 | 1.63e-01 | 0.150000 | 2.56e-01 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 34 | 1.32e-01 | -0.149000 | 2.15e-01 |
| Cell-cell junction organization | 53 | 6.23e-02 | -0.148000 | 1.18e-01 |
| G alpha (12/13) signalling events | 76 | 2.64e-02 | -0.147000 | 5.67e-02 |
| PD-1 signaling | 18 | 2.79e-01 | 0.147000 | 3.85e-01 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 19 | 2.67e-01 | -0.147000 | 3.72e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | 19 | 2.67e-01 | -0.147000 | 3.72e-01 |
| Interleukin-37 signaling | 21 | 2.44e-01 | -0.147000 | 3.46e-01 |
| Extension of Telomeres | 51 | 7.00e-02 | 0.147000 | 1.28e-01 |
| Extracellular matrix organization | 261 | 4.53e-05 | -0.146000 | 2.21e-04 |
| Translation | 293 | 1.57e-05 | 0.146000 | 8.59e-05 |
| Downstream signaling of activated FGFR3 | 23 | 2.25e-01 | -0.146000 | 3.25e-01 |
| Assembly of active LPL and LIPC lipase complexes | 14 | 3.44e-01 | -0.146000 | 4.47e-01 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 3.45e-01 | -0.146000 | 4.48e-01 |
| Regulation of FZD by ubiquitination | 21 | 2.50e-01 | -0.145000 | 3.52e-01 |
| Pyruvate metabolism | 28 | 1.84e-01 | -0.145000 | 2.78e-01 |
| Downstream signaling of activated FGFR1 | 29 | 1.77e-01 | -0.145000 | 2.70e-01 |
| RHO GTPases Activate NADPH Oxidases | 22 | 2.41e-01 | -0.144000 | 3.41e-01 |
| Developmental Biology | 864 | 5.07e-13 | -0.144000 | 1.42e-11 |
| Activation of HOX genes during differentiation | 82 | 2.40e-02 | -0.144000 | 5.24e-02 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | 82 | 2.40e-02 | -0.144000 | 5.24e-02 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 3.69e-01 | 0.144000 | 4.72e-01 |
| IKK complex recruitment mediated by RIP1 | 22 | 2.44e-01 | -0.143000 | 3.45e-01 |
| RIPK1-mediated regulated necrosis | 27 | 1.97e-01 | -0.143000 | 2.92e-01 |
| Regulation of necroptotic cell death | 27 | 1.97e-01 | -0.143000 | 2.92e-01 |
| Sulfur amino acid metabolism | 25 | 2.15e-01 | 0.143000 | 3.14e-01 |
| GRB2 events in EGFR signaling | 13 | 3.72e-01 | -0.143000 | 4.74e-01 |
| Transcriptional regulation by RUNX2 | 116 | 7.85e-03 | -0.143000 | 1.99e-02 |
| Polymerase switching on the C-strand of the telomere | 26 | 2.07e-01 | 0.143000 | 3.05e-01 |
| NCAM signaling for neurite out-growth | 56 | 6.62e-02 | -0.142000 | 1.23e-01 |
| Signaling by FGFR3 in disease | 20 | 2.74e-01 | -0.141000 | 3.80e-01 |
| Signaling by FGFR3 point mutants in cancer | 20 | 2.74e-01 | -0.141000 | 3.80e-01 |
| SUMOylation of DNA methylation proteins | 16 | 3.29e-01 | -0.141000 | 4.35e-01 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 4.19e-01 | 0.141000 | 5.21e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 3.30e-01 | 0.141000 | 4.35e-01 |
| Transport of Mature Transcript to Cytoplasm | 81 | 2.88e-02 | -0.140000 | 6.12e-02 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 4.42e-01 | 0.140000 | 5.43e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes | 48 | 9.23e-02 | -0.140000 | 1.62e-01 |
| Protein folding | 90 | 2.15e-02 | -0.140000 | 4.80e-02 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | 11 | 4.23e-01 | -0.140000 | 5.25e-01 |
| Disorders of transmembrane transporters | 153 | 2.89e-03 | -0.139000 | 8.36e-03 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 2.48e-01 | -0.139000 | 3.50e-01 |
| FGFRL1 modulation of FGFR1 signaling | 12 | 4.04e-01 | -0.139000 | 5.06e-01 |
| Signaling by ERBB2 TMD/JMD mutants | 22 | 2.61e-01 | -0.139000 | 3.66e-01 |
| Synthesis of PE | 13 | 3.89e-01 | -0.138000 | 4.90e-01 |
| Signaling by NOTCH2 | 32 | 1.77e-01 | -0.138000 | 2.70e-01 |
| Formation of the Early Elongation Complex | 33 | 1.72e-01 | -0.137000 | 2.66e-01 |
| Formation of the HIV-1 Early Elongation Complex | 33 | 1.72e-01 | -0.137000 | 2.66e-01 |
| TP53 Regulates Transcription of Cell Death Genes | 43 | 1.21e-01 | -0.137000 | 2.01e-01 |
| Transcriptional regulation by RUNX1 | 187 | 1.30e-03 | -0.136000 | 4.18e-03 |
| Signaling by FGFR2 | 69 | 5.05e-02 | -0.136000 | 9.90e-02 |
| Late endosomal microautophagy | 30 | 1.97e-01 | -0.136000 | 2.92e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere | 45 | 1.15e-01 | 0.136000 | 1.95e-01 |
| Nucleosome assembly | 45 | 1.15e-01 | 0.136000 | 1.95e-01 |
| Biosynthesis of specialized proresolving mediators (SPMs) | 15 | 3.63e-01 | 0.136000 | 4.66e-01 |
| Neuronal System | 334 | 2.06e-05 | -0.135000 | 1.10e-04 |
| Phase 4 - resting membrane potential | 16 | 3.48e-01 | -0.135000 | 4.51e-01 |
| APC-Cdc20 mediated degradation of Nek2A | 26 | 2.33e-01 | 0.135000 | 3.35e-01 |
| Glycogen storage diseases | 14 | 3.82e-01 | 0.135000 | 4.84e-01 |
| MAPK6/MAPK4 signaling | 87 | 2.97e-02 | -0.135000 | 6.30e-02 |
| Ras activation upon Ca2+ influx through NMDA receptor | 19 | 3.09e-01 | -0.135000 | 4.16e-01 |
| Chromosome Maintenance | 110 | 1.52e-02 | 0.134000 | 3.58e-02 |
| G beta:gamma signalling through BTK | 15 | 3.70e-01 | -0.134000 | 4.72e-01 |
| Acetylcholine Neurotransmitter Release Cycle | 15 | 3.75e-01 | -0.132000 | 4.77e-01 |
| Striated Muscle Contraction | 26 | 2.44e-01 | 0.132000 | 3.45e-01 |
| G beta:gamma signalling through PLC beta | 17 | 3.46e-01 | -0.132000 | 4.49e-01 |
| Cyclin D associated events in G1 | 45 | 1.26e-01 | -0.132000 | 2.08e-01 |
| G1 Phase | 45 | 1.26e-01 | -0.132000 | 2.08e-01 |
| Regulation of TP53 Activity through Association with Co-factors | 12 | 4.29e-01 | -0.132000 | 5.31e-01 |
| G alpha (s) signalling events | 95 | 2.65e-02 | -0.132000 | 5.68e-02 |
| Translesion synthesis by POLK | 17 | 3.47e-01 | 0.132000 | 4.50e-01 |
| Formation of Fibrin Clot (Clotting Cascade) | 24 | 2.64e-01 | -0.132000 | 3.69e-01 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | 12 | 4.30e-01 | -0.132000 | 5.32e-01 |
| HIV Transcription Initiation | 47 | 1.19e-01 | -0.132000 | 1.99e-01 |
| RNA Polymerase II HIV Promoter Escape | 47 | 1.19e-01 | -0.132000 | 1.99e-01 |
| RNA Polymerase II Promoter Escape | 47 | 1.19e-01 | -0.132000 | 1.99e-01 |
| RNA Polymerase II Transcription Initiation | 47 | 1.19e-01 | -0.132000 | 1.99e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | 47 | 1.19e-01 | -0.132000 | 1.99e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 47 | 1.19e-01 | -0.132000 | 1.99e-01 |
| Nervous system development | 527 | 2.29e-07 | -0.131000 | 1.93e-06 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 18 | 3.41e-01 | 0.130000 | 4.45e-01 |
| GABA receptor activation | 48 | 1.21e-01 | -0.129000 | 2.01e-01 |
| FGFR3 mutant receptor activation | 10 | 4.80e-01 | 0.129000 | 5.80e-01 |
| Signaling by activated point mutants of FGFR3 | 10 | 4.80e-01 | 0.129000 | 5.80e-01 |
| SLC-mediated transmembrane transport | 201 | 1.71e-03 | -0.128000 | 5.34e-03 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 14 | 4.07e-01 | -0.128000 | 5.09e-01 |
| Olfactory Signaling Pathway | 20 | 3.22e-01 | 0.128000 | 4.28e-01 |
| Positive epigenetic regulation of rRNA expression | 68 | 6.87e-02 | -0.128000 | 1.26e-01 |
| Chondroitin sulfate biosynthesis | 20 | 3.24e-01 | -0.127000 | 4.29e-01 |
| HDR through Single Strand Annealing (SSA) | 37 | 1.80e-01 | 0.127000 | 2.73e-01 |
| FRS-mediated FGFR1 signaling | 21 | 3.13e-01 | -0.127000 | 4.21e-01 |
| mRNA Capping | 29 | 2.36e-01 | -0.127000 | 3.38e-01 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 57 | 9.71e-02 | -0.127000 | 1.69e-01 |
| Platelet degranulation | 110 | 2.13e-02 | -0.127000 | 4.77e-02 |
| Signaling by GPCR | 484 | 1.63e-06 | -0.127000 | 1.15e-05 |
| SHC1 events in ERBB4 signaling | 14 | 4.11e-01 | -0.127000 | 5.12e-01 |
| Incretin synthesis, secretion, and inactivation | 17 | 3.66e-01 | -0.127000 | 4.69e-01 |
| DNA Replication Pre-Initiation | 108 | 2.31e-02 | 0.126000 | 5.11e-02 |
| Transmission across Chemical Synapses | 219 | 1.29e-03 | -0.126000 | 4.17e-03 |
| Triglyceride catabolism | 19 | 3.45e-01 | -0.125000 | 4.48e-01 |
| GPCR downstream signalling | 426 | 1.02e-05 | -0.124000 | 5.98e-05 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | 11 | 4.76e-01 | -0.124000 | 5.77e-01 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 3.37e-01 | 0.124000 | 4.41e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 3.26e-01 | 0.124000 | 4.31e-01 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 3.26e-01 | 0.124000 | 4.31e-01 |
| Initiation of Nuclear Envelope (NE) Reformation | 19 | 3.50e-01 | -0.124000 | 4.53e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 105 | 2.90e-02 | 0.123000 | 6.16e-02 |
| FCERI mediated NF-kB activation | 75 | 6.50e-02 | -0.123000 | 1.21e-01 |
| Peptide hormone metabolism | 67 | 8.19e-02 | -0.123000 | 1.46e-01 |
| Signaling by Insulin receptor | 73 | 6.96e-02 | -0.123000 | 1.28e-01 |
| Homology Directed Repair | 111 | 2.61e-02 | 0.122000 | 5.62e-02 |
| Synthesis of very long-chain fatty acyl-CoAs | 22 | 3.22e-01 | -0.122000 | 4.28e-01 |
| Transport of small molecules | 607 | 2.82e-07 | -0.122000 | 2.32e-06 |
| Nucleotide salvage | 21 | 3.35e-01 | 0.122000 | 4.39e-01 |
| G1/S Transition | 131 | 1.63e-02 | 0.122000 | 3.76e-02 |
| Response to elevated platelet cytosolic Ca2+ | 115 | 2.48e-02 | -0.121000 | 5.38e-02 |
| Regulation of TP53 Activity through Phosphorylation | 91 | 4.64e-02 | -0.121000 | 9.18e-02 |
| RNA Polymerase I Transcription Initiation | 47 | 1.52e-01 | -0.121000 | 2.43e-01 |
| Oxidative Stress Induced Senescence | 83 | 5.77e-02 | -0.120000 | 1.10e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism | 49 | 1.46e-01 | -0.120000 | 2.35e-01 |
| ROS and RNS production in phagocytes | 32 | 2.41e-01 | 0.120000 | 3.41e-01 |
| Neutrophil degranulation | 423 | 2.40e-05 | -0.120000 | 1.25e-04 |
| TRAF6 mediated NF-kB activation | 23 | 3.21e-01 | -0.119000 | 4.28e-01 |
| Interaction between L1 and Ankyrins | 26 | 2.92e-01 | -0.119000 | 3.96e-01 |
| HS-GAG degradation | 20 | 3.56e-01 | -0.119000 | 4.59e-01 |
| Synthesis of PC | 26 | 2.95e-01 | -0.119000 | 3.99e-01 |
| Removal of the Flap Intermediate from the C-strand | 17 | 3.98e-01 | -0.118000 | 4.99e-01 |
| Signaling by ROBO receptors | 211 | 3.16e-03 | 0.118000 | 9.05e-03 |
| Signaling by NOTCH3 | 46 | 1.68e-01 | -0.117000 | 2.62e-01 |
| Diseases of DNA repair | 34 | 2.36e-01 | 0.117000 | 3.38e-01 |
| TP53 Regulates Transcription of DNA Repair Genes | 61 | 1.13e-01 | -0.117000 | 1.91e-01 |
| Resolution of Sister Chromatid Cohesion | 105 | 3.78e-02 | -0.117000 | 7.78e-02 |
| Glycogen breakdown (glycogenolysis) | 15 | 4.35e-01 | -0.116000 | 5.37e-01 |
| Dissolution of Fibrin Clot | 13 | 4.69e-01 | -0.116000 | 5.70e-01 |
| O-linked glycosylation of mucins | 54 | 1.41e-01 | -0.116000 | 2.28e-01 |
| SHC-mediated cascade:FGFR2 | 20 | 3.71e-01 | 0.116000 | 4.73e-01 |
| SHC-mediated cascade:FGFR4 | 17 | 4.10e-01 | 0.115000 | 5.12e-01 |
| Phospholipase C-mediated cascade; FGFR3 | 11 | 5.08e-01 | 0.115000 | 6.05e-01 |
| Organelle biogenesis and maintenance | 272 | 1.06e-03 | -0.115000 | 3.54e-03 |
| Transport of inorganic cations/anions and amino acids/oligopeptides | 92 | 5.61e-02 | -0.115000 | 1.08e-01 |
| Branched-chain amino acid catabolism | 21 | 3.63e-01 | -0.115000 | 4.66e-01 |
| Sensory processing of sound by inner hair cells of the cochlea | 57 | 1.35e-01 | -0.114000 | 2.19e-01 |
| Phase II - Conjugation of compounds | 76 | 8.54e-02 | 0.114000 | 1.52e-01 |
| Meiotic recombination | 47 | 1.77e-01 | 0.114000 | 2.70e-01 |
| Axon guidance | 505 | 1.14e-05 | -0.114000 | 6.52e-05 |
| Interconversion of nucleotide di- and triphosphates | 29 | 2.90e-01 | 0.114000 | 3.94e-01 |
| Glycogen metabolism | 26 | 3.18e-01 | -0.113000 | 4.24e-01 |
| Methylation | 14 | 4.64e-01 | 0.113000 | 5.65e-01 |
| Phase 0 - rapid depolarisation | 30 | 2.84e-01 | 0.113000 | 3.91e-01 |
| Regulation of beta-cell development | 30 | 2.86e-01 | -0.112000 | 3.93e-01 |
| Telomere Maintenance | 85 | 7.32e-02 | 0.112000 | 1.33e-01 |
| Butyrophilin (BTN) family interactions | 11 | 5.20e-01 | -0.112000 | 6.16e-01 |
| Signaling by CSF3 (G-CSF) | 30 | 2.90e-01 | -0.112000 | 3.94e-01 |
| Metabolism of folate and pterines | 16 | 4.39e-01 | 0.112000 | 5.41e-01 |
| Transcriptional regulation of pluripotent stem cells | 31 | 2.87e-01 | -0.111000 | 3.93e-01 |
| Signaling by EGFR in Cancer | 25 | 3.40e-01 | -0.110000 | 4.45e-01 |
| Formation of TC-NER Pre-Incision Complex | 53 | 1.66e-01 | -0.110000 | 2.59e-01 |
| PI-3K cascade:FGFR2 | 20 | 3.95e-01 | -0.110000 | 4.97e-01 |
| Peroxisomal protein import | 60 | 1.43e-01 | -0.109000 | 2.31e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 1.11e-01 | -0.109000 | 1.89e-01 |
| Switching of origins to a post-replicative state | 89 | 7.68e-02 | 0.108000 | 1.39e-01 |
| G alpha (i) signalling events | 197 | 8.84e-03 | -0.108000 | 2.20e-02 |
| Cellular responses to stress | 680 | 1.71e-06 | -0.107000 | 1.20e-05 |
| Signalling to RAS | 20 | 4.07e-01 | -0.107000 | 5.09e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 4.88e-01 | 0.107000 | 5.89e-01 |
| CASP8 activity is inhibited | 10 | 5.58e-01 | -0.107000 | 6.48e-01 |
| Dimerization of procaspase-8 | 10 | 5.58e-01 | -0.107000 | 6.48e-01 |
| Regulation by c-FLIP | 10 | 5.58e-01 | -0.107000 | 6.48e-01 |
| Sensory processing of sound | 62 | 1.46e-01 | -0.107000 | 2.35e-01 |
| EML4 and NUDC in mitotic spindle formation | 96 | 7.21e-02 | -0.106000 | 1.32e-01 |
| Biosynthesis of DHA-derived SPMs | 14 | 4.92e-01 | 0.106000 | 5.92e-01 |
| Ribosomal scanning and start codon recognition | 57 | 1.67e-01 | 0.106000 | 2.60e-01 |
| Telomere Extension By Telomerase | 23 | 3.80e-01 | -0.106000 | 4.82e-01 |
| Chemokine receptors bind chemokines | 28 | 3.34e-01 | 0.105000 | 4.38e-01 |
| Cytosolic sulfonation of small molecules | 21 | 4.03e-01 | -0.105000 | 5.06e-01 |
| RNA Polymerase I Transcription Termination | 30 | 3.21e-01 | -0.105000 | 4.28e-01 |
| Post-chaperonin tubulin folding pathway | 20 | 4.23e-01 | 0.103000 | 5.25e-01 |
| Fertilization | 16 | 4.78e-01 | 0.103000 | 5.78e-01 |
| RNA Polymerase III Chain Elongation | 18 | 4.53e-01 | -0.102000 | 5.54e-01 |
| Translation initiation complex formation | 57 | 1.82e-01 | 0.102000 | 2.75e-01 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 4.29e-01 | 0.102000 | 5.31e-01 |
| Amino acid transport across the plasma membrane | 30 | 3.33e-01 | -0.102000 | 4.38e-01 |
| RA biosynthesis pathway | 18 | 4.54e-01 | 0.102000 | 5.56e-01 |
| Meiotic synapsis | 50 | 2.15e-01 | -0.101000 | 3.14e-01 |
| TCR signaling | 110 | 6.68e-02 | -0.101000 | 1.24e-01 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | 13 | 5.33e-01 | 0.100000 | 6.29e-01 |
| B-WICH complex positively regulates rRNA expression | 53 | 2.10e-01 | -0.099500 | 3.08e-01 |
| Recycling of bile acids and salts | 12 | 5.52e-01 | 0.099200 | 6.46e-01 |
| Mitochondrial protein import | 64 | 1.70e-01 | 0.099000 | 2.64e-01 |
| Orc1 removal from chromatin | 69 | 1.56e-01 | 0.098800 | 2.48e-01 |
| Regulation of PTEN stability and activity | 67 | 1.62e-01 | -0.098700 | 2.56e-01 |
| Nucleotide catabolism | 31 | 3.42e-01 | 0.098600 | 4.46e-01 |
| Cellular responses to stimuli | 690 | 9.85e-06 | -0.098500 | 5.86e-05 |
| Insulin receptor recycling | 24 | 4.04e-01 | 0.098300 | 5.06e-01 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | 15 | 5.10e-01 | -0.098300 | 6.07e-01 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | 15 | 5.10e-01 | -0.098300 | 6.07e-01 |
| Heme biosynthesis | 13 | 5.40e-01 | 0.098200 | 6.37e-01 |
| Downstream signaling events of B Cell Receptor (BCR) | 79 | 1.31e-01 | -0.098100 | 2.15e-01 |
| Pre-NOTCH Transcription and Translation | 55 | 2.08e-01 | -0.098100 | 3.06e-01 |
| Signaling by Hedgehog | 132 | 5.18e-02 | -0.098000 | 1.01e-01 |
| Eicosanoid ligand-binding receptors | 13 | 5.41e-01 | -0.097800 | 6.38e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 13 | 5.42e-01 | -0.097600 | 6.38e-01 |
| Downstream signaling of activated FGFR4 | 24 | 4.11e-01 | -0.096900 | 5.12e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 92 | 1.10e-01 | -0.096400 | 1.88e-01 |
| Amplification of signal from the kinetochores | 92 | 1.10e-01 | -0.096400 | 1.88e-01 |
| APC/C:Cdc20 mediated degradation of Securin | 66 | 1.79e-01 | 0.095600 | 2.72e-01 |
| Diseases associated with O-glycosylation of proteins | 63 | 1.91e-01 | 0.095300 | 2.86e-01 |
| Vif-mediated degradation of APOBEC3G | 52 | 2.38e-01 | 0.094500 | 3.39e-01 |
| Nuclear signaling by ERBB4 | 29 | 3.78e-01 | -0.094500 | 4.81e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA | 17 | 5.01e-01 | 0.094300 | 6.00e-01 |
| p38MAPK events | 13 | 5.58e-01 | -0.093900 | 6.48e-01 |
| FGFR2 mutant receptor activation | 30 | 3.74e-01 | 0.093700 | 4.77e-01 |
| Processing of Capped Intronless Pre-mRNA | 28 | 3.95e-01 | -0.092800 | 4.97e-01 |
| HuR (ELAVL1) binds and stabilizes mRNA | 10 | 6.12e-01 | -0.092700 | 6.97e-01 |
| Adrenaline,noradrenaline inhibits insulin secretion | 24 | 4.33e-01 | -0.092400 | 5.35e-01 |
| Common Pathway of Fibrin Clot Formation | 14 | 5.51e-01 | -0.092000 | 6.46e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance | 58 | 2.26e-01 | -0.091900 | 3.26e-01 |
| Regulation of RUNX2 expression and activity | 70 | 1.84e-01 | -0.091800 | 2.78e-01 |
| LGI-ADAM interactions | 12 | 5.83e-01 | -0.091600 | 6.73e-01 |
| SHC1 events in EGFR signaling | 14 | 5.55e-01 | -0.091100 | 6.47e-01 |
| Assembly of the pre-replicative complex | 91 | 1.34e-01 | 0.090900 | 2.18e-01 |
| FRS-mediated FGFR3 signaling | 18 | 5.07e-01 | -0.090200 | 6.05e-01 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | 74 | 1.82e-01 | 0.089800 | 2.75e-01 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 58 | 2.40e-01 | 0.089200 | 3.41e-01 |
| Mitotic Metaphase and Anaphase | 229 | 2.01e-02 | -0.089000 | 4.55e-02 |
| Transferrin endocytosis and recycling | 30 | 3.99e-01 | 0.088900 | 5.01e-01 |
| Inactivation of CSF3 (G-CSF) signaling | 25 | 4.44e-01 | -0.088400 | 5.45e-01 |
| Prostacyclin signalling through prostacyclin receptor | 16 | 5.42e-01 | -0.088100 | 6.38e-01 |
| Mitotic Anaphase | 228 | 2.20e-02 | -0.088000 | 4.90e-02 |
| Regulation of PLK1 Activity at G2/M Transition | 87 | 1.58e-01 | -0.087500 | 2.51e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE | 27 | 4.38e-01 | -0.086200 | 5.39e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 4.38e-01 | -0.086200 | 5.39e-01 |
| Cleavage of the damaged pyrimidine | 34 | 3.88e-01 | -0.085600 | 4.89e-01 |
| Depyrimidination | 34 | 3.88e-01 | -0.085600 | 4.89e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 34 | 3.88e-01 | -0.085600 | 4.89e-01 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | 10 | 6.39e-01 | -0.085600 | 7.21e-01 |
| Regulated Necrosis | 51 | 2.91e-01 | -0.085400 | 3.95e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 2.41e-01 | 0.084700 | 3.42e-01 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | 12 | 6.11e-01 | 0.084700 | 6.97e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 5.83e-01 | 0.084600 | 6.73e-01 |
| RMTs methylate histone arginines | 44 | 3.37e-01 | -0.083700 | 4.41e-01 |
| MASTL Facilitates Mitotic Progression | 10 | 6.48e-01 | 0.083300 | 7.29e-01 |
| Negative epigenetic regulation of rRNA expression | 71 | 2.26e-01 | -0.083200 | 3.26e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 13 | 6.10e-01 | -0.081800 | 6.97e-01 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 72 | 2.30e-01 | 0.081700 | 3.32e-01 |
| Amino acids regulate mTORC1 | 51 | 3.15e-01 | -0.081300 | 4.22e-01 |
| Asymmetric localization of PCP proteins | 62 | 2.71e-01 | -0.080700 | 3.77e-01 |
| TRP channels | 18 | 5.54e-01 | -0.080500 | 6.47e-01 |
| Stimuli-sensing channels | 83 | 2.07e-01 | -0.080100 | 3.05e-01 |
| TP53 Regulates Metabolic Genes | 85 | 2.02e-01 | -0.080000 | 2.99e-01 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | 10 | 6.62e-01 | -0.079800 | 7.42e-01 |
| Dual Incision in GG-NER | 41 | 3.77e-01 | 0.079800 | 4.79e-01 |
| Downstream TCR signaling | 90 | 1.91e-01 | -0.079700 | 2.86e-01 |
| MicroRNA (miRNA) biogenesis | 24 | 4.99e-01 | -0.079600 | 6.00e-01 |
| Regulation of RAS by GAPs | 64 | 2.71e-01 | -0.079500 | 3.77e-01 |
| Plasma lipoprotein assembly | 13 | 6.22e-01 | 0.079000 | 7.06e-01 |
| DNA methylation | 27 | 4.82e-01 | 0.078100 | 5.82e-01 |
| Recognition of DNA damage by PCNA-containing replication complex | 30 | 4.60e-01 | 0.078000 | 5.62e-01 |
| Transcriptional regulation of granulopoiesis | 52 | 3.32e-01 | -0.077800 | 4.37e-01 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | 29 | 4.68e-01 | -0.077800 | 5.70e-01 |
| M Phase | 371 | 1.03e-02 | -0.077500 | 2.51e-02 |
| Defective CFTR causes cystic fibrosis | 58 | 3.09e-01 | -0.077200 | 4.16e-01 |
| Mitotic G1 phase and G1/S transition | 147 | 1.07e-01 | 0.077000 | 1.84e-01 |
| CDT1 association with the CDC6:ORC:origin complex | 57 | 3.16e-01 | 0.076700 | 4.23e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 2.52e-01 | 0.076500 | 3.54e-01 |
| Class B/2 (Secretin family receptors) | 73 | 2.59e-01 | -0.076400 | 3.63e-01 |
| Acyl chain remodelling of PS | 17 | 5.86e-01 | -0.076400 | 6.75e-01 |
| Bile acid and bile salt metabolism | 35 | 4.36e-01 | -0.076000 | 5.38e-01 |
| Cyclin A/B1/B2 associated events during G2/M transition | 25 | 5.12e-01 | -0.075800 | 6.08e-01 |
| Cytoprotection by HMOX1 | 119 | 1.56e-01 | -0.075200 | 2.48e-01 |
| Cellular response to hypoxia | 73 | 2.66e-01 | -0.075200 | 3.72e-01 |
| Aggrephagy | 21 | 5.52e-01 | -0.075000 | 6.46e-01 |
| Cardiac conduction | 109 | 1.77e-01 | -0.074900 | 2.70e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress | 27 | 5.03e-01 | 0.074500 | 6.01e-01 |
| Loss of Nlp from mitotic centrosomes | 69 | 2.87e-01 | -0.074100 | 3.93e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome | 69 | 2.87e-01 | -0.074100 | 3.93e-01 |
| Hedgehog ‘off’ state | 95 | 2.13e-01 | -0.073900 | 3.12e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 26 | 5.17e-01 | -0.073400 | 6.13e-01 |
| Other semaphorin interactions | 15 | 6.23e-01 | -0.073300 | 7.07e-01 |
| Regulation of HMOX1 expression and activity | 63 | 3.14e-01 | -0.073300 | 4.22e-01 |
| Downstream signaling of activated FGFR2 | 27 | 5.10e-01 | -0.073200 | 6.07e-01 |
| AURKA Activation by TPX2 | 72 | 2.85e-01 | -0.072900 | 3.92e-01 |
| Sensory Perception | 176 | 9.64e-02 | -0.072600 | 1.68e-01 |
| Metabolic disorders of biological oxidation enzymes | 29 | 5.01e-01 | 0.072200 | 6.00e-01 |
| Telomere C-strand synthesis initiation | 13 | 6.53e-01 | -0.072000 | 7.33e-01 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 71 | 2.95e-01 | 0.071900 | 3.99e-01 |
| RNA Polymerase II Transcription Termination | 65 | 3.17e-01 | 0.071800 | 4.23e-01 |
| Ion channel transport | 152 | 1.31e-01 | -0.070900 | 2.15e-01 |
| O-linked glycosylation | 102 | 2.17e-01 | -0.070800 | 3.15e-01 |
| Processing of SMDT1 | 15 | 6.36e-01 | -0.070600 | 7.18e-01 |
| CS/DS degradation | 14 | 6.49e-01 | 0.070300 | 7.29e-01 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 27 | 5.28e-01 | -0.070200 | 6.25e-01 |
| Cilium Assembly | 181 | 1.04e-01 | -0.070000 | 1.79e-01 |
| Defective B3GALTL causes PpS | 37 | 4.61e-01 | 0.070000 | 5.63e-01 |
| CDK-mediated phosphorylation and removal of Cdc6 | 71 | 3.15e-01 | 0.069000 | 4.22e-01 |
| Metalloprotease DUBs | 26 | 5.44e-01 | -0.068800 | 6.39e-01 |
| Negative regulation of NOTCH4 signaling | 54 | 3.84e-01 | 0.068400 | 4.86e-01 |
| Nicotinate metabolism | 29 | 5.25e-01 | 0.068300 | 6.21e-01 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 72 | 3.22e-01 | 0.067500 | 4.28e-01 |
| The canonical retinoid cycle in rods (twilight vision) | 19 | 6.13e-01 | 0.067000 | 6.98e-01 |
| Activation of NF-kappaB in B cells | 65 | 3.51e-01 | -0.066900 | 4.53e-01 |
| S Phase | 160 | 1.46e-01 | 0.066600 | 2.35e-01 |
| Keratinization | 57 | 3.86e-01 | -0.066300 | 4.88e-01 |
| NoRC negatively regulates rRNA expression | 68 | 3.47e-01 | -0.065900 | 4.50e-01 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 4.95e-01 | 0.065800 | 5.95e-01 |
| Diseases of glycosylation | 133 | 1.95e-01 | -0.065100 | 2.90e-01 |
| Biological oxidations | 155 | 1.63e-01 | 0.064900 | 2.56e-01 |
| RNA Polymerase I Promoter Opening | 25 | 5.75e-01 | 0.064800 | 6.65e-01 |
| Nitric oxide stimulates guanylate cyclase | 18 | 6.34e-01 | -0.064800 | 7.18e-01 |
| Generation of second messenger molecules | 29 | 5.47e-01 | 0.064700 | 6.42e-01 |
| Chaperone Mediated Autophagy | 18 | 6.35e-01 | -0.064600 | 7.18e-01 |
| Arachidonic acid metabolism | 43 | 4.64e-01 | 0.064600 | 5.65e-01 |
| NCAM1 interactions | 36 | 5.05e-01 | 0.064200 | 6.03e-01 |
| Tryptophan catabolism | 13 | 6.91e-01 | 0.063800 | 7.67e-01 |
| FGFR2 alternative splicing | 26 | 5.74e-01 | -0.063700 | 6.65e-01 |
| Regulation of RUNX3 expression and activity | 54 | 4.20e-01 | -0.063400 | 5.22e-01 |
| Na+/Cl- dependent neurotransmitter transporters | 11 | 7.17e-01 | -0.063100 | 7.89e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 5.01e-01 | 0.063100 | 6.00e-01 |
| TNFs bind their physiological receptors | 22 | 6.09e-01 | 0.063100 | 6.97e-01 |
| Hedgehog ‘on’ state | 84 | 3.31e-01 | -0.061300 | 4.36e-01 |
| Trafficking of GluR2-containing AMPA receptors | 16 | 6.74e-01 | -0.060600 | 7.53e-01 |
| TICAM1-dependent activation of IRF3/IRF7 | 12 | 7.17e-01 | -0.060500 | 7.89e-01 |
| Biotin transport and metabolism | 11 | 7.28e-01 | -0.060500 | 7.95e-01 |
| Plasma lipoprotein remodeling | 25 | 6.02e-01 | -0.060300 | 6.90e-01 |
| Processing of Capped Intron-Containing Pre-mRNA | 238 | 1.10e-01 | -0.060000 | 1.88e-01 |
| PERK regulates gene expression | 32 | 5.57e-01 | -0.060000 | 6.48e-01 |
| RNA Polymerase I Promoter Clearance | 72 | 3.79e-01 | -0.059900 | 4.81e-01 |
| RNA Polymerase I Transcription | 72 | 3.79e-01 | -0.059900 | 4.81e-01 |
| Other interleukin signaling | 22 | 6.32e-01 | -0.059100 | 7.15e-01 |
| Transcriptional Regulation by VENTX | 38 | 5.32e-01 | -0.058500 | 6.29e-01 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 83 | 3.58e-01 | 0.058400 | 4.60e-01 |
| Apoptosis induced DNA fragmentation | 12 | 7.28e-01 | 0.058100 | 7.95e-01 |
| Voltage gated Potassium channels | 33 | 5.65e-01 | -0.057900 | 6.55e-01 |
| SHC-mediated cascade:FGFR3 | 16 | 6.89e-01 | 0.057900 | 7.67e-01 |
| HDR through MMEJ (alt-NHEJ) | 10 | 7.53e-01 | -0.057400 | 8.13e-01 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 38 | 5.43e-01 | -0.057100 | 6.38e-01 |
| tRNA processing | 124 | 2.75e-01 | 0.056700 | 3.81e-01 |
| G2/M DNA damage checkpoint | 69 | 4.21e-01 | -0.056000 | 5.23e-01 |
| Inwardly rectifying K+ channels | 30 | 6.00e-01 | 0.055400 | 6.88e-01 |
| Mitotic Prometaphase | 186 | 1.94e-01 | -0.055200 | 2.89e-01 |
| Diseases associated with N-glycosylation of proteins | 17 | 6.97e-01 | -0.054600 | 7.73e-01 |
| Protein localization | 158 | 2.37e-01 | -0.054500 | 3.38e-01 |
| Nucleotide Excision Repair | 110 | 3.26e-01 | -0.054200 | 4.31e-01 |
| Peptide ligand-binding receptors | 106 | 3.36e-01 | 0.054000 | 4.40e-01 |
| Inhibition of DNA recombination at telomere | 40 | 5.55e-01 | -0.054000 | 6.47e-01 |
| Mitotic Spindle Checkpoint | 109 | 3.33e-01 | -0.053700 | 4.37e-01 |
| PRC2 methylates histones and DNA | 35 | 5.83e-01 | -0.053700 | 6.73e-01 |
| Cross-presentation of soluble exogenous antigens (endosomes) | 45 | 5.55e-01 | 0.050900 | 6.47e-01 |
| Plasma lipoprotein clearance | 29 | 6.36e-01 | -0.050700 | 7.18e-01 |
| Prefoldin mediated transfer of substrate to CCT/TriC | 27 | 6.48e-01 | -0.050700 | 7.29e-01 |
| Defective pyroptosis | 35 | 6.04e-01 | 0.050600 | 6.92e-01 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 7.19e-01 | -0.050500 | 7.89e-01 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 7.19e-01 | -0.050500 | 7.89e-01 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 7.63e-01 | 0.050300 | 8.21e-01 |
| alpha-linolenic acid (ALA) metabolism | 12 | 7.63e-01 | 0.050300 | 8.21e-01 |
| Regulation of gene expression in beta cells | 14 | 7.45e-01 | -0.050300 | 8.09e-01 |
| Post-translational protein phosphorylation | 86 | 4.24e-01 | -0.049900 | 5.25e-01 |
| Assembly of the ORC complex at the origin of replication | 31 | 6.31e-01 | -0.049800 | 7.15e-01 |
| O-glycosylation of TSR domain-containing proteins | 38 | 5.97e-01 | 0.049600 | 6.87e-01 |
| Diseases of programmed cell death | 62 | 5.00e-01 | -0.049500 | 6.00e-01 |
| Senescence-Associated Secretory Phenotype (SASP) | 72 | 4.74e-01 | -0.048800 | 5.76e-01 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | 19 | 7.14e-01 | -0.048500 | 7.89e-01 |
| Base Excision Repair | 64 | 5.04e-01 | 0.048300 | 6.02e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 96 | 4.15e-01 | -0.048200 | 5.16e-01 |
| Advanced glycosylation endproduct receptor signaling | 11 | 7.83e-01 | -0.048100 | 8.39e-01 |
| Acyl chain remodelling of PE | 22 | 6.99e-01 | 0.047700 | 7.74e-01 |
| Separation of Sister Chromatids | 168 | 2.89e-01 | -0.047400 | 3.94e-01 |
| FGFR1c ligand binding and activation | 10 | 7.96e-01 | -0.047300 | 8.51e-01 |
| Vitamin D (calciferol) metabolism | 10 | 7.96e-01 | -0.047100 | 8.51e-01 |
| UCH proteinases | 92 | 4.41e-01 | -0.046400 | 5.43e-01 |
| Suppression of phagosomal maturation | 13 | 7.75e-01 | 0.045900 | 8.32e-01 |
| G2/M Checkpoints | 140 | 3.52e-01 | 0.045500 | 4.54e-01 |
| APC/C-mediated degradation of cell cycle proteins | 86 | 4.75e-01 | 0.044500 | 5.76e-01 |
| Regulation of mitotic cell cycle | 86 | 4.75e-01 | 0.044500 | 5.76e-01 |
| Amine ligand-binding receptors | 22 | 7.18e-01 | -0.044500 | 7.89e-01 |
| Autodegradation of the E3 ubiquitin ligase COP1 | 49 | 5.91e-01 | 0.044400 | 6.80e-01 |
| Vitamin B5 (pantothenate) metabolism | 17 | 7.54e-01 | 0.044000 | 8.13e-01 |
| cGMP effects | 14 | 7.81e-01 | -0.042900 | 8.38e-01 |
| Transcriptional Regulation by E2F6 | 34 | 6.74e-01 | 0.041700 | 7.53e-01 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 50 | 6.11e-01 | 0.041600 | 6.97e-01 |
| p53-Independent DNA Damage Response | 50 | 6.11e-01 | 0.041600 | 6.97e-01 |
| p53-Independent G1/S DNA damage checkpoint | 50 | 6.11e-01 | 0.041600 | 6.97e-01 |
| Acyl chain remodelling of PC | 21 | 7.44e-01 | 0.041200 | 8.09e-01 |
| Dectin-1 mediated noncanonical NF-kB signaling | 59 | 5.85e-01 | -0.041100 | 6.75e-01 |
| Metabolism of nucleotides | 90 | 5.01e-01 | 0.041000 | 6.00e-01 |
| Metabolism of vitamins and cofactors | 173 | 3.55e-01 | -0.040800 | 4.57e-01 |
| FGFR3 ligand binding and activation | 11 | 8.17e-01 | 0.040400 | 8.67e-01 |
| FGFR3c ligand binding and activation | 11 | 8.17e-01 | 0.040400 | 8.67e-01 |
| SCF(Skp2)-mediated degradation of p27/p21 | 60 | 5.98e-01 | 0.039300 | 6.88e-01 |
| Cleavage of the damaged purine | 29 | 7.16e-01 | -0.039100 | 7.89e-01 |
| Depurination | 29 | 7.16e-01 | -0.039100 | 7.89e-01 |
| Recognition and association of DNA glycosylase with site containing an affected purine | 29 | 7.16e-01 | -0.039100 | 7.89e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 5.54e-01 | -0.038800 | 6.47e-01 |
| Mismatch Repair | 15 | 7.96e-01 | 0.038500 | 8.51e-01 |
| Metabolism | 1885 | 5.44e-03 | -0.038400 | 1.44e-02 |
| Killing mechanisms | 12 | 8.18e-01 | -0.038400 | 8.67e-01 |
| WNT5:FZD7-mediated leishmania damping | 12 | 8.18e-01 | -0.038400 | 8.67e-01 |
| ABC-family proteins mediated transport | 97 | 5.16e-01 | -0.038200 | 6.12e-01 |
| Diseases associated with the TLR signaling cascade | 28 | 7.32e-01 | -0.037400 | 7.97e-01 |
| Diseases of Immune System | 28 | 7.32e-01 | -0.037400 | 7.97e-01 |
| Base-Excision Repair, AP Site Formation | 36 | 6.99e-01 | -0.037200 | 7.74e-01 |
| Xenobiotics | 15 | 8.03e-01 | -0.037200 | 8.56e-01 |
| ER-Phagosome pathway | 87 | 5.49e-01 | -0.037200 | 6.44e-01 |
| Signaling by Retinoic Acid | 38 | 6.94e-01 | -0.036800 | 7.71e-01 |
| Ubiquitin-dependent degradation of Cyclin D | 50 | 6.53e-01 | 0.036800 | 7.33e-01 |
| Activation of G protein gated Potassium channels | 25 | 7.51e-01 | 0.036700 | 8.12e-01 |
| G protein gated Potassium channels | 25 | 7.51e-01 | 0.036700 | 8.12e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 25 | 7.51e-01 | 0.036700 | 8.12e-01 |
| Metabolism of polyamines | 57 | 6.38e-01 | -0.036100 | 7.19e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins | 67 | 6.15e-01 | 0.035600 | 6.99e-01 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | 87 | 5.66e-01 | -0.035500 | 6.56e-01 |
| Diseases of metabolism | 218 | 3.68e-01 | -0.035300 | 4.71e-01 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | 58 | 6.44e-01 | 0.035000 | 7.26e-01 |
| Muscle contraction | 161 | 4.54e-01 | -0.034200 | 5.56e-01 |
| SIRT1 negatively regulates rRNA expression | 30 | 7.52e-01 | -0.033400 | 8.12e-01 |
| GABA synthesis, release, reuptake and degradation | 18 | 8.06e-01 | -0.033300 | 8.59e-01 |
| G2/M Transition | 181 | 4.44e-01 | -0.033000 | 5.44e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 6.02e-01 | -0.032900 | 6.90e-01 |
| Collagen formation | 86 | 5.99e-01 | -0.032800 | 6.88e-01 |
| Fatty acid metabolism | 152 | 4.86e-01 | -0.032700 | 5.86e-01 |
| Signaling by FGFR2 in disease | 40 | 7.21e-01 | -0.032600 | 7.91e-01 |
| Regulation of APC/C activators between G1/S and early anaphase | 79 | 6.20e-01 | 0.032300 | 7.04e-01 |
| Regulation of BACH1 activity | 11 | 8.54e-01 | 0.032100 | 8.99e-01 |
| Degradation of AXIN | 53 | 6.86e-01 | -0.032100 | 7.65e-01 |
| Cell Cycle, Mitotic | 513 | 2.22e-01 | -0.031500 | 3.22e-01 |
| mRNA 3’-end processing | 56 | 6.85e-01 | 0.031300 | 7.64e-01 |
| Condensation of Prophase Chromosomes | 35 | 7.48e-01 | 0.031300 | 8.12e-01 |
| Metabolism of porphyrins | 22 | 8.01e-01 | 0.031100 | 8.54e-01 |
| FRS-mediated FGFR4 signaling | 19 | 8.15e-01 | -0.030900 | 8.67e-01 |
| tRNA modification in the nucleus and cytosol | 43 | 7.26e-01 | 0.030900 | 7.94e-01 |
| Complement cascade | 36 | 7.49e-01 | 0.030800 | 8.12e-01 |
| NIK–>noncanonical NF-kB signaling | 57 | 6.90e-01 | -0.030600 | 7.67e-01 |
| TP53 Regulates Transcription of Death Receptors and Ligands | 11 | 8.61e-01 | -0.030500 | 9.05e-01 |
| DNA Damage Recognition in GG-NER | 38 | 7.46e-01 | -0.030400 | 8.10e-01 |
| Basigin interactions | 23 | 8.01e-01 | -0.030300 | 8.54e-01 |
| RNA Polymerase I Promoter Escape | 53 | 7.05e-01 | -0.030100 | 7.80e-01 |
| Heme degradation | 11 | 8.64e-01 | -0.029900 | 9.06e-01 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 8.64e-01 | -0.029900 | 9.06e-01 |
| Amyloid fiber formation | 60 | 6.91e-01 | 0.029700 | 7.67e-01 |
| Mitotic G2-G2/M phases | 183 | 4.92e-01 | -0.029400 | 5.92e-01 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | 53 | 7.13e-01 | 0.029200 | 7.89e-01 |
| Recruitment of NuMA to mitotic centrosomes | 80 | 6.54e-01 | -0.029000 | 7.33e-01 |
| FGFR1 ligand binding and activation | 14 | 8.52e-01 | -0.028800 | 8.98e-01 |
| ABC transporter disorders | 72 | 6.78e-01 | -0.028300 | 7.57e-01 |
| Assembly of collagen fibrils and other multimeric structures | 54 | 7.22e-01 | -0.028000 | 7.91e-01 |
| Carboxyterminal post-translational modifications of tubulin | 37 | 7.71e-01 | -0.027700 | 8.28e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 8.45e-01 | -0.027300 | 8.94e-01 |
| Potassium Channels | 84 | 6.67e-01 | -0.027200 | 7.46e-01 |
| Intrinsic Pathway of Fibrin Clot Formation | 14 | 8.62e-01 | -0.026900 | 9.06e-01 |
| DNA Damage Bypass | 47 | 7.50e-01 | -0.026800 | 8.12e-01 |
| Acyl chain remodelling of PI | 12 | 8.72e-01 | 0.026800 | 9.11e-01 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 7.42e-01 | 0.026100 | 8.08e-01 |
| ROS sensing by NFE2L2 | 55 | 7.38e-01 | -0.026100 | 8.03e-01 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | 22 | 8.37e-01 | -0.025300 | 8.86e-01 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | 48 | 7.63e-01 | 0.025100 | 8.21e-01 |
| GPCR ligand binding | 270 | 4.77e-01 | -0.025100 | 5.78e-01 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | 13 | 8.78e-01 | 0.024700 | 9.15e-01 |
| DNA Repair | 298 | 4.66e-01 | -0.024500 | 5.68e-01 |
| IL-6-type cytokine receptor ligand interactions | 16 | 8.65e-01 | -0.024500 | 9.06e-01 |
| Diseases of mitotic cell cycle | 38 | 7.96e-01 | 0.024200 | 8.51e-01 |
| Cell Cycle | 638 | 2.99e-01 | -0.024000 | 4.04e-01 |
| NRIF signals cell death from the nucleus | 16 | 8.68e-01 | 0.023900 | 9.09e-01 |
| Cellular response to chemical stress | 149 | 6.24e-01 | -0.023200 | 7.08e-01 |
| Stabilization of p53 | 53 | 7.70e-01 | 0.023200 | 8.28e-01 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 14 | 8.81e-01 | -0.023100 | 9.18e-01 |
| The activation of arylsulfatases | 10 | 9.02e-01 | 0.022500 | 9.35e-01 |
| Nucleotide-like (purinergic) receptors | 10 | 9.03e-01 | 0.022300 | 9.35e-01 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 30 | 8.33e-01 | -0.022200 | 8.82e-01 |
| Cyclin A:Cdk2-associated events at S phase entry | 85 | 7.26e-01 | -0.022000 | 7.94e-01 |
| Vpu mediated degradation of CD4 | 50 | 7.88e-01 | 0.022000 | 8.45e-01 |
| Nicotinamide salvaging | 18 | 8.79e-01 | 0.020800 | 9.16e-01 |
| DNA Double-Strand Break Repair | 140 | 6.72e-01 | 0.020700 | 7.51e-01 |
| Antigen processing-Cross presentation | 98 | 7.24e-01 | -0.020700 | 7.93e-01 |
| Pyroptosis | 24 | 8.65e-01 | -0.020000 | 9.06e-01 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation | 36 | 8.48e-01 | -0.018500 | 8.95e-01 |
| Metabolism of water-soluble vitamins and cofactors | 119 | 7.29e-01 | -0.018400 | 7.95e-01 |
| Trafficking and processing of endosomal TLR | 11 | 9.23e-01 | -0.016800 | 9.50e-01 |
| Sensory perception of taste | 24 | 8.87e-01 | 0.016700 | 9.23e-01 |
| Interleukin-10 signaling | 35 | 8.65e-01 | 0.016600 | 9.06e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 9.03e-01 | -0.016500 | 9.35e-01 |
| Hh mutants are degraded by ERAD | 54 | 8.34e-01 | -0.016500 | 8.83e-01 |
| Phospholipase C-mediated cascade: FGFR1 | 14 | 9.18e-01 | 0.016000 | 9.47e-01 |
| Smooth Muscle Contraction | 32 | 8.77e-01 | -0.015800 | 9.15e-01 |
| Class A/1 (Rhodopsin-like receptors) | 185 | 7.14e-01 | -0.015600 | 7.89e-01 |
| PIWI-interacting RNA (piRNA) biogenesis | 25 | 8.95e-01 | 0.015300 | 9.28e-01 |
| TNFR2 non-canonical NF-kB pathway | 91 | 8.11e-01 | -0.014500 | 8.63e-01 |
| GLI3 is processed to GLI3R by the proteasome | 57 | 8.52e-01 | -0.014300 | 8.98e-01 |
| Cytochrome P450 - arranged by substrate type | 44 | 8.71e-01 | -0.014100 | 9.10e-01 |
| Pregnenolone biosynthesis | 11 | 9.38e-01 | 0.013400 | 9.58e-01 |
| Transcriptional regulation of testis differentiation | 11 | 9.39e-01 | 0.013300 | 9.58e-01 |
| Processive synthesis on the C-strand of the telomere | 19 | 9.21e-01 | -0.013100 | 9.49e-01 |
| Metabolism of RNA | 677 | 5.60e-01 | -0.013100 | 6.50e-01 |
| Meiosis | 77 | 8.47e-01 | -0.012700 | 8.94e-01 |
| Signaling by FGFR2 IIIa TM | 19 | 9.25e-01 | 0.012500 | 9.51e-01 |
| Collagen biosynthesis and modifying enzymes | 64 | 8.69e-01 | 0.011900 | 9.09e-01 |
| Hyaluronan metabolism | 14 | 9.39e-01 | 0.011900 | 9.58e-01 |
| Purine salvage | 12 | 9.46e-01 | -0.011200 | 9.62e-01 |
| Regulation of TP53 Activity through Methylation | 19 | 9.33e-01 | -0.011200 | 9.55e-01 |
| Early Phase of HIV Life Cycle | 13 | 9.46e-01 | -0.010900 | 9.62e-01 |
| FRS-mediated FGFR2 signaling | 22 | 9.30e-01 | -0.010800 | 9.55e-01 |
| mRNA Splicing | 187 | 7.99e-01 | 0.010800 | 8.53e-01 |
| Glucagon-type ligand receptors | 25 | 9.27e-01 | 0.010600 | 9.52e-01 |
| Caspase activation via Death Receptors in the presence of ligand | 15 | 9.44e-01 | -0.010600 | 9.61e-01 |
| Hedgehog ligand biogenesis | 63 | 8.86e-01 | -0.010500 | 9.22e-01 |
| p53-Dependent G1 DNA Damage Response | 62 | 8.94e-01 | -0.009770 | 9.28e-01 |
| p53-Dependent G1/S DNA damage checkpoint | 62 | 8.94e-01 | -0.009770 | 9.28e-01 |
| Collagen chain trimerization | 41 | 9.20e-01 | 0.009020 | 9.49e-01 |
| Signaling by NOTCH4 | 81 | 8.89e-01 | -0.009010 | 9.23e-01 |
| Dual incision in TC-NER | 65 | 9.05e-01 | -0.008560 | 9.35e-01 |
| Metabolism of steroid hormones | 30 | 9.38e-01 | 0.008210 | 9.58e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 15 | 9.57e-01 | -0.007980 | 9.70e-01 |
| Hh mutants abrogate ligand secretion | 57 | 9.18e-01 | -0.007890 | 9.47e-01 |
| Peroxisomal lipid metabolism | 27 | 9.49e-01 | -0.007170 | 9.64e-01 |
| Reproduction | 93 | 9.05e-01 | 0.007150 | 9.35e-01 |
| Cyclin E associated events during G1/S transition | 83 | 9.10e-01 | -0.007140 | 9.40e-01 |
| Degradation of GLI2 by the proteasome | 57 | 9.32e-01 | 0.006560 | 9.55e-01 |
| Cell Cycle Checkpoints | 260 | 8.59e-01 | -0.006400 | 9.04e-01 |
| SHC-mediated cascade:FGFR1 | 19 | 9.62e-01 | -0.006240 | 9.73e-01 |
| G1/S DNA Damage Checkpoints | 64 | 9.32e-01 | -0.006210 | 9.55e-01 |
| Gluconeogenesis | 28 | 9.55e-01 | 0.006190 | 9.68e-01 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | 89 | 9.25e-01 | 0.005810 | 9.51e-01 |
| Iron uptake and transport | 56 | 9.41e-01 | -0.005720 | 9.60e-01 |
| Regulation of ornithine decarboxylase (ODC) | 49 | 9.46e-01 | 0.005600 | 9.62e-01 |
| Phase I - Functionalization of compounds | 75 | 9.34e-01 | -0.005560 | 9.56e-01 |
| Termination of O-glycan biosynthesis | 19 | 9.67e-01 | -0.005410 | 9.76e-01 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 64 | 9.42e-01 | -0.005280 | 9.60e-01 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 17 | 9.71e-01 | 0.005160 | 9.78e-01 |
| SCF-beta-TrCP mediated degradation of Emi1 | 53 | 9.50e-01 | 0.004990 | 9.64e-01 |
| Degradation of DVL | 55 | 9.50e-01 | 0.004870 | 9.64e-01 |
| Translesion Synthesis by POLH | 18 | 9.76e-01 | -0.004060 | 9.83e-01 |
| Processing of DNA double-strand break ends | 72 | 9.59e-01 | -0.003540 | 9.70e-01 |
| Regulation of Complement cascade | 29 | 9.77e-01 | 0.003030 | 9.83e-01 |
| Degradation of GLI1 by the proteasome | 57 | 9.68e-01 | -0.003020 | 9.76e-01 |
| Centrosome maturation | 81 | 9.63e-01 | 0.002940 | 9.73e-01 |
| Recruitment of mitotic centrosome proteins and complexes | 81 | 9.63e-01 | 0.002940 | 9.73e-01 |
| Lysine catabolism | 12 | 9.88e-01 | 0.002480 | 9.92e-01 |
| Glycosphingolipid metabolism | 41 | 9.79e-01 | -0.002410 | 9.84e-01 |
| mRNA Splicing - Major Pathway | 179 | 9.62e-01 | -0.002060 | 9.73e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 9.84e-01 | 0.001490 | 9.88e-01 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | 10 | 9.95e-01 | -0.001120 | 9.96e-01 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | 25 | 9.95e-01 | 0.000742 | 9.96e-01 |
| Regulation of Apoptosis | 51 | 9.93e-01 | 0.000705 | 9.96e-01 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 9.97e-01 | -0.000511 | 9.98e-01 |
| Anchoring of the basal body to the plasma membrane | 97 | 9.94e-01 | 0.000412 | 9.96e-01 |
| Integrin cell surface interactions | 58 | 9.98e-01 | -0.000210 | 9.98e-01 |
Detailed Gene set reports
CLEC7A (Dectin-1) induces NFAT activation
| 136 | |
|---|---|
| set | CLEC7A (Dectin-1) induces NFAT activation |
| setSize | 11 |
| pANOVA | 1.83e-06 |
| s.dist | -0.831 |
| p.adjustANOVA | 1.26e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ITPR1 | -11467 |
| ITPR3 | -10385 |
| NFATC2 | -10372 |
| PPP3R1 | -10363 |
| AHCYL1 | -10321 |
| ITPR2 | -10230 |
| NFATC1 | -10050 |
| NFATC3 | -9699 |
| PPP3CB | -8774 |
| PPP3CA | -6485 |
| CALM1 | -3767 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ITPR1 | -11467 |
| ITPR3 | -10385 |
| NFATC2 | -10372 |
| PPP3R1 | -10363 |
| AHCYL1 | -10321 |
| ITPR2 | -10230 |
| NFATC1 | -10050 |
| NFATC3 | -9699 |
| PPP3CB | -8774 |
| PPP3CA | -6485 |
| CALM1 | -3767 |
Cohesin Loading onto Chromatin
| 206 | |
|---|---|
| set | Cohesin Loading onto Chromatin |
| setSize | 10 |
| pANOVA | 1.05e-05 |
| s.dist | -0.804 |
| p.adjustANOVA | 6.09e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PDS5A | -11387 |
| WAPL | -10612 |
| RAD21 | -10332 |
| STAG2 | -10019 |
| MAU2 | -9731 |
| NIPBL | -9082 |
| PDS5B | -9033 |
| SMC1A | -8262 |
| STAG1 | -5541 |
| SMC3 | -5244 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PDS5A | -11387 |
| WAPL | -10612 |
| RAD21 | -10332 |
| STAG2 | -10019 |
| MAU2 | -9731 |
| NIPBL | -9082 |
| PDS5B | -9033 |
| SMC1A | -8262 |
| STAG1 | -5541 |
| SMC3 | -5244 |
MET activates RAP1 and RAC1
| 660 | |
|---|---|
| set | MET activates RAP1 and RAC1 |
| setSize | 11 |
| pANOVA | 6.11e-06 |
| s.dist | -0.787 |
| p.adjustANOVA | 3.76e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CRKL | -11246 |
| CRK | -10821 |
| GRB2 | -10367 |
| RAP1B | -10068 |
| RAPGEF1 | -9979 |
| MET | -9354 |
| GAB1 | -8583 |
| DOCK7 | -8573 |
| RAP1A | -6032 |
| RAC1 | -5771 |
| HGF | -4913 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CRKL | -11246 |
| CRK | -10821 |
| GRB2 | -10367 |
| RAP1B | -10068 |
| RAPGEF1 | -9979 |
| MET | -9354 |
| GAB1 | -8583 |
| DOCK7 | -8573 |
| RAP1A | -6032 |
| RAC1 | -5771 |
| HGF | -4913 |
APC truncation mutants have impaired AXIN binding
| 11 | |
|---|---|
| set | APC truncation mutants have impaired AXIN binding |
| setSize | 14 |
| pANOVA | 4.19e-07 |
| s.dist | -0.781 |
| p.adjustANOVA | 3.27e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
AXIN missense mutants destabilize the destruction complex
| 24 | |
|---|---|
| set | AXIN missense mutants destabilize the destruction complex |
| setSize | 14 |
| pANOVA | 4.19e-07 |
| s.dist | -0.781 |
| p.adjustANOVA | 3.27e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Signaling by AMER1 mutants
| 1171 | |
|---|---|
| set | Signaling by AMER1 mutants |
| setSize | 14 |
| pANOVA | 4.19e-07 |
| s.dist | -0.781 |
| p.adjustANOVA | 3.27e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Signaling by APC mutants
| 1172 | |
|---|---|
| set | Signaling by APC mutants |
| setSize | 14 |
| pANOVA | 4.19e-07 |
| s.dist | -0.781 |
| p.adjustANOVA | 3.27e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Signaling by AXIN mutants
| 1173 | |
|---|---|
| set | Signaling by AXIN mutants |
| setSize | 14 |
| pANOVA | 4.19e-07 |
| s.dist | -0.781 |
| p.adjustANOVA | 3.27e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Truncations of AMER1 destabilize the destruction complex
| 1412 | |
|---|---|
| set | Truncations of AMER1 destabilize the destruction complex |
| setSize | 14 |
| pANOVA | 4.19e-07 |
| s.dist | -0.781 |
| p.adjustANOVA | 3.27e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
S33 mutants of beta-catenin aren’t phosphorylated
| 1106 | |
|---|---|
| set | S33 mutants of beta-catenin aren’t phosphorylated |
| setSize | 15 |
| pANOVA | 1.66e-07 |
| s.dist | -0.78 |
| p.adjustANOVA | 1.45e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
S37 mutants of beta-catenin aren’t phosphorylated
| 1107 | |
|---|---|
| set | S37 mutants of beta-catenin aren’t phosphorylated |
| setSize | 15 |
| pANOVA | 1.66e-07 |
| s.dist | -0.78 |
| p.adjustANOVA | 1.45e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
S45 mutants of beta-catenin aren’t phosphorylated
| 1108 | |
|---|---|
| set | S45 mutants of beta-catenin aren’t phosphorylated |
| setSize | 15 |
| pANOVA | 1.66e-07 |
| s.dist | -0.78 |
| p.adjustANOVA | 1.45e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Signaling by CTNNB1 phospho-site mutants
| 1178 | |
|---|---|
| set | Signaling by CTNNB1 phospho-site mutants |
| setSize | 15 |
| pANOVA | 1.66e-07 |
| s.dist | -0.78 |
| p.adjustANOVA | 1.45e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Signaling by GSK3beta mutants
| 1205 | |
|---|---|
| set | Signaling by GSK3beta mutants |
| setSize | 15 |
| pANOVA | 1.66e-07 |
| s.dist | -0.78 |
| p.adjustANOVA | 1.45e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
T41 mutants of beta-catenin aren’t phosphorylated
| 1296 | |
|---|---|
| set | T41 mutants of beta-catenin aren’t phosphorylated |
| setSize | 15 |
| pANOVA | 1.66e-07 |
| s.dist | -0.78 |
| p.adjustANOVA | 1.45e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
Signaling by Hippo
| 1207 | |
|---|---|
| set | Signaling by Hippo |
| setSize | 20 |
| pANOVA | 6.57e-09 |
| s.dist | -0.749 |
| p.adjustANOVA | 7.73e-08 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AMOTL1 | -11203 |
| CASP3 | -10662 |
| STK4 | -10633 |
| YAP1 | -10335 |
| AMOTL2 | -10306 |
| LATS1 | -10290 |
| AMOT | -9363 |
| TJP2 | -9213 |
| SAV1 | -9029 |
| DVL2 | -9009 |
| MOB1B | -8852 |
| STK3 | -8788 |
| WWTR1 | -8042 |
| MOB1A | -7934 |
| YWHAE | -7383 |
| TJP1 | -7227 |
| NPHP4 | -6510 |
| LATS2 | -5529 |
| WWC1 | -4350 |
| YWHAB | 668 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AMOTL1 | -11203 |
| CASP3 | -10662 |
| STK4 | -10633 |
| YAP1 | -10335 |
| AMOTL2 | -10306 |
| LATS1 | -10290 |
| AMOT | -9363 |
| TJP2 | -9213 |
| SAV1 | -9029 |
| DVL2 | -9009 |
| MOB1B | -8852 |
| STK3 | -8788 |
| WWTR1 | -8042 |
| MOB1A | -7934 |
| YWHAE | -7383 |
| TJP1 | -7227 |
| NPHP4 | -6510 |
| LATS2 | -5529 |
| WWC1 | -4350 |
| YWHAB | 668 |
Establishment of Sister Chromatid Cohesion
| 373 | |
|---|---|
| set | Establishment of Sister Chromatid Cohesion |
| setSize | 11 |
| pANOVA | 1.81e-05 |
| s.dist | -0.746 |
| p.adjustANOVA | 9.73e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PDS5A | -11387 |
| WAPL | -10612 |
| ESCO1 | -10457 |
| RAD21 | -10332 |
| STAG2 | -10019 |
| PDS5B | -9033 |
| SMC1A | -8262 |
| STAG1 | -5541 |
| SMC3 | -5244 |
| ESCO2 | -4962 |
| CDCA5 | -4010 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PDS5A | -11387 |
| WAPL | -10612 |
| ESCO1 | -10457 |
| RAD21 | -10332 |
| STAG2 | -10019 |
| PDS5B | -9033 |
| SMC1A | -8262 |
| STAG1 | -5541 |
| SMC3 | -5244 |
| ESCO2 | -4962 |
| CDCA5 | -4010 |
Beta-catenin phosphorylation cascade
| 113 | |
|---|---|
| set | Beta-catenin phosphorylation cascade |
| setSize | 17 |
| pANOVA | 1.25e-07 |
| s.dist | -0.74 |
| p.adjustANOVA | 1.16e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| FRAT2 | -5944 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
| FRAT1 | -2421 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| PPP2R5E | -9609 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| FRAT2 | -5944 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
| FRAT1 | -2421 |
ERKs are inactivated
| 358 | |
|---|---|
| set | ERKs are inactivated |
| setSize | 13 |
| pANOVA | 4.14e-06 |
| s.dist | -0.737 |
| p.adjustANOVA | 2.66e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| MAPK1 | -11072 |
| DUSP4 | -10845 |
| MAPK3 | -10415 |
| DUSP7 | -9778 |
| VRK3 | -8696 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| MAPK7 | -6939 |
| DUSP3 | -5115 |
| PPP2R1B | -3752 |
| DUSP6 | -787 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| MAPK1 | -11072 |
| DUSP4 | -10845 |
| MAPK3 | -10415 |
| DUSP7 | -9778 |
| VRK3 | -8696 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| MAPK7 | -6939 |
| DUSP3 | -5115 |
| PPP2R1B | -3752 |
| DUSP6 | -787 |
Interleukin-6 signaling
| 605 | |
|---|---|
| set | Interleukin-6 signaling |
| setSize | 11 |
| pANOVA | 3.09e-05 |
| s.dist | -0.725 |
| p.adjustANOVA | 0.000159 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CBL | -10978 |
| JAK2 | -10798 |
| JAK1 | -10594 |
| STAT1 | -10096 |
| PTPN11 | -9113 |
| STAT3 | -7915 |
| IL6ST | -7508 |
| IL6R | -7013 |
| TYK2 | -6251 |
| SOCS3 | -5490 |
| IL6 | -1086 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CBL | -10978 |
| JAK2 | -10798 |
| JAK1 | -10594 |
| STAT1 | -10096 |
| PTPN11 | -9113 |
| STAT3 | -7915 |
| IL6ST | -7508 |
| IL6R | -7013 |
| TYK2 | -6251 |
| SOCS3 | -5490 |
| IL6 | -1086 |
HDMs demethylate histones
| 511 | |
|---|---|
| set | HDMs demethylate histones |
| setSize | 22 |
| pANOVA | 6.47e-09 |
| s.dist | -0.715 |
| p.adjustANOVA | 7.67e-08 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| KDM7A | -11434 |
| KDM1B | -10992 |
| KDM5B | -10702 |
| KDM4C | -10302 |
| KDM1A | -10261 |
| KDM2A | -10244 |
| KDM4B | -10222 |
| KDM6A | -10140 |
| KDM2B | -10021 |
| KDM5C | -9795 |
| PHF8 | -9160 |
| KDM5A | -9002 |
| KDM3A | -8736 |
| PHF2 | -8710 |
| JMJD6 | -8352 |
| KDM6B | -7756 |
| KDM3B | -6731 |
| KDM4A | -6662 |
| ARID5B | -5854 |
| KDM4D | -5143 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| KDM7A | -11434.0 |
| KDM1B | -10992.0 |
| KDM5B | -10702.0 |
| KDM4C | -10302.0 |
| KDM1A | -10261.0 |
| KDM2A | -10244.0 |
| KDM4B | -10222.0 |
| KDM6A | -10140.0 |
| KDM2B | -10021.0 |
| KDM5C | -9795.0 |
| PHF8 | -9160.0 |
| KDM5A | -9002.0 |
| KDM3A | -8736.0 |
| PHF2 | -8710.0 |
| JMJD6 | -8352.0 |
| KDM6B | -7756.0 |
| KDM3B | -6731.0 |
| KDM4A | -6662.0 |
| ARID5B | -5854.0 |
| KDM4D | -5143.0 |
| H3C1 | 1377.0 |
| H3C15 | 8338.5 |
Synthesis of PIPs at the late endosome membrane
| 1282 | |
|---|---|
| set | Synthesis of PIPs at the late endosome membrane |
| setSize | 11 |
| pANOVA | 7.55e-05 |
| s.dist | -0.689 |
| p.adjustANOVA | 0.000346 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIKFYVE | -11087 |
| MTMR9 | -9769 |
| MTMR2 | -9653 |
| VAC14 | -9543 |
| PIK3C2A | -9163 |
| PIK3C3 | -9077 |
| MTMR4 | -8826 |
| MTM1 | -7734 |
| PIK3R4 | -6977 |
| MTMR7 | -650 |
| FIG4 | 820 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PIKFYVE | -11087 |
| MTMR9 | -9769 |
| MTMR2 | -9653 |
| VAC14 | -9543 |
| PIK3C2A | -9163 |
| PIK3C3 | -9077 |
| MTMR4 | -8826 |
| MTM1 | -7734 |
| PIK3R4 | -6977 |
| MTMR7 | -650 |
| FIG4 | 820 |
Deadenylation of mRNA
| 262 | |
|---|---|
| set | Deadenylation of mRNA |
| setSize | 22 |
| pANOVA | 3.47e-08 |
| s.dist | -0.679 |
| p.adjustANOVA | 3.45e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| TNKS1BP1 | -11414 |
| CNOT7 | -11127 |
| CNOT1 | -10965 |
| EIF4B | -10677 |
| CNOT8 | -10654 |
| PABPC1 | -10283 |
| EIF4E | -10097 |
| EIF4A2 | -9886 |
| CNOT6L | -9450 |
| EIF4G1 | -9102 |
| CNOT11 | -9081 |
| PARN | -8217 |
| PAIP1 | -8170 |
| CNOT3 | -7116 |
| CNOT6 | -6401 |
| EIF4A1 | -6282 |
| PAN3 | -5808 |
| EIF4A3 | -5781 |
| CNOT4 | -5456 |
| CNOT10 | -3665 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| TNKS1BP1 | -11414 |
| CNOT7 | -11127 |
| CNOT1 | -10965 |
| EIF4B | -10677 |
| CNOT8 | -10654 |
| PABPC1 | -10283 |
| EIF4E | -10097 |
| EIF4A2 | -9886 |
| CNOT6L | -9450 |
| EIF4G1 | -9102 |
| CNOT11 | -9081 |
| PARN | -8217 |
| PAIP1 | -8170 |
| CNOT3 | -7116 |
| CNOT6 | -6401 |
| EIF4A1 | -6282 |
| PAN3 | -5808 |
| EIF4A3 | -5781 |
| CNOT4 | -5456 |
| CNOT10 | -3665 |
| CNOT2 | -1026 |
| PAN2 | 10291 |
Unwinding of DNA
| 1420 | |
|---|---|
| set | Unwinding of DNA |
| setSize | 12 |
| pANOVA | 4.94e-05 |
| s.dist | 0.676 |
| p.adjustANOVA | 0.000239 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| GINS2 | 14333 |
| MCM3 | 14216 |
| CDC45 | 14049 |
| MCM5 | 13881 |
| MCM8 | 13686 |
| GINS3 | 13167 |
| MCM2 | 12866 |
| MCM4 | 12553 |
| GINS1 | 12125 |
| GINS4 | 11929 |
| MCM7 | -513 |
| MCM6 | -8231 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| GINS2 | 14333 |
| MCM3 | 14216 |
| CDC45 | 14049 |
| MCM5 | 13881 |
| MCM8 | 13686 |
| GINS3 | 13167 |
| MCM2 | 12866 |
| MCM4 | 12553 |
| GINS1 | 12125 |
| GINS4 | 11929 |
| MCM7 | -513 |
| MCM6 | -8231 |
Cell-extracellular matrix interactions
| 174 | |
|---|---|
| set | Cell-extracellular matrix interactions |
| setSize | 16 |
| pANOVA | 3.25e-06 |
| s.dist | -0.672 |
| p.adjustANOVA | 2.14e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FLNA | -11412 |
| FLNC | -11404 |
| FERMT2 | -11265 |
| ITGB1 | -10823 |
| LIMS1 | -10564 |
| PXN | -10479 |
| ACTN1 | -10130 |
| PARVB | -9617 |
| VASP | -8523 |
| ILK | -8046 |
| PARVA | -6732 |
| TESK1 | -6722 |
| LIMS2 | -5399 |
| ARHGEF6 | -4187 |
| RSU1 | -1626 |
| FBLIM1 | 11772 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FLNA | -11412 |
| FLNC | -11404 |
| FERMT2 | -11265 |
| ITGB1 | -10823 |
| LIMS1 | -10564 |
| PXN | -10479 |
| ACTN1 | -10130 |
| PARVB | -9617 |
| VASP | -8523 |
| ILK | -8046 |
| PARVA | -6732 |
| TESK1 | -6722 |
| LIMS2 | -5399 |
| ARHGEF6 | -4187 |
| RSU1 | -1626 |
| FBLIM1 | 11772 |
Ephrin signaling
| 369 | |
|---|---|
| set | Ephrin signaling |
| setSize | 19 |
| pANOVA | 4.19e-07 |
| s.dist | -0.67 |
| p.adjustANOVA | 3.27e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PAK1 | -11332 |
| EPHB6 | -11224 |
| SRC | -11039 |
| EPHB4 | -10939 |
| SDCBP | -10764 |
| EPHB2 | -10272 |
| EFNB2 | -10181 |
| PAK2 | -9919 |
| EFNB3 | -9779 |
| FYN | -9643 |
| NCK2 | -8772 |
| EPHB1 | -7019 |
| RAC1 | -5771 |
| PAK3 | -4223 |
| GIT1 | -3711 |
| EFNB1 | -3364 |
| MYL12A | -2453 |
| ARHGEF7 | -2315 |
| EPHB3 | 6369 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PAK1 | -11332 |
| EPHB6 | -11224 |
| SRC | -11039 |
| EPHB4 | -10939 |
| SDCBP | -10764 |
| EPHB2 | -10272 |
| EFNB2 | -10181 |
| PAK2 | -9919 |
| EFNB3 | -9779 |
| FYN | -9643 |
| NCK2 | -8772 |
| EPHB1 | -7019 |
| RAC1 | -5771 |
| PAK3 | -4223 |
| GIT1 | -3711 |
| EFNB1 | -3364 |
| MYL12A | -2453 |
| ARHGEF7 | -2315 |
| EPHB3 | 6369 |
tRNA processing in the mitochondrion
| 1479 | |
|---|---|
| set | tRNA processing in the mitochondrion |
| setSize | 20 |
| pANOVA | 2.52e-07 |
| s.dist | 0.666 |
| p.adjustANOVA | 2.11e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MT-CO3 | 14510 |
| MT-CYB | 14392 |
| MT-CO1 | 14342 |
| MT-ND3 | 14280 |
| MT-CO2 | 14237 |
| MT-RNR2 | 13980 |
| MT-ATP8 | 13926 |
| MT-ND2 | 13898 |
| MT-RNR1 | 13892 |
| MT-ATP6 | 13802 |
| MT-ND4 | 13703 |
| MT-ND1 | 13666 |
| MT-ND4L | 13647 |
| MT-ND5 | 13494 |
| MT-ND6 | 13393 |
| HSD17B10 | 12939 |
| TRMT10C | 1336 |
| TRNT1 | -4293 |
| ELAC2 | -7408 |
| PRORP | -7800 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MT-CO3 | 14510 |
| MT-CYB | 14392 |
| MT-CO1 | 14342 |
| MT-ND3 | 14280 |
| MT-CO2 | 14237 |
| MT-RNR2 | 13980 |
| MT-ATP8 | 13926 |
| MT-ND2 | 13898 |
| MT-RNR1 | 13892 |
| MT-ATP6 | 13802 |
| MT-ND4 | 13703 |
| MT-ND1 | 13666 |
| MT-ND4L | 13647 |
| MT-ND5 | 13494 |
| MT-ND6 | 13393 |
| HSD17B10 | 12939 |
| TRMT10C | 1336 |
| TRNT1 | -4293 |
| ELAC2 | -7408 |
| PRORP | -7800 |
FOXO-mediated transcription of cell cycle genes
| 404 | |
|---|---|
| set | FOXO-mediated transcription of cell cycle genes |
| setSize | 15 |
| pANOVA | 1.01e-05 |
| s.dist | -0.658 |
| p.adjustANOVA | 5.98e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CDKN1A | -11319 |
| FOXO3 | -11182 |
| SMAD4 | -10729 |
| BTG1 | -10371 |
| RBL2 | -10063 |
| SMAD2 | -10012 |
| SMAD3 | -9453 |
| CDKN1B | -8708 |
| CAV1 | -8579 |
| FOXO1 | -8481 |
| CCNG2 | -7777 |
| FOXO4 | -5888 |
| KLF4 | -3806 |
| GADD45A | -2655 |
| PCBP4 | 13739 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CDKN1A | -11319 |
| FOXO3 | -11182 |
| SMAD4 | -10729 |
| BTG1 | -10371 |
| RBL2 | -10063 |
| SMAD2 | -10012 |
| SMAD3 | -9453 |
| CDKN1B | -8708 |
| CAV1 | -8579 |
| FOXO1 | -8481 |
| CCNG2 | -7777 |
| FOXO4 | -5888 |
| KLF4 | -3806 |
| GADD45A | -2655 |
| PCBP4 | 13739 |
RHO GTPases activate KTN1
| 951 | |
|---|---|
| set | RHO GTPases activate KTN1 |
| setSize | 11 |
| pANOVA | 0.000159 |
| s.dist | -0.658 |
| p.adjustANOVA | 0.000676 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| KIF5B | -10270 |
| RHOA | -9853 |
| CDC42 | -9105 |
| KTN1 | -8591 |
| RHOG | -7757 |
| KLC2 | -7044 |
| KLC1 | -5920 |
| RAC1 | -5771 |
| KLC3 | -4947 |
| KIF5A | -4739 |
| KLC4 | -3143 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| KIF5B | -10270 |
| RHOA | -9853 |
| CDC42 | -9105 |
| KTN1 | -8591 |
| RHOG | -7757 |
| KLC2 | -7044 |
| KLC1 | -5920 |
| RAC1 | -5771 |
| KLC3 | -4947 |
| KIF5A | -4739 |
| KLC4 | -3143 |
Synthesis of PIPs at the Golgi membrane
| 1280 | |
|---|---|
| set | Synthesis of PIPs at the Golgi membrane |
| setSize | 15 |
| pANOVA | 1.39e-05 |
| s.dist | -0.648 |
| p.adjustANOVA | 7.7e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PIKFYVE | -11087 |
| VAC14 | -9543 |
| PI4KB | -9496 |
| PIK3C2A | -9163 |
| PIK3C3 | -9077 |
| OCRL | -8600 |
| SACM1L | -8271 |
| PI4K2A | -8075 |
| ARF1 | -7673 |
| PI4K2B | -7236 |
| PIK3R4 | -6977 |
| ARF3 | -6010 |
| INPP5E | -4476 |
| FIG4 | 820 |
| PI4KA | 1574 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PIKFYVE | -11087 |
| VAC14 | -9543 |
| PI4KB | -9496 |
| PIK3C2A | -9163 |
| PIK3C3 | -9077 |
| OCRL | -8600 |
| SACM1L | -8271 |
| PI4K2A | -8075 |
| ARF1 | -7673 |
| PI4K2B | -7236 |
| PIK3R4 | -6977 |
| ARF3 | -6010 |
| INPP5E | -4476 |
| FIG4 | 820 |
| PI4KA | 1574 |
Synthesis of PIPs at the early endosome membrane
| 1281 | |
|---|---|
| set | Synthesis of PIPs at the early endosome membrane |
| setSize | 16 |
| pANOVA | 7.56e-06 |
| s.dist | -0.646 |
| p.adjustANOVA | 4.61e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MTMR12 | -11333 |
| PIKFYVE | -11087 |
| MTMR2 | -9653 |
| VAC14 | -9543 |
| PIK3C2A | -9163 |
| PIK3C3 | -9077 |
| INPP4A | -8977 |
| MTMR4 | -8826 |
| INPP5F | -8508 |
| PI4K2A | -8075 |
| MTM1 | -7734 |
| PI4K2B | -7236 |
| PIK3R4 | -6977 |
| MTMR10 | -1463 |
| FIG4 | 820 |
| INPP4B | 6986 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MTMR12 | -11333 |
| PIKFYVE | -11087 |
| MTMR2 | -9653 |
| VAC14 | -9543 |
| PIK3C2A | -9163 |
| PIK3C3 | -9077 |
| INPP4A | -8977 |
| MTMR4 | -8826 |
| INPP5F | -8508 |
| PI4K2A | -8075 |
| MTM1 | -7734 |
| PI4K2B | -7236 |
| PIK3R4 | -6977 |
| MTMR10 | -1463 |
| FIG4 | 820 |
| INPP4B | 6986 |
RAF-independent MAPK1/3 activation
| 939 | |
|---|---|
| set | RAF-independent MAPK1/3 activation |
| setSize | 23 |
| pANOVA | 8.89e-08 |
| s.dist | -0.644 |
| p.adjustANOVA | 8.44e-07 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| MAPK1 | -11072 |
| DUSP1 | -10961 |
| DUSP4 | -10845 |
| JAK2 | -10798 |
| DUSP5 | -10695 |
| JAK1 | -10594 |
| MAPK3 | -10415 |
| DUSP16 | -10122 |
| MAP2K1 | -9906 |
| DUSP7 | -9778 |
| PTPN11 | -9113 |
| PEA15 | -8056 |
| IL6ST | -7508 |
| IL6R | -7013 |
| DUSP8 | -6809 |
| TYK2 | -6251 |
| DUSP2 | -5283 |
| DUSP9 | -4623 |
| MAP2K2 | -4059 |
| DUSP10 | -4048 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| MAPK1 | -11072 |
| DUSP1 | -10961 |
| DUSP4 | -10845 |
| JAK2 | -10798 |
| DUSP5 | -10695 |
| JAK1 | -10594 |
| MAPK3 | -10415 |
| DUSP16 | -10122 |
| MAP2K1 | -9906 |
| DUSP7 | -9778 |
| PTPN11 | -9113 |
| PEA15 | -8056 |
| IL6ST | -7508 |
| IL6R | -7013 |
| DUSP8 | -6809 |
| TYK2 | -6251 |
| DUSP2 | -5283 |
| DUSP9 | -4623 |
| MAP2K2 | -4059 |
| DUSP10 | -4048 |
| IL6 | -1086 |
| DUSP6 | -787 |
| CDK1 | 12683 |
Signaling by Activin
| 1174 | |
|---|---|
| set | Signaling by Activin |
| setSize | 15 |
| pANOVA | 1.82e-05 |
| s.dist | -0.639 |
| p.adjustANOVA | 9.75e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| INHBA | -11377 |
| MAPK1 | -11072 |
| SMAD4 | -10729 |
| MAPK3 | -10415 |
| SMAD2 | -10012 |
| SMAD3 | -9453 |
| FSTL3 | -9248 |
| ACVR2B | -9085 |
| ACVR2A | -7472 |
| DRAP1 | -6016 |
| ACVR1C | -5189 |
| ACVR1B | -5120 |
| FST | -4186 |
| INHBB | -2225 |
| FOXH1 | 10037 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| INHBA | -11377 |
| MAPK1 | -11072 |
| SMAD4 | -10729 |
| MAPK3 | -10415 |
| SMAD2 | -10012 |
| SMAD3 | -9453 |
| FSTL3 | -9248 |
| ACVR2B | -9085 |
| ACVR2A | -7472 |
| DRAP1 | -6016 |
| ACVR1C | -5189 |
| ACVR1B | -5120 |
| FST | -4186 |
| INHBB | -2225 |
| FOXH1 | 10037 |
RORA activates gene expression
| 1001 | |
|---|---|
| set | RORA activates gene expression |
| setSize | 18 |
| pANOVA | 3.1e-06 |
| s.dist | -0.635 |
| p.adjustANOVA | 2.08e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPARA | -11218 |
| HELZ2 | -11079 |
| CREBBP | -10976 |
| EP300 | -10826 |
| NCOA2 | -10725 |
| CARM1 | -10579 |
| MED1 | -10330 |
| TBL1X | -9308 |
| TBL1XR1 | -8542 |
| TGS1 | -8525 |
| NCOA6 | -8418 |
| RXRA | -8406 |
| RORA | -8157 |
| CHD9 | -8138 |
| NCOA1 | -7559 |
| CPT1A | -5402 |
| SREBF1 | 13240 |
| SMARCD3 | 14082 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPARA | -11218 |
| HELZ2 | -11079 |
| CREBBP | -10976 |
| EP300 | -10826 |
| NCOA2 | -10725 |
| CARM1 | -10579 |
| MED1 | -10330 |
| TBL1X | -9308 |
| TBL1XR1 | -8542 |
| TGS1 | -8525 |
| NCOA6 | -8418 |
| RXRA | -8406 |
| RORA | -8157 |
| CHD9 | -8138 |
| NCOA1 | -7559 |
| CPT1A | -5402 |
| SREBF1 | 13240 |
| SMARCD3 | 14082 |
Formation of ATP by chemiosmotic coupling
| 419 | |
|---|---|
| set | Formation of ATP by chemiosmotic coupling |
| setSize | 18 |
| pANOVA | 3.19e-06 |
| s.dist | 0.634 |
| p.adjustANOVA | 2.11e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ATP5PD | 14418 |
| ATP5MC1 | 14370 |
| ATP5ME | 14326 |
| ATP5MG | 14131 |
| ATP5F1D | 14051 |
| ATP5MF | 14007 |
| MT-ATP8 | 13926 |
| MT-ATP6 | 13802 |
| ATP5PO | 13339 |
| ATP5F1C | 13210 |
| ATP5PF | 13153 |
| ATP5MC2 | 12496 |
| ATP5MC3 | 11608 |
| DMAC2L | 11333 |
| ATP5F1E | 9900 |
| ATP5PB | -4314 |
| ATP5F1A | -7964 |
| ATP5F1B | -9680 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ATP5PD | 14418 |
| ATP5MC1 | 14370 |
| ATP5ME | 14326 |
| ATP5MG | 14131 |
| ATP5F1D | 14051 |
| ATP5MF | 14007 |
| MT-ATP8 | 13926 |
| MT-ATP6 | 13802 |
| ATP5PO | 13339 |
| ATP5F1C | 13210 |
| ATP5PF | 13153 |
| ATP5MC2 | 12496 |
| ATP5MC3 | 11608 |
| DMAC2L | 11333 |
| ATP5F1E | 9900 |
| ATP5PB | -4314 |
| ATP5F1A | -7964 |
| ATP5F1B | -9680 |
ALK mutants bind TKIs
| 10 | |
|---|---|
| set | ALK mutants bind TKIs |
| setSize | 12 |
| pANOVA | 0.000152 |
| s.dist | -0.631 |
| p.adjustANOVA | 0.000653 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| FN1 | -11331 |
| CLTC | -10972 |
| EIF2AK3 | -10501 |
| STRN | -9522 |
| HIP1 | -9100 |
| BIRC6 | -8991 |
| PRKAR1A | -8908 |
| ALK | -8478 |
| PPM1B | -8081 |
| EML4 | -4306 |
| NPM1 | -1994 |
| BCL11A | 12105 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| FN1 | -11331 |
| CLTC | -10972 |
| EIF2AK3 | -10501 |
| STRN | -9522 |
| HIP1 | -9100 |
| BIRC6 | -8991 |
| PRKAR1A | -8908 |
| ALK | -8478 |
| PPM1B | -8081 |
| EML4 | -4306 |
| NPM1 | -1994 |
| BCL11A | 12105 |
Activation of RAC1
| 48 | |
|---|---|
| set | Activation of RAC1 |
| setSize | 13 |
| pANOVA | 8.69e-05 |
| s.dist | -0.629 |
| p.adjustANOVA | 0.000395 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PAK1 | -11332 |
| SLIT2 | -11082 |
| NCK1 | -10455 |
| SOS1 | -10061 |
| PAK2 | -9919 |
| ROBO1 | -9823 |
| NCK2 | -8772 |
| PAK4 | -8769 |
| RAC1 | -5771 |
| SOS2 | -5653 |
| PAK3 | -4223 |
| PAK6 | 1398 |
| PAK5 | 8211 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PAK1 | -11332 |
| SLIT2 | -11082 |
| NCK1 | -10455 |
| SOS1 | -10061 |
| PAK2 | -9919 |
| ROBO1 | -9823 |
| NCK2 | -8772 |
| PAK4 | -8769 |
| RAC1 | -5771 |
| SOS2 | -5653 |
| PAK3 | -4223 |
| PAK6 | 1398 |
| PAK5 | 8211 |
Regulation of PTEN mRNA translation
| 1044 | |
|---|---|
| set | Regulation of PTEN mRNA translation |
| setSize | 12 |
| pANOVA | 0.000231 |
| s.dist | -0.614 |
| p.adjustANOVA | 0.000932 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AGO2 | -11303 |
| VAPA | -10560 |
| TNRC6B | -10436 |
| AGO3 | -10305 |
| CNOT6L | -9450 |
| PTEN | -9332 |
| AGO1 | -7708 |
| TNRC6C | -6209 |
| AGO4 | -5344 |
| TNRC6A | -4569 |
| PTENP1 | -3981 |
| MOV10 | 11874 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AGO2 | -11303 |
| VAPA | -10560 |
| TNRC6B | -10436 |
| AGO3 | -10305 |
| CNOT6L | -9450 |
| PTEN | -9332 |
| AGO1 | -7708 |
| TNRC6C | -6209 |
| AGO4 | -5344 |
| TNRC6A | -4569 |
| PTENP1 | -3981 |
| MOV10 | 11874 |
CTLA4 inhibitory signaling
| 146 | |
|---|---|
| set | CTLA4 inhibitory signaling |
| setSize | 17 |
| pANOVA | 1.21e-05 |
| s.dist | -0.613 |
| p.adjustANOVA | 6.77e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| YES1 | -11157 |
| SRC | -11039 |
| AKT3 | -10071 |
| PPP2R5A | -9839 |
| FYN | -9643 |
| PPP2R5E | -9609 |
| PTPN11 | -9113 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
| AKT1 | -2828 |
| LYN | 6229 |
| AKT2 | 10214 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| YES1 | -11157 |
| SRC | -11039 |
| AKT3 | -10071 |
| PPP2R5A | -9839 |
| FYN | -9643 |
| PPP2R5E | -9609 |
| PTPN11 | -9113 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| PPP2R5B | -7063 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
| AKT1 | -2828 |
| LYN | 6229 |
| AKT2 | 10214 |
STAT5 activation downstream of FLT3 ITD mutants
| 1130 | |
|---|---|
| set | STAT5 activation downstream of FLT3 ITD mutants |
| setSize | 10 |
| pANOVA | 0.000826 |
| s.dist | -0.611 |
| p.adjustANOVA | 0.00283 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CDKN1A | -11319 |
| GRB2 | -10367 |
| GAB2 | -9456 |
| PIM1 | -9154 |
| PTPN11 | -9113 |
| STAT5A | -8517 |
| BCL2L1 | -5576 |
| NOX4 | -5505 |
| STAT5B | -5411 |
| FLT3 | 10394 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CDKN1A | -11319 |
| GRB2 | -10367 |
| GAB2 | -9456 |
| PIM1 | -9154 |
| PTPN11 | -9113 |
| STAT5A | -8517 |
| BCL2L1 | -5576 |
| NOX4 | -5505 |
| STAT5B | -5411 |
| FLT3 | 10394 |
ERK/MAPK targets
| 357 | |
|---|---|
| set | ERK/MAPK targets |
| setSize | 22 |
| pANOVA | 8.88e-07 |
| s.dist | -0.605 |
| p.adjustANOVA | 6.51e-06 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| MAPK1 | -11072 |
| DUSP4 | -10845 |
| MAPK3 | -10415 |
| RPS6KA3 | -10402 |
| DUSP7 | -9778 |
| RPS6KA2 | -9623 |
| MAPK14 | -9489 |
| ELK1 | -8837 |
| VRK3 | -8696 |
| RPS6KA5 | -8526 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| MAPK7 | -6939 |
| MEF2C | -6540 |
| MEF2A | -6074 |
| DUSP3 | -5115 |
| PPP2R1B | -3752 |
| DUSP6 | -787 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| MAPK1 | -11072 |
| DUSP4 | -10845 |
| MAPK3 | -10415 |
| RPS6KA3 | -10402 |
| DUSP7 | -9778 |
| RPS6KA2 | -9623 |
| MAPK14 | -9489 |
| ELK1 | -8837 |
| VRK3 | -8696 |
| RPS6KA5 | -8526 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| MAPK7 | -6939 |
| MEF2C | -6540 |
| MEF2A | -6074 |
| DUSP3 | -5115 |
| PPP2R1B | -3752 |
| DUSP6 | -787 |
| MAPK11 | 11137 |
| RPS6KA1 | 13794 |
Complex I biogenesis
| 214 | |
|---|---|
| set | Complex I biogenesis |
| setSize | 57 |
| pANOVA | 5.61e-15 |
| s.dist | 0.598 |
| p.adjustANOVA | 2.08e-13 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NDUFB1 | 14506 |
| NDUFA7 | 14483 |
| NDUFAF3 | 14437 |
| ACAD9 | 14363 |
| NDUFA1 | 14353 |
| NDUFA12 | 14348 |
| NDUFV2 | 14312 |
| NDUFB8 | 14309 |
| NDUFA2 | 14297 |
| MT-ND3 | 14280 |
| NDUFS5 | 14273 |
| NDUFB4 | 14220 |
| NDUFA3 | 14207 |
| NDUFA11 | 14169 |
| NDUFB2 | 14156 |
| COA1 | 14073 |
| MT-ND2 | 13898 |
| NDUFA13 | 13815 |
| MT-ND4 | 13703 |
| MT-ND1 | 13666 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NDUFB1 | 14506 |
| NDUFA7 | 14483 |
| NDUFAF3 | 14437 |
| ACAD9 | 14363 |
| NDUFA1 | 14353 |
| NDUFA12 | 14348 |
| NDUFV2 | 14312 |
| NDUFB8 | 14309 |
| NDUFA2 | 14297 |
| MT-ND3 | 14280 |
| NDUFS5 | 14273 |
| NDUFB4 | 14220 |
| NDUFA3 | 14207 |
| NDUFA11 | 14169 |
| NDUFB2 | 14156 |
| COA1 | 14073 |
| MT-ND2 | 13898 |
| NDUFA13 | 13815 |
| MT-ND4 | 13703 |
| MT-ND1 | 13666 |
| MT-ND5 | 13494 |
| NDUFS7 | 13425 |
| MT-ND6 | 13393 |
| NDUFA8 | 13317 |
| NDUFAF2 | 13267 |
| NDUFB3 | 13112 |
| NDUFB7 | 13062 |
| NDUFC1 | 12738 |
| NDUFS8 | 12718 |
| NDUFB9 | 12633 |
| NDUFS3 | 12474 |
| NDUFA6 | 12455 |
| NDUFS6 | 11867 |
| NDUFV3 | 11569 |
| NDUFB6 | 11337 |
| NDUFC2 | 11100 |
| NDUFA9 | 10641 |
| NDUFAF7 | 10299 |
| NDUFB11 | 10281 |
| NDUFB10 | 10249 |
| NDUFAF1 | 9621 |
| NDUFA5 | 9255 |
| NDUFAF6 | 8858 |
| NDUFAF5 | 8736 |
| NDUFS4 | 5902 |
| ECSIT | 4595 |
| TIMMDC1 | 4050 |
| NDUFV1 | 3727 |
| TMEM126B | -1581 |
| NDUFAF4 | -2850 |
| TMEM186 | -4724 |
| NDUFB5 | -5794 |
| NUBPL | -6091 |
| NDUFA10 | -6273 |
| NDUFAB1 | -6736 |
| NDUFS1 | -8887 |
| NDUFS2 | -8924 |
Signal transduction by L1
| 1167 | |
|---|---|
| set | Signal transduction by L1 |
| setSize | 21 |
| pANOVA | 2.3e-06 |
| s.dist | -0.595 |
| p.adjustANOVA | 1.58e-05 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| ITGA5 | -11448 |
| PAK1 | -11332 |
| CSNK2A2 | -11291 |
| CSNK2A1 | -11139 |
| MAPK1 | -11072 |
| ITGB1 | -10823 |
| ITGB3 | -10603 |
| FGFR1 | -10522 |
| EGFR | -10456 |
| MAPK3 | -10415 |
| ITGAV | -9963 |
| MAP2K1 | -9906 |
| VAV2 | -7675 |
| L1CAM | -6965 |
| NRP1 | -6060 |
| RAC1 | -5771 |
| MAP2K2 | -4059 |
| ITGA2B | 4408 |
| NCAM1 | 4642 |
| CSNK2B | 8404 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| ITGA5 | -11448 |
| PAK1 | -11332 |
| CSNK2A2 | -11291 |
| CSNK2A1 | -11139 |
| MAPK1 | -11072 |
| ITGB1 | -10823 |
| ITGB3 | -10603 |
| FGFR1 | -10522 |
| EGFR | -10456 |
| MAPK3 | -10415 |
| ITGAV | -9963 |
| MAP2K1 | -9906 |
| VAV2 | -7675 |
| L1CAM | -6965 |
| NRP1 | -6060 |
| RAC1 | -5771 |
| MAP2K2 | -4059 |
| ITGA2B | 4408 |
| NCAM1 | 4642 |
| CSNK2B | 8404 |
| ITGA9 | 11807 |
Signaling by Leptin
| 1211 | |
|---|---|
| set | Signaling by Leptin |
| setSize | 10 |
| pANOVA | 0.00111 |
| s.dist | -0.595 |
| p.adjustANOVA | 0.0037 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| JAK2 | -10798 |
| IRS1 | -10066 |
| IRS2 | -10059 |
| PTPN11 | -9113 |
| STAT5A | -8517 |
| LEPR | -8359 |
| STAT3 | -7915 |
| SOCS3 | -5490 |
| STAT5B | -5411 |
| SH2B1 | 13691 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| JAK2 | -10798 |
| IRS1 | -10066 |
| IRS2 | -10059 |
| PTPN11 | -9113 |
| STAT5A | -8517 |
| LEPR | -8359 |
| STAT3 | -7915 |
| SOCS3 | -5490 |
| STAT5B | -5411 |
| SH2B1 | 13691 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation
| 212 | |
|---|---|
| set | Competing endogenous RNAs (ceRNAs) regulate PTEN translation |
| setSize | 11 |
| pANOVA | 0.000651 |
| s.dist | -0.594 |
| p.adjustANOVA | 0.00235 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| AGO2 | -11303 |
| VAPA | -10560 |
| TNRC6B | -10436 |
| AGO3 | -10305 |
| CNOT6L | -9450 |
| AGO1 | -7708 |
| TNRC6C | -6209 |
| AGO4 | -5344 |
| TNRC6A | -4569 |
| PTENP1 | -3981 |
| MOV10 | 11874 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| AGO2 | -11303 |
| VAPA | -10560 |
| TNRC6B | -10436 |
| AGO3 | -10305 |
| CNOT6L | -9450 |
| AGO1 | -7708 |
| TNRC6C | -6209 |
| AGO4 | -5344 |
| TNRC6A | -4569 |
| PTENP1 | -3981 |
| MOV10 | 11874 |
Prolonged ERK activation events
| 918 | |
|---|---|
| set | Prolonged ERK activation events |
| setSize | 14 |
| pANOVA | 0.000127 |
| s.dist | -0.591 |
| p.adjustANOVA | 0.000558 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CRKL | -11246 |
| MAPK1 | -11072 |
| CRK | -10821 |
| MAPK3 | -10415 |
| RAPGEF1 | -9979 |
| MAP2K1 | -9906 |
| FRS2 | -9394 |
| BRAF | -7448 |
| RAP1A | -6032 |
| MAP2K2 | -4059 |
| KIDINS220 | -2079 |
| NTRK1 | -1564 |
| YWHAB | 668 |
| NGF | 7236 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CRKL | -11246 |
| MAPK1 | -11072 |
| CRK | -10821 |
| MAPK3 | -10415 |
| RAPGEF1 | -9979 |
| MAP2K1 | -9906 |
| FRS2 | -9394 |
| BRAF | -7448 |
| RAP1A | -6032 |
| MAP2K2 | -4059 |
| KIDINS220 | -2079 |
| NTRK1 | -1564 |
| YWHAB | 668 |
| NGF | 7236 |
Signaling by WNT in cancer
| 1248 | |
|---|---|
| set | Signaling by WNT in cancer |
| setSize | 33 |
| pANOVA | 4.49e-09 |
| s.dist | -0.59 |
| p.adjustANOVA | 5.74e-08 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| TNKS | -11151 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| FZD8 | -10164 |
| LRP6 | -9991 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| TNKS2 | -9768 |
| FZD4 | -9761 |
| PPP2R5E | -9609 |
| FZD5 | -9574 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| KREMEN2 | -8049 |
| FZD6 | -7908 |
| CTBP2 | -7367 |
| PPP2R1A | -7348 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| PPP2R5D | -11385 |
| PPP2CB | -11199 |
| TNKS | -11151 |
| AXIN1 | -11038 |
| CSNK1A1 | -11023 |
| FZD8 | -10164 |
| LRP6 | -9991 |
| GSK3B | -9938 |
| PPP2R5A | -9839 |
| TNKS2 | -9768 |
| FZD4 | -9761 |
| PPP2R5E | -9609 |
| FZD5 | -9574 |
| AMER1 | -8611 |
| CTNNB1 | -8504 |
| APC | -8095 |
| KREMEN2 | -8049 |
| FZD6 | -7908 |
| CTBP2 | -7367 |
| PPP2R1A | -7348 |
| PPP2CA | -7314 |
| KREMEN1 | -7224 |
| PPP2R5B | -7063 |
| PORCN | -6198 |
| DKK2 | -5439 |
| DKK1 | -5426 |
| PPP2R5C | -4400 |
| PPP2R1B | -3752 |
| RNF43 | 1822 |
| WNT3A | 2357 |
| CTBP1 | 8786 |
| TCF7L2 | 9371 |
| LRP5 | 12739 |
Frs2-mediated activation
| 436 | |
|---|---|
| set | Frs2-mediated activation |
| setSize | 12 |
| pANOVA | 0.000425 |
| s.dist | -0.587 |
| p.adjustANOVA | 0.00163 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| CRKL | -11246 |
| MAPK1 | -11072 |
| MAPK3 | -10415 |
| RAPGEF1 | -9979 |
| MAP2K1 | -9906 |
| FRS2 | -9394 |
| BRAF | -7448 |
| RAP1A | -6032 |
| MAP2K2 | -4059 |
| NTRK1 | -1564 |
| YWHAB | 668 |
| NGF | 7236 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| CRKL | -11246 |
| MAPK1 | -11072 |
| MAPK3 | -10415 |
| RAPGEF1 | -9979 |
| MAP2K1 | -9906 |
| FRS2 | -9394 |
| BRAF | -7448 |
| RAP1A | -6032 |
| MAP2K2 | -4059 |
| NTRK1 | -1564 |
| YWHAB | 668 |
| NGF | 7236 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression
| 1445 | |
|---|---|
| set | YAP1- and WWTR1 (TAZ)-stimulated gene expression |
| setSize | 12 |
| pANOVA | 0.000444 |
| s.dist | -0.585 |
| p.adjustANOVA | 0.0017 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| HIPK1 | -10895 |
| YAP1 | -10335 |
| TEAD1 | -10153 |
| TEAD4 | -9286 |
| TEAD2 | -9164 |
| TEAD3 | -8524 |
| WWTR1 | -8042 |
| GATA4 | -6335 |
| RUNX2 | -5578 |
| HIPK2 | -4908 |
| NPPA | 3503 |
| KAT2B | 6820 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| HIPK1 | -10895 |
| YAP1 | -10335 |
| TEAD1 | -10153 |
| TEAD4 | -9286 |
| TEAD2 | -9164 |
| TEAD3 | -8524 |
| WWTR1 | -8042 |
| GATA4 | -6335 |
| RUNX2 | -5578 |
| HIPK2 | -4908 |
| NPPA | 3503 |
| KAT2B | 6820 |
Synthesis of bile acids and bile salts via 27-hydroxycholesterol
| 1288 | |
|---|---|
| set | Synthesis of bile acids and bile salts via 27-hydroxycholesterol |
| setSize | 10 |
| pANOVA | 0.00148 |
| s.dist | -0.58 |
| p.adjustANOVA | 0.00469 |
Top enriched genes
| GeneID | Gene Rank |
|---|---|
| NCOA2 | -10725 |
| RXRA | -8406 |
| HSD3B7 | -8010 |
| NCOA1 | -7559 |
| AKR1C1 | -6748 |
| AKR1C3 | -5292 |
| CYP27A1 | -5167 |
| PTGIS | -3939 |
| AKR1C2 | -3789 |
| CYP8B1 | -447 |
Click HERE to show all gene set members
| GeneID | Gene Rank |
|---|---|
| NCOA2 | -10725 |
| RXRA | -8406 |
| HSD3B7 | -8010 |
| NCOA1 | -7559 |
| AKR1C1 | -6748 |
| AKR1C3 | -5292 |
| CYP27A1 | -5167 |
| PTGIS | -3939 |
| AKR1C2 | -3789 |
| CYP8B1 | -447 |
Here is the session info with all the versions of packages used.
sessionInfo()## R version 4.2.0 (2022-04-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] parallel stats4 stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.2.4 GGally_2.1.2
## [3] gtools_3.9.2 echarts4r_0.4.3
## [5] beeswarm_0.4.0 vioplot_0.3.7
## [7] sm_2.2-5.7 kableExtra_1.3.4
## [9] topconfects_1.8.0 limma_3.48.3
## [11] eulerr_6.1.1 mitch_1.4.1
## [13] MASS_7.3-56 fgsea_1.18.0
## [15] gplots_3.1.1 DESeq2_1.32.0
## [17] SummarizedExperiment_1.22.0 Biobase_2.52.0
## [19] MatrixGenerics_1.4.3 matrixStats_0.61.0
## [21] GenomicRanges_1.44.0 GenomeInfoDb_1.28.4
## [23] IRanges_2.26.0 S4Vectors_0.30.2
## [25] BiocGenerics_0.38.0 reshape2_1.4.4
## [27] forcats_0.5.1 stringr_1.4.0
## [29] dplyr_1.0.8 purrr_0.3.4
## [31] readr_2.1.2 tidyr_1.2.0
## [33] tibble_3.1.6 ggplot2_3.3.5
## [35] tidyverse_1.3.1 zoo_1.8-9
##
## loaded via a namespace (and not attached):
## [1] readxl_1.3.1 backports_1.4.1 fastmatch_1.1-3
## [4] systemfonts_1.0.4 plyr_1.8.6 polylabelr_0.2.0
## [7] splines_4.2.0 BiocParallel_1.26.2 digest_0.6.29
## [10] htmltools_0.5.2 fansi_1.0.2 magrittr_2.0.2
## [13] memoise_2.0.1 tzdb_0.2.0 Biostrings_2.60.2
## [16] annotate_1.70.0 modelr_0.1.8 svglite_2.1.0
## [19] colorspace_2.0-3 blob_1.2.2 rvest_1.0.2
## [22] haven_2.4.3 xfun_0.30 crayon_1.5.0
## [25] RCurl_1.98-1.6 jsonlite_1.8.0 genefilter_1.74.1
## [28] survival_3.3-1 glue_1.6.2 polyclip_1.10-0
## [31] gtable_0.3.0 zlibbioc_1.38.0 XVector_0.32.0
## [34] webshot_0.5.2 DelayedArray_0.18.0 scales_1.1.1
## [37] DBI_1.1.2 Rcpp_1.0.8.2 viridisLite_0.4.0
## [40] xtable_1.8-4 bit_4.0.4 htmlwidgets_1.5.4
## [43] httr_1.4.2 RColorBrewer_1.1-2 ellipsis_0.3.2
## [46] pkgconfig_2.0.3 reshape_0.8.8 XML_3.99-0.9
## [49] sass_0.4.0 dbplyr_2.1.1 locfit_1.5-9.5
## [52] utf8_1.2.2 tidyselect_1.1.2 rlang_1.0.2
## [55] later_1.3.0 AnnotationDbi_1.54.1 munsell_0.5.0
## [58] cellranger_1.1.0 tools_4.2.0 cachem_1.0.6
## [61] cli_3.2.0 generics_0.1.2 RSQLite_2.2.10
## [64] broom_0.7.12 evaluate_0.15 fastmap_1.1.0
## [67] yaml_2.3.5 knitr_1.37 bit64_4.0.5
## [70] fs_1.5.2 caTools_1.18.2 KEGGREST_1.32.0
## [73] mime_0.12 xml2_1.3.3 compiler_4.2.0
## [76] rstudioapi_0.13 png_0.1-7 reprex_2.0.1
## [79] geneplotter_1.70.0 bslib_0.3.1 stringi_1.7.6
## [82] highr_0.9 desc_1.4.1 lattice_0.20-45
## [85] Matrix_1.4-1 vctrs_0.3.8 pillar_1.7.0
## [88] lifecycle_1.0.1 jquerylib_0.1.4 data.table_1.14.2
## [91] bitops_1.0-7 httpuv_1.6.5 R6_2.5.1
## [94] promises_1.2.0.1 KernSmooth_2.23-20 gridExtra_2.3
## [97] assertthat_0.2.1 rprojroot_2.0.2 withr_2.5.0
## [100] GenomeInfoDbData_1.2.6 hms_1.1.1 grid_4.2.0
## [103] rmarkdown_2.13 shiny_1.7.1 lubridate_1.8.0END of report